Primary Site >> Colorectal Cancer
Gene >> BRAF
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. PMID: 12198537 Ref: Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. PMID: 12438234 |
Ref: High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. PMID: 12670889 Ref: Raf proteins and cancer: B-Raf is identified as a mutational target. PMID: 12781369 Ref: BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas. PMID: 12941809 Ref: BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. PMID: 14500346 Ref: Elevated ERK-MAP kinase activity protects the FOS family member FRA-1 against proteasomal degradation in colon carcinoma cells. PMID: 14625389 Ref: Carcinogenesis in MYH-associated polyposis follows a distinct genetic pathway. PMID: 14633673 Ref: BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. PMID: 14668801 Ref: Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. PMID: 14678966 |
Ref: Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. PMID: 14688025 Ref: Activated BRAF targets proximal colon tumors with mismatch repair deficiency and MLH1 inactivation. PMID: 14695993 Ref: BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. PMID: 14734469 Ref: K-ras and B-raf gene mutations are not associated with gastrin- and CCK2-receptor mRNA expression in human colorectal tumour tissues. PMID: 14764072 Ref: In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. PMID: 14991899 Ref: Inverse PCR-based RFLP scanning identifies low-level mutation signatures in colon cells and tumors. PMID: 15059910 Ref: Rapid detection of mutations in the BRAF gene using real-time polymerase chain reaction and melting curve analysis. PMID: 15104286 Ref: RAS/RAF mutation and defective DNA mismatch repair in endometrial cancers. PMID: 15118616 Ref: Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular tra PMID: 15150094 Ref: Both BRAF and KRAS mutations are rare in colorectal carcinomas from patients with hereditary nonpolyposis colorectal cancer. PMID: 15194222 Ref: My approach to serrated polyps of the colorectum. PMID: 15220357 Ref: High sensitivity scanning of colorectal tumors and matched plasma DNA for mutations in APC, TP53, K-RAS, and BRAF genes with a novel DHPLC fluorescence detection platform. PMID: 15251969 Ref: Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E. PMID: 15294323 Ref: HNPCC and sporadic MSI-H colorectal cancer: a review of the morphological similarities and differences. PMID: 15340259 Ref: Promoter hypermethylation frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer. PMID: 15340260 Ref: BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. PMID: 15342696 Ref: Mutational analysis of OGG1, MYH, MTH1 in FAP, HNPCC and sporadic colorectal cancer patients: R154H OGG1 polymorphism is associated with sporadic colorectal cancer patients. PMID: 15449173 Ref: BRAF and KRAS Mutations in hyperplastic polyps and serrated adenomas of the colorectum: relationship to histology and CpG island methylation status. PMID: 15489648 Ref: Mutational activation of the RAS-RAF-MAPK and the Wnt pathway in small intestinal adenocarcinomas. PMID: 15513360 Ref: Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. PMID: 15542810 |
Ref: Mutational analysis of the ARAF gene in human cancers. PMID: 15676015 Ref: Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression. PMID: 15702478 Ref: Mutations of the BRAF gene in ulcerative colitis-related colorectal carcinoma. PMID: 15704157 Ref: BRAF mutation associated with dysregulation of apoptosis in human colorectal neoplasms. PMID: 15729718 Ref: Evidence for BRAF mutation and variable levels of microsatellite instability in a syndrome of familial colorectal cancer. PMID: 15765445 Ref: Transformation of immortalized colorectal crypt cells by microcystin involving constitutive activation of Akt and MAPK cascade. PMID: 15774489 Ref: BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. PMID: 15782118 Ref: BRAF mutations in aberrant crypt foci and hyperplastic polyposis. PMID: 15793287 Ref: Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models. PMID: 15841378 Ref: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. PMID: 15863375 Ref: The prevalence of PIK3CA mutations in gastric and colon cancer. PMID: 15994075 Ref: Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur preferentially in MSI sporadic colorectal cancer. PMID: 16007118 Ref: The Ras effector RASSF2 is a novel tumor-suppressor gene in human colorectal cancer. PMID: 16012945 Ref: BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors. PMID: 16015629 Ref: Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. PMID: 16024606 Ref: Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. PMID: 16143123 Ref: Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. PMID: 16166444 |
Ref: Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. PMID: 16118624 Ref: Somatic mutations of the ERBB4 kinase domain in human cancers. PMID: 16187281 Ref: Oligonucleotide microarray analysis of distinct gene expression patterns in colorectal cancer tissues harboring BRAF and K-ras mutations. PMID: 16219636 Ref: Relationship between genetic alterations and prognosis in sporadic colorectal cancer. PMID: 16231316 Ref: Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines. PMID: 16376301 Ref: BRAF mutation, CpG island methylator phenotype and microsatellite instability occur more frequently and concordantly in mucinous than non-mucinous colorectal cancer. PMID: 16381005 Ref: Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. PMID: 16397024 Ref: BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. PMID: 16403224 Ref: CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. PMID: 16407376 Ref: Mitogen-activated protein kinase signaling is activated in prostate tumors but not mediated by B-RAF mutations. PMID: 16413100 Ref: Aberrant crypt foci. PMID: 16475686 Ref: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. PMID: 16618717 Ref: Cancer genetics of sporadic colorectal cancer: BRAF and PI3KCA mutations, their impact on signaling and novel targeted therapies. PMID: 16619509 Ref: BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors. PMID: 16628650 Ref: Epigenetic profiling of synchronous colorectal neoplasias by quantitative DNA methylation analysis. PMID: 16699497 Ref: Epidermal growth factor receptor signaling is up-regulated in human colonic aberrant crypt foci. PMID: 16740703 Ref: CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. PMID: 16804544 Ref: Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer. PMID: 16850502 Ref: Advanced colorectal polyps with the molecular and morphological features of serrated polyps and adenomas: concept of a 'fusion' pathway to colorectal cancer. PMID: 16879389 Ref: Phenotype-genotype correlation: challenge of intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses. PMID: 16906516 Ref: Frequent involvement of ras-signalling pathways in both polypoid-type and flat-type early-stage colorectal cancers. PMID: 16918136 Ref: Genetic and epigenetic changes in primary metastatic and nonmetastatic colorectal cancer. PMID: 16969349 Ref: APC gene methylation is inversely correlated with features of the CpG island methylator phenotype in colorectal cancer. PMID: 16981189 Ref: KRAS, p53 and BRAF gene mutations and aneuploidy in sporadic colorectal cancer progression. PMID: 16988471 Ref: The case for a genetic predisposition to serrated neoplasia in the colorectum: hypothesis and review of the literature. PMID: 17035382 Ref: Detection of BRAF V600E mutation in colorectal cancer: comparison of automatic sequencing and real-time chemistry methodology. PMID: 17065421 Ref: CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. PMID: 17065427 Ref: Improved marker combination for detection of de novo genetic variation and aberrant DNA in colorectal neoplasia. PMID: 17082247 Ref: High prevalence of sessile serrated adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy. PMID: 17101316 Ref: Somatic BRAF-V600E mutations in familial colorectal cancer. PMID: 17119056 Ref: Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points. PMID: 17122504 Ref: Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. PMID: 17148775 Ref: New aspects in molecular diagnosis of Lynch syndrome (HNPCC). PMID: 17192058 Ref: BRAF mutations in papillary thyroid carcinoma. PMID: 17201587 Ref: Colorectal cancer: a multipathway disease. PMID: 17425506 Ref: Types of colorectal adenoma. PMID: 17867575 Ref: [A new quantitative DNA-methylation analysis of MSI colorectal cancers helps to separate sporadic colorectal cancers from HNPCC-candidates]. PMID: 17867602 |
Ref: KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. PMID: 16953233 Ref: Correlation between hypermethylation of the RASSF2A promoter and K-ras/BRAF mutations in microsatellite-stable colorectal cancers. PMID: 17013898 Ref: Loss of nuclear p27 (CDKN1B/KIP1) in colorectal cancer is correlated with microsatellite instability and CIMP. PMID: 17086168 Ref: The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. PMID: 17087942 Ref: Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer. PMID: 17096326 Ref: Role of the BRAF mutations in the microsatellite instability genetic pathway in sporadic colorectal cancer. PMID: 17195912 Ref: Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. PMID: 17204026 Ref: Colorectal serrated adenocarcinoma. PMID: 17204027 Ref: Cytoplasmic localization of p27 (cyclin-dependent kinase inhibitor 1B/KIP1) in colorectal cancer: inverse correlations with nuclear p27 loss, microsatellite instability, and CpG island methylator phenotype. PMID: 17239930 Ref: Development and applications of a BRAF oligonucleotide microarray. PMID: 17251336 Ref: Homozygous PMS2 deletion causes a severe colorectal cancer and multiple adenoma phenotype without extraintestinal cancer. PMID: 17258725 Ref: Promoter methylation of the mutated in colorectal cancer gene is a frequent early event in colorectal cancer. PMID: 17260021 Ref: TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer. PMID: 17270239 Ref: APC mutations and other genetic and epigenetic changes in colon cancer. PMID: 17293392 Ref: Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics. PMID: 17312306 Ref: Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. PMID: 17314276 Ref: Fatty acid synthase overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype. PMID: 17350669 Ref: Highly conserved sequence of exon 15 BRAF gene and KRAS codon 12 mutation among Greek patients with colorectal cancer. PMID: 17393356 Ref: Chk1 frameshift mutation in sporadic and hereditary non-polyposis colorectal cancers with microsatellite instability. PMID: 17408908 Ref: Role of BRAF-V600E in the serrated pathway of colorectal tumourigenesis. PMID: 17427169 Ref: Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. PMID: 17431102 Ref: Mutations in BRAF and KRAS differentially distinguish serrated versus non-serrated hyperplastic aberrant crypt foci in humans. PMID: 17440063 Ref: Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer. PMID: 17453358 Ref: Targeting aberrant chromatin structure in colorectal carcinomas. PMID: 17464246 Ref: 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high. PMID: 17474983 Ref: Molecular classification and genetic pathways in hyperplastic polyposis syndrome. PMID: 17503413 Ref: Distinction of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through quantification of MLH1 methylation by real-time PCR. PMID: 17545526 Ref: Frequency and application of the hot spot BRAF gene mutation (p.V600E) in the diagnostic strategy for Hereditary Nonpolyposis Colorectal Cancer. PMID: 17566669 Ref: Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. PMID: 17591929 Ref: Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer. PMID: 17606714 Ref: MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer. PMID: 17621591 Ref: Heterogeneous staining for mismatch repair proteins during population-based prescreening for hereditary nonpolyposis colorectal cancer. PMID: 17652638 Ref: Involvement of Kruppel-like factor 6 (KLF6) mutation in the development of nonpolypoid colorectal carcinoma. PMID: 17663506 Ref: Genetic pathways and mutation profiles of human cancers: site- and exposure-specific patterns. PMID: 17693665 Ref: Context-dependent roles of mutant B-Raf signaling in melanoma and colorectal carcinoma cell growth. PMID: 17699719 Ref: Correlation of beta-catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in colorectal cancer. PMID: 17710160 Ref: Promoter methylation status of multiple genes in uveal melanoma. PMID: 17898258 Ref: Molecular analysis of colorectal cancer tumors from patients with mismatch repair proficient hereditary nonpolyposis colorectal cancer suggests novel carcinogenic pathways. PMID: 17908962 Ref: Involvement of the serrated neoplasia pathway in inflammatory bowel disease-related colorectal oncogenesis. PMID: 17914558 Ref: Molecular testing for microsatellite instability and DNA mismatch repair defects in hereditary and sporadic colorectal cancers--ready for prime time? PMID: 17962726 Ref: Hyperplastic and serrated polyps of the colorectum. PMID: 17996799 Ref: Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. PMID: 18003927 Ref: Frequency of defective DNA mismatch repair in colorectal cancer among the Alaska Native people. PMID: 18006922 Ref: Highly methylated genes in colorectal neoplasia: implications for screening. PMID: 18086775 Ref: Flat colorectal cancers are genetically determined and progress to invasion without going through a polypoid stage. PMID: 18089788 Ref: Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex. PMID: 18220746 Ref: [Colorectal serrated adenoma: diagnostic criteria and clinical implications]. PMID: 18314605 Ref: Therapeutic strategies for targeting BRAF in human cancer. PMID: 18473997 Ref: [How and when to search for microsatellite instability in colorectal cancer in 2008?]. PMID: 18554553 |
Ref: Strategy in clinical practice for classification of unselected colorectal tumours based on mismatch repair deficiency. PMID: 17868408 Ref: Relationship of BRAF mutation, morphology, and apoptosis in early colorectal cancer. PMID: 17924122 Ref: Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature. PMID: 17974567 Ref: PIK3CA cancer mutations display gender and tissue specificity patterns. PMID: 18022911 Ref: Integrated analysis of chromosomal, microsatellite and epigenetic instability in colorectal cancer identifies specific associations between promoter methylation of pivotal tumour suppressor and DNA repair genes and specific chromosomal alterations. PMID: 18048385 Ref: Validation and extension of the PREMM1,2 model in a population-based cohort of colorectal cancer patients. PMID: 18061181 Ref: WRN promoter methylation possibly connects mucinous differentiation, microsatellite instability and CpG island methylator phenotype in colorectal cancer. PMID: 18084250 Ref: A prospective, multicenter, population-based study of BRAF mutational analysis for Lynch syndrome screening. PMID: 18096441 Ref: BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations. PMID: 18098337 Ref: Rapid identification of somatic mutations in colorectal and breast cancer tissues using mismatch repair detection (MRD). PMID: 18186519 Ref: Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation. PMID: 18199160 Ref: Clinicopathologic factors identify sporadic mismatch repair-defective colon cancers. PMID: 18208804 Ref: Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. PMID: 18224685 Ref: Serrated polyps with "intermediate features" of sessile serrated polyp and microvesicular hyperplastic polyp: a practical approach to the classification of nondysplastic serrated polyps. PMID: 18300810 Ref: Bone morphogenic protein 3 inactivation is an early and frequent event in colorectal cancer development. PMID: 18311777 Ref: Associations of dietary methyl donor intake with MLH1 promoter hypermethylation and related molecular phenotypes in sporadic colorectal cancer. PMID: 18339680 Ref: PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. PMID: 18339877 Ref: LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. PMID: 18366060 Ref: The CpG island methylator phenotype correlates with long-range epigenetic silencing in colorectal cancer. PMID: 18403637 Ref: Sixty years of follow-up of Hiroshima and Nagasaki survivors: current progress in molecular epidemiology studies. PMID: 18406659 Ref: Detection of BRAF V600E mutation by pyrosequencing. PMID: 18428050 Ref: Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer. PMID: 18435933 Ref: Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma. PMID: 18451217 Ref: BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. PMID: 18458053 Ref: Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer. PMID: 18470905 Ref: Proximal and distal colorectal cancers show distinct gene-specific methylation profiles and clinical and molecular characteristics. PMID: 18486467 Ref: Clinicopathologic characteristics, CpG island methylator phenotype, and BRAF mutations in microsatellite-stable colorectal cancers without chromosomal instability. PMID: 18517279 Ref: Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. PMID: 18519771 Ref: In vitro differential sensitivity of melanomas to phenothiazines is based on the presence of codon 600 BRAF mutation. PMID: 18524847 Ref: Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite instability testing. PMID: 18556776 Ref: Heterogeneity of colorectal adenomas, the serrated adenoma, and implications for screening and surveillance. PMID: 18567071 Ref: Analysis of the K-ras/B-raf/Erk signal cascade, p53 and CMAP as markers for tumor progression in colorectal cancer patients. PMID: 18575712 Ref: Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. PMID: 18577988 Ref: Mutated in colorectal cancer, a putative tumor suppressor for serrated colorectal cancer, selectively represses beta-catenin-dependent transcription. PMID: 18591935 Ref: RAS signaling in colorectal carcinomas through alteration of RAS, RAF, NF1, and/or RASSF1A. PMID: 18592002 Ref: B-Raf(V600E) cooperates with alternative spliced Rac1b to sustain colorectal cancer cell survival. PMID: 18602919 Ref: The MLH1 -93 G>A promoter polymorphism and genetic and epigenetic alterations in colon cancer. PMID: 18615680 Ref: Genetic alterations in colorectal cancers with demethylation of insulin-like growth factor II. PMID: 18619647 Ref: High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. PMID: 18628094 Ref: Ethnicity and risk for colorectal cancers showing somatic BRAF V600E mutation or CpG island methylator phenotype. PMID: 18628431 Ref: [The RAS paradox of the EGFR-targeted therapy in colorectal cancer]. PMID: 18640895 Ref: Oxidative stress plays a critical role in inactivating mutant BRAF by geldanamycin derivatives. PMID: 18676857 Ref: Impact of BRAF, MLH1 on the incidence of microsatellite instability high colorectal cancer in populations based study. PMID: 18718023 Ref: Identification in daily practice of patients with Lynch syndrome (hereditary nonpolyposis colorectal cancer): revised Bethesda guidelines-based approach versus molecular screening. PMID: 18759827 Ref: BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis? PMID: 18782444 Ref: Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901. PMID: 18790789 Ref: Distinct CpG island methylation profiles and BRAF mutation status in serrated and adenomatous colorectal polyps. PMID: 18798261 Ref: Significance of serrated polyps of the colon. PMID: 18799125 Ref: Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM. PMID: 18806830 Ref: CpG island methylator phenotype associates with low-degree chromosomal abnormalities in colorectal cancer. PMID: 18829479 Ref: CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels. PMID: 18834226 Ref: Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. PMID: 18922929 Ref: Epigenetic events in normal colonic mucosa surrounding colorectal cancer lesions. PMID: 18938072 Ref: Cohort study of fatty acid synthase expression and patient survival in colon cancer. PMID: 18955444 Ref: Cyclin D1 is frequently overexpressed in microsatellite unstable colorectal cancer, independent of CpG island methylator phenotype. PMID: 18983468 Ref: Prevalence of mutations in APC, CTNNB1, and BRAF in Tunisian patients with sporadic colorectal cancer. PMID: 18992635 Ref: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. PMID: 19001320 Ref: Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PMID: 19002263 Ref: Statistical strategies to improve the efficiency of molecular studies of colorectal cancer prognosis. PMID: 19018265 Ref: A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. PMID: 19033568 Ref: Gene expression deregulation by KRAS G12D and G12V in a BRAF V600E context. PMID: 19087308 Ref: Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. PMID: 19088039 Ref: Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers. PMID: 19117505 Ref: Management of serrated adenomas and hyperplastic polyps. PMID: 20011438 |
Ref: PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. PMID: 18669866 Ref: Oncogenetic tree model of somatic mutations and DNA methylation in colon tumors. PMID: 18767147 Ref: BRAF mutation is associated with the CpG island methylator phenotype in colorectal cancer from young patients. PMID: 18778891 Ref: CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. PMID: 18832519 Ref: Tumour cell survival signalling by the ERK1/2 pathway. PMID: 18846109 Ref: Endometrial cancer and somatic G>T KRAS transversion in patients with constitutional MUTYH biallelic mutations. PMID: 18980800 Ref: High detection rates of colorectal neoplasia by stool DNA testing with a novel digital melt curve assay. PMID: 19026650 Ref: Clinical, pathologic, and molecular features of early-onset colorectal carcinoma. PMID: 19047896 Ref: Population-based detection of Lynch syndrome in young colorectal cancer patients using microsatellite instability as the initial test. PMID: 19072991 Ref: JC virus T-antigen in colorectal cancer is associated with p53 expression and chromosomal instability, independent of CpG island methylator phenotype. PMID: 19107235 Ref: Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. PMID: 19117687 Ref: Microsatellite instability, MLH1 promoter methylation, and BRAF mutation analysis in sporadic colorectal cancers of different ethnic groups in Israel. PMID: 19127559 Ref: Microsatellite instability-low colorectal cancer acquires a KRAS mutation during the progression from Dukes' A to Dukes' B. PMID: 19147861 Ref: MGMT and MLH1 promoter methylation versus APC, KRAS and BRAF gene mutations in colorectal cancer: indications for distinct pathways and sequence of events. PMID: 19164452 Ref: Colorectal cancer expression of peroxisome proliferator-activated receptor gamma (PPARG, PPARgamma) is associated with good prognosis. PMID: 19186181 Ref: Distinct BRAF (V600E) and KRAS mutations in high microsatellite instability sporadic colorectal cancer in African Americans. PMID: 19190129 Ref: TGF-beta receptor inactivation and mutant Kras induce intestinal neoplasms in mice via a beta-catenin-independent pathway. PMID: 19208363 Ref: Evaluation of high-resolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors. PMID: 19213871 Ref: PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. PMID: 19223544 Ref: PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. PMID: 19237633 Ref: Analysis of families with Lynch syndrome complicated by advanced serrated neoplasia: the importance of pathology review and pedigree analysis. PMID: 19241144 Ref: Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. PMID: 19293803 Ref: Frequent inactivation of axon guidance molecule RGMA in human colon cancer through genetic and epigenetic mechanisms. PMID: 19303019 Ref: Luteolin, quercetin and ursolic acid are potent inhibitors of proliferation and inducers of apoptosis in both KRAS and BRAF mutated human colorectal cancer cells. PMID: 19344998 Ref: Somatic alterations, metabolizing genes and smoking in rectal cancer. PMID: 19358278 Ref: Identification of pyrazolo[1,5-a]pyrimidine-3-carboxylates as B-Raf kinase inhibitors. PMID: 19362830 Ref: KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. PMID: 19372556 Ref: Selective inhibition of proliferation in colorectal carcinoma cell lines expressing mutant APC or activated B-Raf. PMID: 19378335 Ref: Utility of p16 immunohistochemistry for the identification of Lynch syndrome. PMID: 19383812 Ref: MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas. PMID: 19411838 Ref: Aurora-A expression is independently associated with chromosomal instability in colorectal cancer. PMID: 19412426 Ref: Analysis of a correlation between the BRAF V600E mutation and abnormal DNA mismatch repair in patients with sporadic endometrial cancer. PMID: 19424571 Ref: Efficient molecular screening of Lynch syndrome by specific 3' promoter methylation of the MLH1 or BRAF mutation in colorectal cancer with high-frequency microsatellite instability. PMID: 19424639 Ref: Implementation of novel pyrosequencing assays to screen for common mutations of BRAF and KRAS in a cohort of sporadic colorectal cancers. PMID: 19430299 Ref: SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. PMID: 19430421 Ref: Allelotyping, microsatellite instability, and BRAF mutation analyses in common and atypical melanocytic nevi and primary cutaneous melanomas. PMID: 19461239 Ref: DNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancer. PMID: 19470733 Ref: Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer. PMID: 19474002 Ref: Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors. PMID: 19492075 Ref: A cohort study of p27 localization in colon cancer, body mass index, and patient survival. PMID: 19505918 Ref: A cohort study of STMN1 expression in colorectal cancer: body mass index and prognosis. PMID: 19513025 Ref: Clinical biomarkers in oncology: focus on colorectal cancer. PMID: 19537845 Ref: A cohort study of cyclin D1 expression and prognosis in 602 colon cancer cases. PMID: 19549773 Ref: Pathologic features and biologic importance of colorectal serrated polyps. PMID: 19550369 Ref: Genetic pathways to colorectal cancer. PMID: 19576232 Ref: Chromosomally and microsatellite stable colorectal carcinomas without the CpG island methylator phenotype in a molecular classification. PMID: 19578746 Ref: Divergent oncogenic changes influence survival differences between colon and rectal adenocarcinomas. PMID: 19581844 Ref: MSH6 G39E polymorphism and CpG island methylator phenotype in colon cancer. PMID: 19582761 Ref: Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer. PMID: 19584150 Ref: Down-regulation of epidermal growth factor receptor by selective expansion of a 5'-end regulatory dinucleotide repeat in colon cancer with microsatellite instability. PMID: 19584170 Ref: KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. PMID: 19603018 Ref: [Status of components in EGFR-related signal transduction as predictive markers for anti-EGFR antibody therapy in colorectal cancer treatment]. PMID: 19620792 Ref: Genetic and molecular diversity of colon cancer hepatic metastases. PMID: 19628078 Ref: Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. PMID: 19637312 Ref: TRAIL receptor upregulation and the implication of KRAS/BRAF mutations in human colon cancer tumors. PMID: 19637313 Ref: A novel K-ras mutation in colorectal cancer. A case report and literature review. PMID: 19661358 Ref: Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. PMID: 19661383 Ref: Anti-EGFR therapy in colorectal cancer: how to choose the right patient. PMID: 19663767 Ref: Microsatellite instability and survival in rectal cancer. PMID: 19669908 Ref: Oncogenic activating mutations are associated with local copy gain. PMID: 19671679 Ref: A gene marker panel covering the Wnt and the Ras-Raf-MEK-MAPK signalling pathways allows to detect gene mutations in 80% of early (UICC I) colon cancer stages in humans. PMID: 19679059 Ref: A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers. PMID: 19686742 Ref: Tissue biomarker development in a multicentre trial context: a feasibility study on the PETACC3 stage II and III colon cancer adjuvant treatment trial. PMID: 19690194 Ref: Oncogenic Ras, but not (V600E)B-RAF, protects from cholesterol depletion-induced apoptosis through the PI3K/AKT pathway in colorectal cancer cells. PMID: 19700418 Ref: Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers. PMID: 19704056 Ref: p21 expression in colon cancer and modifying effects of patient age and body mass index on prognosis. PMID: 19723919 Ref: Concordant DNA methylation in synchronous colorectal carcinomas. PMID: 19737982 Ref: Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. PMID: 19738166 Ref: Beta-catenin nuclear labeling is a common feature of sessile serrated adenomas and correlates with early neoplastic progression after BRAF activation. PMID: 19745699 Ref: Methylation in p14(ARF) is frequently observed in colorectal cancer with low-level microsatellite instability. PMID: 19761686 Ref: Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer. PMID: 19787768 Ref: An A13 repeat within the 3'-untranslated region of epidermal growth factor receptor (EGFR) is frequently mutated in microsatellite instability colon cancers and is associated with increased EGFR expression. PMID: 19789347 Ref: Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer. PMID: 19789368 Ref: Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PMID: 19806185 Ref: Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. PMID: 19825961 Ref: Oncogenic KRAS and BRAF differentially regulate hypoxia-inducible factor-1alpha and -2alpha in colon cancer. PMID: 19843849 Ref: Efficacy of IGFBP7 for treatment of metastatic melanoma and other cancers in mouse models and human cell lines. PMID: 19861408 Ref: BRAF(V600E) efficient transformation and induction of microsatellite instability versus KRAS(G12V) induction of senescence markers in human colon cancer cells. PMID: 19881948 Ref: KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. PMID: 19884549 Ref: PIK3CA mutations predict local recurrences in rectal cancer patients. PMID: 19903786 Ref: Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers. PMID: 19911194 Ref: Assessing tumor mutations to gain insight into base excision repair sequence polymorphisms and smoking in colon cancer. PMID: 19959686 Ref: Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling. PMID: 20027224 Ref: The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway. PMID: 20130433 Ref: Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy. PMID: 20300583 Ref: Medical treatment of advanced colorectal cancer in 2009. PMID: 21789113 |
Ref: IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype. PMID: 19638426 Ref: CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation, other molecular alterations and patient survival. PMID: 19790197 Ref: Negative lymph node count is associated with survival of colorectal cancer patients, independent of tumoral molecular alterations and lymphocytic reaction. PMID: 19809407 Ref: Geldanamycin and its anti-cancer activities. PMID: 19850405 Ref: Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis. PMID: 19908233 Ref: KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy. PMID: 19913317 Ref: Prognostic and predictive value of TOPK stratified by KRAS and BRAF gene alterations in sporadic, hereditary and metastatic colorectal cancer patients. PMID: 19935791 Ref: Selection of patients with germline MLH1 mutated Lynch syndrome by determination of MLH1 methylation and BRAF mutation. PMID: 19949877 Ref: Mixed lineage kinase 3 gene mutations in mismatch repair deficient gastrointestinal tumours. PMID: 19955118 Ref: Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. PMID: 20008640 Ref: Mismatch repair protein expression and colorectal cancer in Hispanics from Puerto Rico. PMID: 20012372 Ref: Three DNA methylation epigenotypes in human colorectal cancer. PMID: 20028768 Ref: Taiwan hospital-based detection of Lynch syndrome distinguishes 2 types of microsatellite instabilities in colorectal cancers. PMID: 20045164 Ref: KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. PMID: 20049644 Ref: Performance of clinical guidelines compared with molecular tumour screening methods in identifying possible Lynch syndrome among colorectal cancer patients: a Norwegian population-based study. PMID: 20051945 Ref: [Prerequisites to the administration and prevention of adverse effects of chemotherapy in colorectal cancer]. PMID: 20080456 Ref: Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients. PMID: 20088793 Ref: Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes. PMID: 20098682 Ref: Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. PMID: 20100961 Ref: Aberrant DNA methylation in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency. PMID: 20102720 Ref: Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. PMID: 20103678 Ref: Predicting response to EGFR inhibitors in metastatic colorectal cancer: current practice and future directions. PMID: 20133499 Ref: TAp73 is one of the genes responsible for the lack of response to chemotherapy depending on B-Raf mutational status. PMID: 20146801 Ref: Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer. PMID: 20162668 Ref: High Erk activity suppresses expression of the cell cycle inhibitor p27Kip1 in colorectal cancer cells. PMID: 20181064 Ref: Rapid multiplex real-time PCR by molecular beacons for different BRAF allele detection in papillary thyroid carcinoma. PMID: 20186005 Ref: The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status. PMID: 20197478 Ref: PTGER2 overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype. PMID: 20200425 Ref: Smoking, gender, and ethnicity predict somatic BRAF mutations in colorectal cancer. PMID: 20200438 Ref: Dietary, lifestyle and clinicopathological factors associated with BRAF and K-ras mutations arising in distinct subsets of colorectal cancers in the EPIC Norfolk study. PMID: 20233436 Ref: A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. PMID: 20233444 Ref: Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients. PMID: 20234366 Ref: Is BRAF mutation associated with interval colorectal cancers? PMID: 20300843 Ref: HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers. PMID: 20363910 Ref: KRas and BRaf mutational status analysis from formalin-fixed, paraffin-embedded tissues using multiplex polymerase chain reaction-based assay. PMID: 20367313 Ref: Polymorphisms in methyl-group metabolism genes and risk of sporadic colorectal cancer with relation to the CpG island methylator phenotype. PMID: 20381446 Ref: Oncogenic mutations as predictive factors in colorectal cancer. PMID: 20383189 Ref: Colorectal cancer screening - methodology. PMID: 20400027 Ref: Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. PMID: 20413299 Ref: Molecular biology from bench-to-bedside - which colorectal cancer patients should be referred for genetic counselling and risk assessment. PMID: 20417091 Ref: Early onset MSI-H colon cancer with MLH1 promoter methylation, is there a genetic predisposition? PMID: 20444249 Ref: Sulindac reverses aberrant expression and localization of beta-catenin in papillary thyroid cancer cells with the BRAFV600E mutation. PMID: 20470206 Ref: Methylation analysis of MLH1 improves the selection of patients for genetic testing in Lynch syndrome. PMID: 20489114 Ref: Comprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clinicopathological and molecular features. PMID: 20492682 Ref: Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. PMID: 20494973 Ref: PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma. PMID: 20496265 Ref: BRAF mutations in sporadic colorectal carcinoma from polish patients. PMID: 20496269 Ref: The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. PMID: 20501503 Ref: Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors. PMID: 20507599 Ref: Molecular markers in the treatment of metastatic colorectal cancer. PMID: 20526105 Ref: Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development. PMID: 20530704 Ref: Increased cancer predisposition in family members of colorectal cancer patients harboring the p.V600E BRAF mutation: a population-based study. PMID: 20570909 Ref: A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. PMID: 20584808 Ref: Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. PMID: 20587792 Ref: Novel hinge binder improves activity and pharmacokinetic properties of BRAF inhibitors. PMID: 20597484 Ref: T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells. PMID: 20616015 Ref: The use of COLD-PCR and high-resolution melting analysis improves the limit of detection of KRAS and BRAF mutations in colorectal cancer. PMID: 20616366 Ref: Cycleave polymerase chain reaction method is practically applicable for V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)/V-raf murine sarcoma viral oncogene homolog B1 (BRAF) genotyping in colorectal cancer. PMID: 20627194 Ref: Integrating biomarkers into clinical decision making for colorectal cancer. PMID: 20630847 Ref: Targeted therapy in advanced colorectal cancer: more data, more questions. PMID: 20631611 Ref: KRAS and BRAF mutation analysis from liquid-based cytology brushings of colorectal carcinoma in comparison with formalin-fixed, paraffin-embedded tissue. PMID: 20651341 Ref: Gene mutations in epidermal growth factor receptor signaling network and their association with survival in Chinese patients with metastatic colorectal cancers. PMID: 20652941 Ref: Low frequency of Lynch syndrome among young patients with non-familial colorectal cancer. PMID: 20655395 Ref: Characterization of rectal, proximal and distal colon cancers based on clinicopathological, molecular and protein profiles. PMID: 20664940 Ref: BRAF mutation testing in colorectal cancer. PMID: 20670148 Ref: Hypomethylation of the IGF2 DMR in colorectal tumors, detected by bisulfite pyrosequencing, is associated with poor prognosis. PMID: 20682317 Ref: The genetic basis of colorectal cancer in a population-based incident cohort with a high rate of familial disease. PMID: 20682701 Ref: Mutations in the WTX-gene are found in some high-grade microsatellite instable (MSI-H) colorectal cancers. PMID: 20696052 Ref: Improved testing for microsatellite instability in colorectal cancer using a simplified 3-marker assay. PMID: 20703819 Ref: Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. PMID: 20713879 Ref: KRAS mutation testing of colorectal cancer for anti-EGFR therapy: dogmas versus evidence. PMID: 20718705 Ref: Predictive molecular markers of response to epidermal growth factor receptor(EGFR) family-targeted therapies. PMID: 20718710 Ref: BRAF testing in advanced colorectal cancer: is it ready for prime time? PMID: 20733556 Ref: NRAS mutations are rare in colorectal cancer. PMID: 20736745 Ref: Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer. PMID: 20808308 Ref: Cathepsin B expression and survival in colon cancer: implications for molecular detection of neoplasia. PMID: 20833970 Ref: Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer. PMID: 20923857 Ref: MSH6 and MUTYH deficiency is a frequent event in early-onset colorectal cancer. PMID: 20924129 Ref: Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. PMID: 20927778 Ref: Colorectal cancer: cetuximab, KRAS, BRAF, PIK3CA mutations and beyond. PMID: 20932136 Ref: The serine protease inhibitor serpinE2 is a novel target of ERK signaling involved in human colorectal tumorigenesis. PMID: 20942929 Ref: Development of sporadic microsatellite instability in colorectal tumors involves hypermethylation at methylated-in-tumor loci in adenoma. PMID: 20952593 Ref: BRAF p.Val600Glu (V600E) Testing for Assessment of Treatment Options in Metastatic Colorectal Cancer. PMID: 20972475 Ref: Colorectal carcinomas with microsatellite instability display a different pattern of target gene mutations according to large bowel site of origin. PMID: 20979647 Ref: Novel application of structural equation modeling to correlation structure analysis of CpG island methylation in colorectal cancer. PMID: 21037082 Ref: Activation of signal pathways and the resistance to anti-EGFR treatment in colorectal cancer. PMID: 21053280 Ref: [Colorectal serrated lesions: current insight on their role in colorectal carcinogenesis]. PMID: 21053517 Ref: BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. PMID: 21098728 Ref: DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CA-PTEN-TP53 related to age at disease onset. PMID: 21103049 Ref: Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? PMID: 21129611 Ref: Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer. PMID: 21139621 Ref: Mutation analysis of BRAF exon 15 and KRAS codons 12 and 13 in Moroccan patients with colorectal cancer. PMID: 21161938 Ref: Predictive and prognostic factors in the complex treatment of patients with colorectal cancer. PMID: 21163770 Ref: [Clinical significance of BRAF mutations in colorectal cancer]. PMID: 21220223 Ref: Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study. PMID: 21474966 Ref: Detection of up to 65% of Precancerous Lesions of the Human Colon and Rectum by Mutation Analysis of APC, K-Ras, B-Raf and CTNNB1. PMID: 24212608 |
Ref: Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review. PMID: 20473920 Ref: KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer. PMID: 20563851 Ref: PIK3CA mutations in KRAS and BRAF wild type colorectal cancer patients. A study of Spanish population. PMID: 20571907 Ref: Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. PMID: 20635392 Ref: Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer. PMID: 20645028 Ref: Signet-ring cell carcinoma of colorectum--current perspectives and molecular biology. PMID: 20686774 Ref: Germline mutation in BRAF codon 600 is compatible with human development: de novo p.V600G mutation identified in a patient with CFC syndrome. PMID: 20735442 Ref: EGFR and HER3 mRNA expression levels predict distant metastases in locally advanced rectal cancer. PMID: 20824716 Ref: KRAS and BRAF mutation analysis can be reliably performed on aspirated cytological specimens of metastatic colorectal carcinoma. PMID: 21029218 Ref: Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. PMID: 21036793 Ref: Co-expression of matrix metalloproteinase-7 (MMP-7) and phosphorylated insulin growth factor receptor I (pIGF-1R) correlates with poor prognosis in patients with wild-type KRAS treated with cetuximab or panitumumab: a GEMCAD study. PMID: 21099348 Ref: Methylation of the 3p22 region encompassing MLH1 is representative of the CpG island methylator phenotype in colorectal cancer. PMID: 21102416 Ref: Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab. PMID: 21104178 Ref: Gene-environment interactions in the pre-Industrial Era: the cancer of King Ferrante I of Aragon (1431-1494). PMID: 21111451 Ref: MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers. PMID: 21140203 Ref: Two groups of DNA methylation markers to classify colorectal cancer into three epigenotypes. PMID: 21159060 Ref: KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. PMID: 21163703 Ref: Effect of classification based on combination of mutation and methylation in colorectal cancer prognosis. PMID: 21174064 Ref: PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. PMID: 21216929 Ref: Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping. PMID: 21227396 Ref: Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer. PMID: 21233242 Ref: Downregulation of the hedgehog receptor PTCH1 in colorectal serrated adenocarcinomas is not caused by PTCH1 mutations. PMID: 21234763 Ref: KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. PMID: 21239505 Ref: A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer. PMID: 21273607 Ref: B-Raf mutations, microsatellite instability and p53 protein expression in sporadic basal cell carcinomas. PMID: 21274671 Ref: Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in >/= 2 line cetuximab-based therapy of colorectal cancer patients. PMID: 21283802 Ref: BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. PMID: 21285991 Ref: BRAF p.Val600Glu (V600E) somatic mutation is mainly associated with MSS phenotype in metastatic colorectal cancer. PMID: 21289333 Ref: Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. PMID: 21305640 Ref: STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers. PMID: 21310826 Ref: A novel case of rhabdoid colon carcinoma associated with a positive CpG island methylator phenotype and BRAF mutation. PMID: 21315413 Ref: Analysis of K-ras, BRAF, and PIK3CA mutations in laterally-spreading tumors of the colorectum. PMID: 21332555 Ref: Clinicopathological and molecular characterization of colorectal micropapillary carcinoma. PMID: 21336262 Ref: Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer. PMID: 21340604 Ref: The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer. PMID: 21356164 Ref: Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. PMID: 21383284 Ref: Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients. PMID: 21390154 Ref: Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. PMID: 21398618 Ref: Up and downregulation of p16(Ink4a) expression in BRAF-mutated polyps/adenomas indicates a senescence barrier in the serrated route to colon cancer. PMID: 21423154 Ref: KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer. PMID: 21424126 Ref: Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers. PMID: 21425139 Ref: Molecular predictors of response to chemotherapy in colorectal cancer. PMID: 21427555 Ref: Clinically important molecular features of Peruvian colorectal tumours: high prevalence of DNA mismatch repair deficiency and low incidence of KRAS mutations. PMID: 21436632 Ref: Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. PMID: 21447798 Ref: High frequency of genes' promoter methylation, but lack of BRAF V600E mutation among Iranian colorectal cancer patients. PMID: 21455633 Ref: Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. PMID: 21456008 Ref: The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models. PMID: 21464044 Ref: Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing. PMID: 21483104 Ref: DNA methylation predicts recurrence from resected stage III proximal colon cancer. PMID: 21509761 Ref: Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls. PMID: 21516079 Ref: Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. PMID: 21521850 Ref: Molecular diagnostics of colorectal cancer. PMID: 21526956 Ref: Mutations in BRAF correlate with poor survival of colorectal cancers in Chinese population. PMID: 21553007 Ref: Analysis of the anti-tumor effect of cetuximab using protein kinetics and mouse xenograft models. PMID: 21554739 Ref: Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer. PMID: 21558395 Ref: Promoter methylation of Wnt5a is associated with microsatellite instability and BRAF V600E mutation in two large populations of colorectal cancer patients. PMID: 21587258 Ref: Clinical features and molecular alterations of traditional serrated adenoma in sporadic colorectal carcinogenesis. PMID: 21615873 Ref: Relative role of methylator and tumor suppressor pathways in ulcerative colitis-associated colon cancer. PMID: 21618350 Ref: Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. PMID: 21632860 Ref: A serrated colorectal cancer pathway predominates over the classic WNT pathway in patients with hyperplastic polyposis syndrome. PMID: 21641392 Ref: Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. PMID: 21641636 Ref: Molecular profile and copy number analysis of sporadic colorectal cancer in Taiwan. PMID: 21645411 Ref: Impact of KRAS and BRAF gene mutations on targeted therapies in colorectal cancer. PMID: 21646605 Ref: Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. PMID: 21646616 Ref: Serrated polyposis: an enigmatic model of colorectal cancer predisposition. PMID: 21660283 Ref: Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features. PMID: 21660972 Ref: Distinctive patterns of p53 protein expression and microsatellite instability in human colorectal cancer. PMID: 21665242 Ref: The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy. PMID: 21671463 Ref: Molecular alterations associated with liver metastases development in colorectal cancer patients. PMID: 21673680 Ref: A correction to the research article titled: "Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells" by A. S. Little, K. Balmanno, M. J. Sale, S. Newman, J. R. Dry, M. Hampson, P PMID: 21674991 Ref: Use of bevacizumab in metastatic colorectal cancer: report from the Mexican opinion and analysis forum on colorectal cancer treatment with bevacizumab (September 2009). PMID: 21679003 Ref: Cten is targeted by Kras signalling to regulate cell motility in the colon and pancreas. PMID: 21698197 Ref: KRAS, NRAS, PIK3CA exon 20, and BRAF genotypes in synchronous and metachronous primary colorectal cancers diagnostic and therapeutic implications. PMID: 21704278 Ref: Comparison of allelic discrimination by dHPLC, HRM, and TaqMan in the detection of BRAF mutation V600E. PMID: 21708284 Ref: Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours. PMID: 21712828 Ref: Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? PMID: 21729677 Ref: Development of molecular biomarkers in individualized treatment of colorectal cancer. PMID: 21729679 Ref: B vitamins, methionine and alcohol intake and risk of colon cancer in relation to BRAF mutation and CpG island methylator phenotype (CIMP). PMID: 21738611 Ref: Selective BRAFV600E inhibitor PLX4720, requires TRAIL assistance to overcome oncogenic PIK3CA resistance. PMID: 21738740 Ref: Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review. PMID: 21742964 Ref: VEGFA gene locus (6p12) amplification identifies a small but highly aggressive subgroup of colorectal cancer [corrected] patients. PMID: 21743435 Ref: Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. PMID: 21768580 Ref: [Predictive biomarkers of anti-EGFR monoclonal anti-body in colorectal cancer]. PMID: 21772090 Ref: Validation microsatellite path score in a population-based cohort of patients with colorectal cancer. PMID: 21788563 Ref: Predictive molecular classifiers in colorectal cancer. PMID: 21810517 Ref: [KRAS mutation test]. PMID: 21815483 Ref: Cancer immunology--analysis of host and tumor factors for personalized medicine. PMID: 21826083 Ref: The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy. PMID: 21827707 Ref: PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PMID: 21829508 Ref: Lynch syndrome screening implementation: business analysis by a healthcare system. PMID: 21851136 Ref: Quantitative validation of GJC1 promoter hypermethylation in benign and malignant colorectal tumors. PMID: 21868474 Ref: Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. PMID: 21900593 Ref: Alcohol intake and colorectal cancer risk by molecularly defined subtypes in a prospective study of older women. PMID: 21900595 Ref: Molecular genetic analysis of 103 sporadic colorectal tumours in Czech patients. PMID: 21901162 Ref: Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy. PMID: 21910869 Ref: Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients. PMID: 21931273 Ref: [Tm analysis method using a quenching probe is a simple and rapid way to simultaneously detect KRAS and BRAF mutations]. PMID: 21942085 Ref: BRAF and RAS oncogenes regulate Rho GTPase pathways to mediate migration and invasion properties in human colon cancer cells: a comparative study. PMID: 21943101 Ref: Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing. PMID: 21943394 Ref: Analysis of DNA mismatch repair proteins expression and BRAF V600E mutation in a subset of early- and late-onset colorectal carcinoma patients in Mexico. PMID: 21945875 Ref: TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancers. PMID: 21949851 Ref: Microsatellite instability and colorectal cancer. PMID: 21970482 Ref: Anti-EGFR therapy in first-line colorectal cancer. PMID: 21999123 Ref: Detection of KRAS and BRAF mutations in advanced colorectal cancer by allele-specific single-base primer extension. PMID: 22022941 Ref: BRAF mutations in advanced cancers: clinical characteristics and outcomes. PMID: 22039425 Ref: Biomarker use in colorectal cancer therapy. PMID: 22056657 Ref: Frequency of KRAS, BRAF, and PIK3CA mutations in advanced colorectal cancers: Comparison of peptide nucleic acid-mediated PCR clamping and direct sequencing in formalin-fixed, paraffin-embedded tissue. PMID: 22070922 Ref: KRAS and BRAF mutation status in patients with sporadic colorectal cancer: data from two different Mediterranean countries. PMID: 22139644 Ref: [Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer]. PMID: 22145213 Ref: Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. PMID: 22174910 Ref: Neuroendocrine and squamous colonic composite carcinoma: case report with molecular analysis. PMID: 22180717 Ref: Signaling pathways in hepatocellular carcinoma. PMID: 22212931 Ref: Digital pathology in personalized cancer therapy. PMID: 22252751 Ref: A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. PMID: 22586653 Ref: Sessile serrated adenoma shares similar genetic and epigenetic features with microsatellite unstable colon cancer in a location-dependent manner. PMID: 22977561 Ref: Wild-Type KRAS and BRAF Could Predict Response to Cetuximab in Chinese Colorectal Cancer Patients. PMID: 23357879 Ref: Predictive and prognostic factors in colorectal cancer: a personalized approach. PMID: 24212777 Ref: Review of histopathological and molecular prognostic features in colorectal cancer. PMID: 24212832 |
Ref: Review of biomarkers in colorectal cancer. PMID: 21040359 Ref: Increased frequency of 20q gain and copy-neutral loss of heterozygosity in mismatch repair proficient familial colorectal carcinomas. PMID: 21445971 Ref: A distinct DNA methylation profile associated with microsatellite and chromosomal stable sporadic colorectal cancers. PMID: 21455990 Ref: Evaluation of predictive models in daily practice for the identification of patients with Lynch syndrome. PMID: 21520036 Ref: p53 mutation is common in microsatellite stable, BRAF mutant colorectal cancers. PMID: 21557216 Ref: Genome-scale analysis of aberrant DNA methylation in colorectal cancer. PMID: 21659424 Ref: Association between methylation in mismatch repair genes, V600E BRAF mutation and microsatellite instability in colorectal cancer patients. PMID: 21681432 Ref: Rhabdoid carcinoma of the colon: a distinct entity with a very aggressive behavior: a case report associated with a polyposis coli and review of the literature. PMID: 21791485 Ref: Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer. PMID: 21813336 Ref: The effect of a dimeric Affibody molecule (ZEGFR:1907)2 targeting EGFR in combination with radiation in colon cancer cell lines. PMID: 21879255 Ref: Oncogenic PIK3CA mutations in colorectal cancers and polyps. PMID: 21932420 Ref: CpG island methylator phenotype infers a poor disease-free survival in locally advanced rectal cancer. PMID: 22001634 Ref: Assessment of three epigenotypes in colorectal cancer by combined bisulfite restriction analysis. PMID: 22006538 Ref: Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. PMID: 22012135 Ref: Postmenopausal hormone therapy and colorectal cancer risk by molecularly defined subtypes among older women. PMID: 22027477 Ref: Tumor TP53 expression status, body mass index and prognosis in colorectal cancer. PMID: 22038927 Ref: Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers? PMID: 22043994 Ref: Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution. PMID: 22114137 Ref: Intermediate methylation epigenotype and its correlation to KRAS mutation in conventional colorectal adenoma. PMID: 22115708 Ref: A state-wide population-based program for detection of lynch syndrome based upon immunohistochemical and molecular testing of colorectal tumours. PMID: 22120844 Ref: Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. PMID: 22147942 Ref: No evidence for PML-RARa bcr1 fusion gene in colorectal cancer. PMID: 22167334 Ref: Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment. PMID: 22173549 Ref: Externalization of saw-tooth architecture in small serrated polyps implies the presence of methylation of IGFBP7. PMID: 22173745 Ref: Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. PMID: 22180495 Ref: Prognostic significance and molecular associations of tumor growth pattern in colorectal cancer. PMID: 22189472 Ref: High-frequency microsatellite instability and BRAF mutation (V600E) in unselected Serbian patients with colorectal cancer. PMID: 22210186 Ref: BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis. PMID: 22228154 Ref: Clinicopathologic and molecular characteristics of synchronous colorectal cancers: heterogeneity of clinical outcome depending on microsatellite instability status of individual tumors. PMID: 22228162 Ref: Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. PMID: 22228631 Ref: Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients:implications for cancer therapy. PMID: 22229245 Ref: A novel pit pattern identifies the precursor of colorectal cancer derived from sessile serrated adenoma. PMID: 22233696 Ref: Role of oncogenic pathways and KRAS/BRAF mutations in the behavior of colon adenocarcinoma in renal transplant patients. PMID: 22245873 Ref: Real-time PCR-based analysis of BRAF V600E mutation in low and intermediate grade lymphomas confirms frequent occurrence in hairy cell leukaemia. PMID: 22246856 Ref: Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling. PMID: 22260668 Ref: The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. PMID: 22261800 Ref: mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors. PMID: 22262166 Ref: Emerging role of cetuximab in the treatment of colorectal cancer. PMID: 22264223 Ref: MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study. PMID: 22274583 Ref: Clinical and molecular detection of inherited colorectal cancers in northeast Italy: a first prospective study of incidence of Lynch syndrome and MUTYH-related colorectal cancer in Italy. PMID: 22278153 Ref: Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. PMID: 22281684 Ref: Relationship between 18F-fluorodeoxyglucose accumulation and KRAS/BRAF mutations in colorectal cancer. PMID: 22282467 Ref: PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. PMID: 22285706 Ref: Colorectal serrated adenocarcinoma shows a different profile of oncogene mutations, MSI status and DNA repair protein expression compared to conventional and sporadic MSI-H carcinomas. PMID: 22287190 Ref: [Prognostic marker profiles for risk of distant metastases in colorectal cancer]. PMID: 22293788 Ref: Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. PMID: 22302899 Ref: BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. PMID: 22314188 Ref: CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity. PMID: 22319199 Ref: Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. PMID: 22357840 Ref: Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification. PMID: 22368298 Ref: KRAS mutational test for metastatic colorectal cancer patients: not just a technical problem. PMID: 22369372 Ref: ERK/pERK expression and B-raf mutations in colon adenocarcinomas: correlation with clinicopathological characteristics. PMID: 22376079 Ref: Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. PMID: 22392911 Ref: Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer. PMID: 22393095 Ref: Molecular alterations in colitis-associated colorectal neoplasia: study from a low prevalence area using magnifying chromo colonoscopy. PMID: 22398042 Ref: Combined mutational analysis of KRAS, NRAS and BRAF genes in Indian patients with colorectal carcinoma. PMID: 22427190 Ref: Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. PMID: 22427238 Ref: Development of invasive colon cancer with microsatellite instability in a patient with hyperplastic polyposis syndrome. PMID: 22438407 Ref: Concordance in KRAS and BRAF mutations in endoscopic biopsy samples and resection specimens of colorectal adenocarcinoma. PMID: 22446020 Ref: EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. PMID: 22448344 Ref: Aberrant B-Raf signaling in human cancer -- 10 years from bench to bedside. PMID: 22471666 Ref: Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). PMID: 22473163 Ref: Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features. PMID: 22481281 Ref: Mutation pattern of KRAS and BRAF oncogenes in colorectal cancer patients. PMID: 22489692 Ref: Mutations in the Ras-Raf Axis underlie the prognostic value of CD133 in colorectal cancer. PMID: 22496204 Ref: Predictors of lymph node count in colorectal cancer resections: data from US nationwide prospective cohort studies. PMID: 22508672 Ref: Phenotype and polyp landscape in serrated polyposis syndrome: a series of 100 patients from genetics clinics. PMID: 22510757 Ref: A molecular signature for oncogenic BRAF in human colon cancer cells is revealed by microarray analysis. PMID: 22515520 Ref: Meta-analysis of the predictive value of KRAS mutations in treatment response using cetuximab in colorectal cancer. PMID: 22517696 Ref: Body size and risk for colorectal cancers showing BRAF mutations or microsatellite instability: a pooled analysis. PMID: 22531127 Ref: Regorafenib for cancer. PMID: 22577890 Ref: Characteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population. PMID: 22579930 Ref: KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer. PMID: 22586484 Ref: Utility of cell-free tumour DNA for post-surgical follow-up of colorectal cancer patients. PMID: 22593440 Ref: The importance of examining the proportion of circulating DNA originating from tumor, microenvironment and normal cells in colorectal cancer patients. PMID: 22594497 Ref: Hypericum androsaemum water extract inhibits proliferation in human colorectal cancer cells through effects on MAP kinases and PI3K/Akt pathway. PMID: 22596086 Ref: Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. PMID: 22608338 Ref: Clinical outcomes of patients with microsatellite-unstable colorectal carcinomas depend on L1 methylation level. PMID: 22618722 Ref: [Biomarker for colorectal cancer]. PMID: 22620004 Ref: A role for the epidermal growth factor receptor signaling in development of intestinal serrated polyps in mice and humans. PMID: 22643351 Ref: Serrated polyposis syndrome: molecular, pathological and clinical aspects. PMID: 22654442 Ref: Stratification and Prognostic Relevance of Jass's Molecular Classification of Colorectal Cancer. PMID: 22655257 Ref: Comparative genomic analysis of primary versus metastatic colorectal carcinomas. PMID: 22665543 Ref: KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. PMID: 22675430 Ref: Histological and molecular evaluation of patient-derived colorectal cancer explants. PMID: 22675560 Ref: Proximal colon cancers and the serrated pathway: a systematic analysis of precursor histology and BRAF mutation status. PMID: 22684223 Ref: Influence of patient preferences on the cost-effectiveness of screening for Lynch syndrome. PMID: 22694112 Ref: Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior. PMID: 22712570 Ref: KRAS mutant colorectal tumors: past and present. PMID: 22714415 Ref: Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials. PMID: 22723336 Ref: Acquired/intratumoral mutation of KRAS during metastatic progression of colorectal carcinogenesis. PMID: 22740969 Ref: Prognostic relevance of occult metastases detected by cytokeratin 20 and mucin 2 mRNA levels in sentinel lymph nodes from colon cancer patients. PMID: 22752373 Ref: Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. PMID: 22753589 Ref: A comprehensive procedural approach to genotyping KRAS and BRAF from paraffin embedded tissues for diagnostic purposes. PMID: 22773565 Ref: Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. PMID: 22773810 Ref: Qualities of sessile serrated adenoma/polyp/lesion and its borderline variant in the context of synchronous colorectal carcinoma. PMID: 22782936 Ref: CpG Island Methylation, Microsatellite Instability, and BRAF Mutations and Their Clinical Application in the Treatment of Colon Cancer. PMID: 22792460 Ref: KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the lung. PMID: 22797671 Ref: The impact of CpG island methylator phenotype and microsatellite instability on tumour budding in colorectal cancer. PMID: 22803799 Ref: Expression of Abelson interactor 1 (Abi1) correlates with inflammation, KRAS mutation and adenomatous change during colonic carcinogenesis. PMID: 22808230 Ref: K-Ras and B-Raf oncogenes inhibit colon epithelial polarity establishment through up-regulation of c-myc. PMID: 22826122 Ref: Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer. PMID: 22840368 Ref: Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing. PMID: 22845480 Ref: Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). PMID: 22855150 Ref: A comprehensive characterization of genome-wide copy number aberrations in colorectal cancer reveals novel oncogenes and patterns of alterations. PMID: 22860045 Ref: The response to PAK1 inhibitor IPA3 distinguishes between cancer cells with mutations in BRAF and Ras oncogenes. PMID: 22869096 Ref: Prognostic impact of FoxP3+ regulatory T cells in relation to CD8+ T lymphocyte density in human colon carcinomas. PMID: 22879926 Ref: The utility of diagnostic biopsy specimens for predictive molecular testing in colorectal cancer. PMID: 22882224 Ref: Influence of anatomical subsite on the incidence of microsatellite instability, and KRAS and BRAF mutation rates in patients with colon carcinoma. PMID: 22898351 Ref: BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics. PMID: 22899730 Ref: K-Ras gene mutation status as a prognostic and predictive factor in patients with colorectal cancer undergoing irinotecan- or oxaliplatin-based chemotherapy. PMID: 22909976 Ref: Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations. PMID: 22911782 Ref: Combination therapy targeting Raf-1 and MEK causes apoptosis of HCT116 colon cancer cells. PMID: 22922669 Ref: Characterization of CDKN2A(p16) methylation and impact in colorectal cancer: systematic analysis using pyrosequencing. PMID: 22925370 Ref: Digital pathology in personalized cancer therapy. PMID: 22925795 Ref: Aberrant promoter methylation of beta-1,4 galactosyltransferase 1 as potential cancer-specific biomarker of colorectal tumors. PMID: 22927297 Ref: Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia. PMID: 22931052 Ref: High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS , BRAF , PIK3CA , and AKT1 mutations in formalin-fixed, paraffin-embedded tissues. PMID: 22938585 Ref: Influence of patient preferences on the cost-effectiveness of screening for lynch syndrome. PMID: 22942831 Ref: Possibility of molecular targeting therapy for the treatment of cancer of unknown primary origin by analysis of intracellular signaling molecules. PMID: 22969927 Ref: Molecular dissection of premalignant colorectal lesions reveals early onset of the CpG island methylator phenotype. PMID: 22995252 Ref: Mutation specific antibodies: tool or dinosaur? PMID: 23006938 Ref: KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab. PMID: 23027075 Ref: KRAS and BRAF mutations in Serbian patients with colorectal cancer. PMID: 23033302 Ref: Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. PMID: 23045248 Ref: Up-regulation of c-MYC and SIRT1 expression correlates with malignant transformation in the serrated route to colorectal cancer. PMID: 23045412 Ref: A high degree of LINE-1 hypomethylation is a unique feature of early-onset colorectal cancer. PMID: 23049789 Ref: Meeting the biologic challenge of colorectal metastases. PMID: 23053740 Ref: Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer. PMID: 23055745 Ref: The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PMID: 23056577 Ref: Associations between intake of folate and related micronutrients with molecularly defined colorectal cancer risks in the Iowa Women's Health Study. PMID: 23061900 Ref: Synthesis and evaluation of apoptosis induction of thienopyrimidine compounds on KRAS and BRAF mutated colorectal cancer cell lines. PMID: 23063521 Ref: KRAS mutation testing in metastatic colorectal cancer. PMID: 23066310 Ref: The response of cancers to BRAF inhibition underscores the importance of cancer systems biology. PMID: 23074264 Ref: Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. PMID: 23094721 Ref: Integrative marker analysis allows risk assessment for metastasis in stage II colon cancer. PMID: 23095620 Ref: MUC5AC/beta-catenin expression and KRAS gene alteration in laterally spreading colorectal tumors. PMID: 23112547 Ref: Colorectal neuroendocrine carcinomas and adenocarcinomas share oncogenic pathways. A clinico-pathologic study of 12 cases. PMID: 23114745 Ref: Survey of KRAS, BRAF and PIK3CA mutational status in 209 consecutive Italian colorectal cancer patients. PMID: 23125007 Ref: BRAF mutations in colorectal cancer: clinical relevance and role in targeted therapy. PMID: 23138171 Ref: [Predictive biomarkers for anti-EGFR antibodies]. PMID: 23152013 Ref: Loss of expression of the double strand break repair protein ATM is associated with worse prognosis in colorectal cancer and loss of Ku70 expression is associated with CIN. PMID: 23154512 Ref: [Mutations of KRAS and BRAF in Chinese patients with colorectal carcinoma: analyses of 966 cases]. PMID: 23157823 Ref: [KRAS and BRAF gene mutations in correlation with clinicopathologic features of colorectal carcinoma in Chinese]. PMID: 23157824 Ref: [Detection of KRAS, BRAF, PIK3CA and EGFR gene mutations in colorectal carcinoma]. PMID: 23157825 Ref: MED12 controls the response to multiple cancer drugs through regulation of TGF-beta receptor signaling. PMID: 23178117 Ref: Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel. PMID: 23213241 Ref: Tumor phosphatidylinositol-3-kinase signaling and development of metastatic disease in locally advanced rectal cancer. PMID: 23226389 Ref: Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells. PMID: 23227266 Ref: Prevalence of different subtypes of serrated polyps and risk of synchronous advanced colorectal neoplasia in average-risk population undergoing first-time colonoscopy. PMID: 23238028 Ref: Establishment, characterization and chemosensitivity of three mismatch repair deficient cell lines from sporadic and inherited colorectal carcinomas. PMID: 23300683 Ref: Mutational analysis of key EGFR pathway genes in Chinese breast cancer patients. PMID: 23317280 Ref: Analysis of the BRAF(V600E) Mutation in Central Nervous System Tumors. PMID: 23323158 Ref: [Genetic and epigenetic changes in colorectal cancer and genetic testing for personalized medicine]. PMID: 23323463 Ref: High-resolution melting analysis of the common c.1905+1G>A mutation causing dihydropyrimidine dehydrogenase deficiency and lethal 5-fluorouracil toxicity. PMID: 23335937 Ref: Colorectal carcinoma under microscopy: patohistology or much more? PMID: 23373356 Ref: [Progress of anti-tumor study based on BRAF]. PMID: 23460959 |
Ref: Oncogenic KRAS and BRAF activation of the MEK/ERK signaling pathway promotes expression of dual-specificity phosphatase 4 (DUSP4/MKP2) resulting in nuclear ERK1/2 inhibition. PMID: 22430215 Ref: Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer. PMID: 22638623 Ref: Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations. PMID: 22647972 Ref: KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials. PMID: 22672749 Ref: Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases. PMID: 22786759 Ref: A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction. PMID: 22798500 Ref: MLH1-silenced and non-silenced subgroups of hypermutated colorectal carcinomas have distinct mutational landscapes. PMID: 22899370 Ref: Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer. PMID: 22936063 Ref: A multifactorial likelihood model for MMR gene variant classification incorporating probabilities based on sequence bioinformatics and tumor characteristics: a report from the Colon Cancer Family Registry. PMID: 22949379 Ref: The rs6983267 SNP is associated with MYC transcription efficiency, which promotes progression and worsens prognosis of colorectal cancer. PMID: 22976378 Ref: Molecular diagnostics and personalized medicine in oncology: challenges and opportunities. PMID: 22991232 Ref: Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability. PMID: 23010994 Ref: Molecular patterns in the evolution of serrated lesion of the colorectum. PMID: 23011871 Ref: KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines. PMID: 23015072 Ref: Bevacizumab in combination with chemotherapy in the first-line treatment of metastatic colorectal carcinoma. PMID: 23067221 Ref: Association between genomic alterations and metastatic behavior of colorectal cancer identified by array-based comparative genomic hybridization. PMID: 23073979 Ref: Protein tyrosine phosphatase receptor-like genes are frequently hypermethylated in sporadic colorectal cancer. PMID: 23096495 Ref: Non-CpG island promoter hypomethylation and miR-149 regulate the expression of SRPX2 in colorectal cancer. PMID: 23115050 Ref: Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression. PMID: 23128394 Ref: Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. PMID: 23136247 Ref: Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome. PMID: 23158210 Ref: Use of multivariate analysis to suggest a new molecular classification of colorectal cancer. PMID: 23165447 Ref: Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer. PMID: 23188063 Ref: Serrated polyps of the large intestine: current understanding of diagnosis, pathogenesis, and clinical management. PMID: 23208018 Ref: Multiplicity and molecular heterogeneity of colorectal carcinomas in individuals with serrated polyposis. PMID: 23211288 Ref: Knockdown of PAK4 or PAK1 inhibits the proliferation of mutant KRAS colon cancer cells independently of RAF/MEK/ERK and PI3K/AKT signaling. PMID: 23233484 Ref: The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance. PMID: 23234544 Ref: BRAF mutations in melanoma and colorectal cancer: a single oncogenic mutation with different tumour phenotypes and clinical implications. PMID: 23246082 Ref: Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. PMID: 23251002 Ref: Comparison of KRAS/BRAF mutations between primary tumors and serum in colorectal cancer: Biological and clinical implications. PMID: 23255930 Ref: KRAS and BRAF mutations in 203 esophageal squamous cell carcinomas: pyrosequencing technology and literature review. PMID: 23274581 Ref: A population-based study of hereditary non-polyposis colorectal cancer: evidence of pathologic and genetic heterogeneity. PMID: 23278430 Ref: Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. PMID: 23281932 Ref: Analysis of colorectal cancers in British Bangladeshi identifies early onset, frequent mucinous histotype and a high prevalence of RBFOX1 deletion. PMID: 23286373 Ref: The proto-oncogene KRAS and BRAF profiles and some clinical characteristics in colorectal cancer in the Turkish population. PMID: 23297805 Ref: Mixed lineage kinase MLK4 is activated in colorectal cancers where it synergistically cooperates with activated RAS signaling in driving tumorigenesis. PMID: 23319808 Ref: Sensitive electrochemical analysis of BRAF V600E mutation based on an amplification-refractory mutation system coupled with multienzyme functionalized Fe3O4/Au nanoparticles. PMID: 23321558 Ref: BRAF mutation-specific promoter methylation of FOX genes in colorectal cancer. PMID: 23324568 Ref: Duplex reverse-hybridization assay for the simultaneous detection of KRAS/BRAF mutations in FFPE-extracted genomic DNA from colorectal cancer specimens. PMID: 23324583 Ref: SATB1 expression is associated with biologic behavior in colorectal carcinoma in vitro and in vivo. PMID: 23326301 Ref: The serrated pathway to colorectal carcinoma: current concepts and challenges. PMID: 23339363 Ref: Epigenetic alterations in colorectal cancer: the CpG island methylator phenotype. PMID: 23341177 Ref: 3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer. PMID: 23341544 Ref: Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease. PMID: 23347191 Ref: Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features. PMID: 23348904 Ref: A correlation of the endoscopic characteristics of colonic laterally spreading tumours with genetic alterations. PMID: 23354161 Ref: Alternative splicing of BRAF transcripts and characterization of C-terminally truncated B-Raf isoforms in colorectal cancer. PMID: 23354951 Ref: Targeted therapies in colorectal cancer-an integrative view by PPPM. PMID: 23356214 Ref: Ibuprofen inhibits colitis-induced overexpression of tumor-related Rac1b. PMID: 23359345 Ref: Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. PMID: 23365119 Ref: Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. PMID: 23374602 Ref: Clinical subtypes and molecular characteristics of serrated polyposis syndrome. PMID: 23376323 Ref: Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing lynch syndrome in a large academic medical center. PMID: 23401454 Ref: Molecular pathways: mitogen-activated protein kinase pathway mutations and drug resistance. PMID: 23406774 Ref: Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial. PMID: 23412099 Ref: Right-sided rhabdoid colorectal tumors might be related to the serrated pathway. PMID: 23425390 Ref: Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy? PMID: 23429431 Ref: Regorafenib for gastrointestinal malignancies : from preclinical data to clinical results of a novel multi-target inhibitor. PMID: 23435872 Ref: Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision. PMID: 23446022 Ref: The role of EGFR monoclonal antibodies (MoABs) cetuximab/panitumab, and BRAF inhibitors in BRAF mutated colorectal cancer. PMID: 23451330 Ref: EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma. PMID: 23459231 Ref: Family history of colorectal cancer in BRAF p.V600E-mutated colorectal cancer cases. PMID: 23462926 Ref: RAC1b overexpression in papillary thyroid carcinoma: a role to unravel. PMID: 23482591 Ref: The KRAS StripAssay for detection of KRAS mutation in Egyptian patients with colorectal cancer (CRC): a pilot study. PMID: 23499205 Ref: Downregulation of DLC-1 gene by promoter methylation during primary colorectal cancer progression. PMID: 23509688 Ref: Molecular markers to predict outcome to antiangiogenic therapies in colorectal cancer: current evidence and future perspectives. PMID: 23510598 Ref: KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers. PMID: 23511557 Ref: KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: results from a large international multicentre study. PMID: 23511561 Ref: Genotyping by induced Forster Resonance Energy Transfer(iFRET) mechanism and simultaneous mutation scanning. PMID: 23520118 Ref: Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancer. PMID: 23520486 Ref: [Molecular biological diagnostics of KRAS and BRAF mutations in patients with colorectal cancer - laboratory experience]. PMID: 23528169 Ref: KRAS, BRAF, and TP53 deep sequencing for colorectal carcinoma patient diagnostics. PMID: 23531339 Ref: Somatic mutations of K-ras and BRAF in Thai colorectal cancer and their prognostic value. PMID: 23534748 Ref: A new microarray substrate for ultra-sensitive genotyping of KRAS and BRAF gene variants in colorectal cancer. PMID: 23536897 Ref: Associations between cigarette smoking status and colon cancer prognosis among participants in North Central Cancer Treatment Group Phase III Trial N0147. PMID: 23547084 Ref: High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer. PMID: 23548132 Ref: Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer. PMID: 23549875 Ref: BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer. PMID: 23553055 Ref: MLH1 promoter methylation frequency in colorectal cancer patients and related clinicopathological and molecular features. PMID: 23555617 Ref: Rare Though Not Mutually Exclusive: A Report of Three Cases of Concomitant KRAS and BRAF Mutation and a Review of the Literature. PMID: 23569465 Ref: Oncogenic mutations and microsatellite instability phenotype predict specific anatomical subsite in colorectal cancer patients. PMID: 23572025 Ref: Van-Gogh-like 2 antagonises the canonical WNT pathway and is methylated in colorectal cancers. PMID: 23579212 Ref: Stage III & IV colon and rectal cancers share a similar genetic profile: a review of the Oregon Colorectal Cancer Registry. PMID: 23592171 Ref: Clinicopathological relevance of BRAF mutations in human cancer. PMID: 23594689 Ref: The BRAF mutation in MLH1-deficient colorectal cancer. PMID: 23604240 Ref: KRAS and BRAF mutation analysis in colorectal adenocarcinoma specimens with a low percentage of tumor cells. PMID: 23606169 Ref: Critical appraisal of the use of regorafenib in the management of colorectal cancer. PMID: 23610528 Ref: Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery. PMID: 23617638 Ref: Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells. PMID: 23629727 Ref: Geographic analysis of RKIP expression and its clinical relevance in colorectal cancer. PMID: 23632477 Ref: PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer. PMID: 23633456 Ref: Phase I/II RAF kinase inhibitors in cancer therapy. PMID: 23642225 Ref: High-level microsatellite instability in appendiceal carcinomas. PMID: 23648460 Ref: BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma. PMID: 23650027 Ref: Companion biomarkers: paving the pathway to personalized treatment for cancer. PMID: 23656699 Ref: Mutation-specific antibody detects mutant BRAFV600E protein expression in human colon carcinomas. PMID: 23657789 Ref: The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer. PMID: 23660947 Ref: Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women. PMID: 23665275 Ref: A novel fully automated molecular diagnostic system (AMDS) for colorectal cancer mutation detection. PMID: 23671647 Ref: Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PMID: 23700391 Ref: Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. PMID: 23725851 Ref: Descriptive profile of PIK3CA-mutated colorectal cancer in postmenopausal women. PMID: 23728594 Ref: Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF Mutation Load. PMID: 23730412 Ref: Signature of microsatellite instability, KRAS and BRAF gene mutations in German patients with locally advanced rectal adenocarcinoma before and after neoadjuvant 5-FU radiochemotherapy. PMID: 23730514 Ref: Population-based molecular screening for Lynch syndrome: implications for personalized medicine. PMID: 23733757 Ref: Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy +/- cetuximab. PMID: 23741067 Ref: Overexpression of hypoxia inducible factor-1 alpha is an independent risk factor for recurrence after curative resection of colorectal liver metastases. PMID: 23748663 Ref: Combination of CYP inhibitor with MEK/ERK inhibitor enhances the inhibitory effect on ERK in BRAF mutant colon cancer cells. PMID: 23749901 Ref: Network quantification of EGFR signaling unveils potential for targeted combination therapy. PMID: 23752269 Ref: Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma. PMID: 23763264 Ref: Methylation levels of LINE-1 in primary lesion and matched metastatic lesions of colorectal cancer. PMID: 23764749 Ref: Molecular classification of colorectal cancer: a dream that can become a reality. PMID: 23771065 Ref: Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing. PMID: 23773459 Ref: PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival. PMID: 23785428 Ref: A prospective study of duration of smoking cessation and colorectal cancer risk by epigenetics-related tumor classification. PMID: 23788674 Ref: FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer. PMID: 23792567 Ref: Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer. PMID: 23792568 Ref: BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome. PMID: 23797718 Ref: Aspirin use and risk of colorectal cancer according to BRAF mutation status. PMID: 23800934 Ref: Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. PMID: 23806981 Ref: Expression of MUC2, MUC5AC, MUC5B, and MUC6 mucins in colorectal cancers and their association with the CpG island methylator phenotype. PMID: 23807779 Ref: Similarities of molecular genetic changes in synchronous and metachronous colorectal cancers are limited and related to the cancers' proximities to each other. PMID: 23810502 Ref: Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. PMID: 23836465 Ref: Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions. PMID: 23844038 Ref: BRAF: a driver of the serrated pathway in colon cancer. PMID: 23845435 Ref: Trametinib: first global approval. PMID: 23846731 Ref: Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer. PMID: 23849768 Ref: DUSP 4 expression identifies a subset of colorectal cancer tumors that differ in MAPK activation, regardless of the genotype. PMID: 23875912 Ref: Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer Center. PMID: 23876834 Ref: BRAF mutation and microsatellite instability status in colonic and rectal carcinoma: context really does matter. PMID: 23878351 Ref: Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. PMID: 23878352 Ref: Clinicopathologic features of synchronous colorectal carcinoma: A distinct subset arising from multiple sessile serrated adenomas and associated with high levels of microsatellite instability and favorable prognosis. PMID: 23887157 Ref: Colorectal cancer diagnostics: biomarkers, cell-free DNA, circulating tumor cells and defining heterogeneous populations by single-cell analysis. PMID: 23895128 Ref: BRAF V600E mutation analysis simplifies the testing algorithm for Lynch syndrome. PMID: 23897252 Ref: The growing galectin network in colon cancer and clinical relevance of cytoplasmic galectin-3 reactivity. PMID: 23898060 Ref: Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location. PMID: 23900220 Ref: Microsatellite instability affecting the T17 repeats in intron 8 of HSP110, as well as five mononucleotide repeats in patients with colorectal carcinoma. PMID: 23905898 Ref: Validation of next generation sequencing technologies in comparison to current diagnostic gold standards for BRAF, EGFR and KRAS mutational analysis. PMID: 23922754 Ref: Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab. PMID: 23930204 Ref: EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patients. PMID: 23930206 Ref: Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis. PMID: 23934607 Ref: Serrated polyps: clinical implications and future directions. PMID: 23934652 Ref: Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. PMID: 23938455 Ref: Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI. PMID: 23942066 Ref: Pattern of clinically relevant mutations in consecutive series of Russian colorectal cancer patients. PMID: 23943423 Ref: Morphological change of a laterally spreading rectal tumor over a short period. PMID: 23957258 Ref: Distinct molecular features of colorectal cancer in Ghana. PMID: 23962701 Ref: BRAF mutation in sporadic colorectal cancer and Lynch syndrome. PMID: 23963522 Ref: Influence of microsatellite instability and KRAS and BRAF mutations on lymph node harvest in stage I-III colon cancers. PMID: 23979710 Ref: [Association of epithermal growth factor receptor expression and its downstream gene mutation status with radiosensitivity of colorectal carcinoma cell lines in vitro]. PMID: 23980047 Ref: Somatic molecular changes and histo-pathological features of colorectal cancer in Tunisia. PMID: 23983431 Ref: Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia. PMID: 23992303 Ref: Integrating anti-EGFR therapies in metastatic colorectal cancer. PMID: 23997940 Ref: Markers of resistance to anti-EGFR therapy in colorectal cancer. PMID: 23997942 Ref: Simultaneous identification of 36 mutations in KRAS codons 61 and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit. PMID: 24006859 Ref: Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. PMID: 24019539 Ref: Sex differences in the prognostic significance of KRAS codons 12 and 13, and BRAF mutations in colorectal cancer: a cohort study. PMID: 24020794 Ref: Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. PMID: 24024839 Ref: Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: Clinical outcome and biomarkers of efficacy. PMID: 24025413 Ref: Loss of CDX2/CK20 expression is associated with poorly differentiated carcinoma, the CpG island methylator phenotype, and adverse prognosis in microsatellite-unstable colorectal cancer. PMID: 24025523 Ref: Lynch syndrome-associated colorectal carcinoma: frequent involvement of the left colon and rectum and late-onset presentation supports a universal screening approach. PMID: 24034859 Ref: Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations. PMID: 24042191 Ref: Epigenetic and genetic features of 24 colon cancer cell lines. PMID: 24042735 Ref: The role of tumor markers and biomarkers in colorectal cancer. PMID: 24050544 Ref: Epidermal growth factor receptor: pathway, therapies, and pipeline. PMID: 24054705 Ref: Colorectal cancers from distinct ancestral populations show variations in BRAF mutation frequency. PMID: 24066160 Ref: Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas. PMID: 24071017 Ref: Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer. PMID: 24073892 Ref: Ultra-deep sequencing confirms immunohistochemistry as a highly sensitive and specific method for detecting BRAF V600E mutations in colorectal carcinoma. PMID: 24085553 Ref: Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. PMID: 24092809 Ref: Molecular and clinical characteristics of MSH6 germline variants detected in colorectal cancer patients. PMID: 24100870 Ref: Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. PMID: 24104864 Ref: BRAF V600E is a determinant of sensitivity to proteasome inhibitors. PMID: 24107445 Ref: BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta-analysis. PMID: 24112392 Ref: Loss of Cdx2 Expression in Primary Tumors and Lymph Node Metastases is Specific for Mismatch Repair-Deficiency in Colorectal Cancer. PMID: 24130965 Ref: Use of molecular biomarkers to inform adjuvant therapy for colon cancer. PMID: 24133820 Ref: Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer. PMID: 24135855 Ref: HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab. PMID: 24146218 Ref: Association of candidate single nucleotide polymorphisms with somatic mutation of the epidermal growth factor receptor pathway. PMID: 24152305 Ref: [Clinical-pathological features and gene profile in colorectal cancer]. PMID: 24152396 Ref: PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival. PMID: 24156022 Ref: Multigene assays in metastatic colorectal cancer. PMID: 24158971 Ref: B-Raf mutation: a key player in molecular biology of cancer. PMID: 24161954 Ref: BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition. PMID: 24190114 Ref: Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study. PMID: 24196786 Ref: Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. PMID: 24231454 Ref: The homeobox gene MEIS1 is methylated in BRAF (p.V600E) mutated colon tumors. PMID: 24244575 Ref: Evaluating many treatments and biomarkers in oncology: a new design. PMID: 24248692 Ref: Molecular diagnostics in colorectal carcinoma. PMID: 24267189 Ref: Personalized treatment for advanced colorectal cancer: KRAS and beyond. PMID: 24294007 Ref: Toward a Molecular Classification of Colorectal Cancer: The Role of BRAF. PMID: 24298448 Ref: Sessile serrated polyps: an important route to colorectal cancer. PMID: 24335690 Ref: Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine. PMID: 24339949 Ref: RAS, BRAF, and TP53 gene mutations in Taiwanese colorectal cancer patients. PMID: 24356563 Ref: Somatic gene mutations in African Americans may predict worse outcomes in colorectal cancer. PMID: 24440976 Ref: Mucinous differentiation in colorectal cancer: molecular, histological and clinical aspects. PMID: 24494463 Ref: Analysis of the anatomic subsites, gender and age in unresectable advanced colorectal carcinomas in Tochigi, Japan suggests a shift in location towards the right side colon in elderly patients treated with cetuximab. PMID: 24649163 Ref: BRAF mutation in multiple primary cancer with colorectal cancer and stomach cancer. PMID: 24759670 Ref: Biomarkers in precision therapy in colorectal cancer. PMID: 24759962 Ref: Clinical implications of BRAF mutation test in colorectal cancer. PMID: 24834238 Ref: Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors. PMID: 24900673 |
Ref: A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer. PMID: 23211222 Ref: Prognostic significance of C-reactive protein polymorphism and KRAS/BRAF in synchronous liver metastasis from colorectal cancer. PMID: 23755178 Ref: Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology. PMID: 23792451 Ref: Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. PMID: 23852808 Ref: Endometrial tumour BRAF mutations and MLH1 promoter methylation as predictors of germline mismatch repair gene mutation status: a literature review. PMID: 23880961 Ref: Improved molecular classification of serrated lesions of the colon by immunohistochemical detection of BRAF V600E. PMID: 23887306 Ref: Intergenic polymorphisms in the amphiregulin gene region as biomarkers in metastatic colorectal cancer patients treated with anti-EGFR plus irinotecan. PMID: 23959273 Ref: Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer. PMID: 24006244 Ref: Cancer risk and overall survival in mismatch repair proficient hereditary non-polyposis colorectal cancer, Lynch syndrome and sporadic colorectal cancer. PMID: 24061861 Ref: BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer. PMID: 24157612 Ref: mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. PMID: 24163374 Ref: Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency. PMID: 24166180 Ref: Age at onset should be a major criterion for subclassification of colorectal cancer. PMID: 24184227 Ref: The role of tumor markers and biomarkers in colorectal cancer. PMID: 24195503 Ref: PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17. PMID: 24218517 Ref: Association of microRNA-31 with BRAF mutation, colorectal cancer survival and serrated pathway. PMID: 24242331 Ref: Overexpression of miR-145 increases the sensitivity of vemurafenib in drug-resistant colo205 cell line. PMID: 24248543 Ref: KRAS mutations and CDKN2A promoter methylation show an interactive adverse effect on survival and predict recurrence of rectal cancer. PMID: 24259266 Ref: EGFR, BRAF and KRAS status in patients undergoing pulmonary metastasectomy from primary colorectal carcinoma: a prospective follow-up study. PMID: 24281417 Ref: ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers. PMID: 24296758 Ref: PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms. PMID: 24316730 Ref: BRAF inhibitors in cancer therapy. PMID: 24325952 Ref: Aspirin and colorectal cancer: back to the future. PMID: 24327271 Ref: Tumor heterogeneity revealed by KRAS, BRAF, and PIK3CA pyrosequencing: KRAS and PIK3CA intratumor mutation profile differences and their therapeutic implications. PMID: 24352906 Ref: DNA testing and molecular screening for colon cancer. PMID: 24355100 Ref: Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation. PMID: 24379162 Ref: Fusobacterium in colonic flora and molecular features of colorectal carcinoma. PMID: 24385213 Ref: Effect of BRAF V600E mutation on tumor response of anti-EGFR monoclonal antibodies for first-line metastatic colorectal cancer treatment: a meta-analysis of randomized studies. PMID: 24390240 Ref: Molecular heterogeneity and prognostic implications of synchronous advanced colorectal neoplasia. PMID: 24434431 Ref: BRAF inhibitor therapy for melanoma, thyroid and colorectal cancers: development of resistance and future prospects. PMID: 24446739 Ref: Influence of pre-diagnostic cigarette smoking on colorectal cancer survival: overall and by tumour molecular phenotype. PMID: 24448365 Ref: DNA content analysis of colorectal cancer defines a distinct 'microsatellite and chromosome stable' group but does not predict response to radiotherapy. PMID: 24456329 Ref: Biomarkers for predicting the efficacy of anti-epidermal growth factor receptor antibody in the treatment of colorectal cancer. PMID: 24458108 Ref: Population-based screening for Lynch syndrome in Western Australia. PMID: 24474394 Ref: GNAS mutations identify a set of right-sided, RAS mutant, villous colon cancers. PMID: 24498230 Ref: Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS. PMID: 24500024 Ref: Mutational analysis and clinical correlation of metastatic colorectal cancer. PMID: 24500602 Ref: Immunohistochemistry for myc predicts survival in colorectal cancer. PMID: 24503701 Ref: SMARCB1 (INI1)-negative rhabdoid carcinomas of the gastrointestinal tract: clinicopathologic and molecular study of a highly aggressive variant with literature review. PMID: 24503755 Ref: CpG island methylator phenotype and its association with malignancy in sporadic duodenal adenomas. PMID: 24518818 Ref: Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAF (V600E)-mutant metastatic colorectal carcinoma. PMID: 24523613 Ref: Immunohistochemical detection of BRAF V600E mutant protein using the VE1 antibody in colorectal carcinoma is highly concordant with molecular testing but requires rigorous antibody optimization. PMID: 24529329 Ref: RAD21 cohesin overexpression is a prognostic and predictive marker exacerbating poor prognosis in KRAS mutant colorectal carcinomas. PMID: 24548858 Ref: Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. PMID: 24553387 Ref: EGFR, KRAS, BRAF-mutations and microsatellite instability are absent in goblet cell carcinoids of the appendix. PMID: 24560515 Ref: Prevalence and molecular characterisation of the sessile serrated adenoma in a subset of the Chinese population. PMID: 24570042 Ref: A peptide-based positron emission tomography probe for in vivo detection of caspase activity in apoptotic cells. PMID: 24573549 Ref: RAS mutations and cetuximab in locally advanced rectal cancer: results of the EXPERT-C trial. PMID: 24582914 Ref: Molecular and immunohistochemical profile of a basaloid (cloacogenic) carcinoma of the sigmoid colon: possible predictive value for clinical outcomes. PMID: 24584270 Ref: Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). PMID: 24585723 Ref: Identification and optimization of new dual inhibitors of B-Raf and epidermal growth factor receptor kinases for overcoming resistance against vemurafenib. PMID: 24588073 Ref: Methylation epigenotypes and genetic features in colorectal laterally spreading tumors. PMID: 24590867 Ref: KRAS insertions in colorectal cancer: what do we know about unusual KRAS mutations? PMID: 24594115 Ref: BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis. PMID: 24594804 Ref: EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab. PMID: 24595598 Ref: [Perspective of personalized (precise) cancer therapy based on predictive biomarkers]. PMID: 24597345 Ref: Traditional serrated adenoma has two pathways of neoplastic progression that are distinct from the sessile serrated pathway of colorectal carcinogenesis. PMID: 24603588 Ref: Distinct profile of HIF1alpha, PTCH, EphB2, or DNA repair protein expression and BRAF mutation in colorectal serrated adenoma. PMID: 24612059 Ref: [Lynch syndrome in the hands of pathologists]. PMID: 24624982 Ref: Immunohistochemistry for annexin A10 can distinguish sporadic from Lynch syndrome-associated microsatellite-unstable colorectal carcinoma. PMID: 24625416 Ref: Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancer. PMID: 24626880 Ref: Serrated pathway in colorectal carcinogenesis. PMID: 24627599 Ref: [Surgical treatment of metastases and its impact on prognosis in patients with metastatic colorectal carcinoma]. PMID: 24635436 Ref: Multiple sporadic colorectal cancers display a unique methylation phenotype. PMID: 24643221 Ref: Microsatellite stable colorectal cancers stratified by the BRAF V600E mutation show distinct patterns of chromosomal instability. PMID: 24651849 Ref: Translating clinical research of Molecular Biology into a personalized, multidisciplinary approach of colorectal cancer patients. PMID: 24653752 Ref: Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma. PMID: 24659028 Ref: Differential gene expression of chemokines in KRAS and BRAF mutated colorectal cell lines: role of cytokines. PMID: 24659889 Ref: DNA methylation subgroups and the CpG island methylator phenotype in gastric cancer: a comprehensive profiling approach. PMID: 24674026 Ref: Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing. PMID: 24676216 Ref: Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status. PMID: 24691006 Ref: The frequencies and clinical implications of mutations in 33 kinase-related genes in locally advanced rectal cancer: a pilot study. PMID: 24700299 Ref: Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial. PMID: 24703531 Ref: Genetic mechanisms in interval colon cancers. PMID: 24705641 Ref: VE1 immunohistochemistry accurately detects BRAF V600E mutations in colorectal carcinoma and can be utilized in the detection of poorly differentiated colorectal serrated adenocarcinoma. PMID: 24722974 Ref: Expression analysis of heat shock protein 90 (HSP90) and Her2 in colon carcinoma. PMID: 24733427 Ref: Clinical applications using digital PCR. PMID: 24740231 Ref: [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas]. PMID: 24742565 Ref: Moguntinones--new selective inhibitors for the treatment of human colorectal cancer. PMID: 24743703 Ref: A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine? PMID: 24743706 Ref: MicroRNA-31 expression in relation to BRAF mutation, CpG island methylation and colorectal continuum in serrated lesions. PMID: 24752710 Ref: Vemurafenib. PMID: 24756795 Ref: Trametinib. PMID: 24756797 Ref: The Emerging Role of NRAS Mutations in Colorectal Cancer Patients Selected for Anti-EGFR Therapies. PMID: 24758538 Ref: Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer. PMID: 24764661 Ref: Clinical meaning of BRAF mutation in Korean patients with advanced colorectal cancer. PMID: 24764675 Ref: KRAS and BRAF genotyping of synchronous colorectal carcinomas. PMID: 24765171 Ref: Mismatch repair protein immunohistochemistry: a useful population screening strategy for Lynch syndrome. PMID: 24768606 Ref: Molecular biomarkers and classification models in the evaluation of the prognosis of colorectal cancer. PMID: 24778007 Ref: BRAFV600E mutation analysis by immunohistochemistry in patients with thoracic metastases from colorectal cancer. PMID: 24798160 Ref: Pyrosequencing evaluation of low-frequency KRAS mutant alleles for EGF receptor therapy selection in metastatic colorectal carcinoma. PMID: 24799053 Ref: Molecular patterns in deficient mismatch repair colorectal tumours: results from a French prospective multicentric biological and genetic study. PMID: 24800948 Ref: The utility of BRAFV600E mutation-specific antibody for colon cancers with microsatellite instability. PMID: 24805134 Ref: Clinicopathological characteristics and prognostic impact of colorectal cancers with NRAS mutations. PMID: 24806883 Ref: Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition. PMID: 24812410 Ref: Detection of the BRAF V600E mutation in colon carcinoma: critical evaluation of the imunohistochemical approach. PMID: 24832158 Ref: RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy. PMID: 24833563 Ref: Impact of genetic profiles on the efficacy of anti-EGFR antibodies in metastatic colorectal cancer with KRAS mutation. PMID: 24839940 Ref: Comprehensive molecular characterisation of hereditary non-polyposis colorectal tumours with mismatch repair proficiency. PMID: 24841217 Ref: Clinical relevance of alterations in quantity and quality of plasma DNA in colorectal cancer patients: based on the mutation spectra detected in primary tumors. PMID: 24841357 Ref: A new generation of companion diagnostics: cobas BRAF, KRAS and EGFR mutation detection tests. PMID: 24844134 Ref: Colorectal advanced neoplasms occur through dual carcinogenesis pathways in individuals with coexisting serrated polyps. PMID: 24849572 Ref: Prognostic implication of mucinous histology in resected colorectal cancer liver metastases. PMID: 24856126 Ref: The evolution of our molecular understanding of colorectal cancer: what we are doing now, what the future holds, and how tumor profiling is just the beginning. PMID: 24857065 Ref: CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. PMID: 24859205 Ref: KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study. PMID: 24859998 Ref: [BRAF gene mutation in wild-type KRAS patients with colorectal cancers]. PMID: 24861115 Ref: Mutations of KRAS and PIK3CA as independent predictors of distant metastases in colorectal cancer. PMID: 24861917 Ref: Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection. PMID: 24863535 Ref: Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review. PMID: 24885062 Ref: Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAF-mutant colorectal cancer cells. PMID: 24885690 Ref: BRAF-mutated microsatellite stable colorectal carcinoma: an aggressive adenocarcinoma with reduced CDX2 and increased cytokeratin 7 immunohistochemical expression. PMID: 24908142 Ref: Invasion pattern and histologic features of tumor aggressiveness correlate with MMR protein expression, but are independent of activating KRAS and BRAF mutations in CRC. PMID: 24915895 Ref: Associations of anthropometric factors with KRAS and BRAF mutation status of primary colorectal cancer in men and women: a cohort study. PMID: 24918610 Ref: Predicted 25(OH)D score and colorectal cancer risk according to vitamin D receptor expression. PMID: 24920642 Ref: BRAF V600E immunohistochemistry is reliable in primary and metastatic colorectal carcinoma regardless of treatment status and shows high intratumoral homogeneity. PMID: 24921639 Ref: Loss of ARID1A expression in colorectal carcinoma is strongly associated with mismatch repair deficiency. PMID: 24925223 Ref: Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. PMID: 24925349 Ref: CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer. PMID: 24928946 Ref: 'Druggable' alterations detected by Ion Torrent in metastatic colorectal cancer patients. PMID: 24932229 Ref: Progress and opportunities in molecular pathological epidemiology of colorectal premalignant lesions. PMID: 24935274 Ref: Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. PMID: 24942275 Ref: The BRAF mutation is associated with the prognosis in colorectal cancer. PMID: 24942334 Ref: Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations. PMID: 24947927 Ref: The MAPK pathway across different malignancies: a new perspective. PMID: 24948110 Ref: Claudin-1 Expression Is Elevated in Colorectal Cancer Precursor Lesions Harboring the BRAF V600E Mutation. PMID: 24954356 Ref: BRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies. PMID: 24955706 Ref: TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial. PMID: 24957073 Ref: Hyperplastic polyps identified during screening endoscopy: reevaluated by histological examinations and genetic alterations. PMID: 24961182 Ref: The prognostic role of microsatellite instability, codon-specific KRAS, and BRAF mutations in colon cancer. PMID: 24964758 Ref: DNA methylation alterations of AXIN2 in serrated adenomas and colon carcinomas with microsatellite instability. PMID: 24964857 Ref: Next-generation sequencing analysis of lung and colon carcinomas reveals a variety of genetic alterations. PMID: 24990411 Ref: A very low incidence of BRAF mutations in Middle Eastern colorectal carcinoma. PMID: 25005754 Ref: Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer. PMID: 25009008 Ref: SOX2 expression is regulated by BRAF and contributes to poor patient prognosis in colorectal cancer. PMID: 25010701 Ref: Excess of proximal microsatellite-stable colorectal cancer in African Americans from a multiethnic study. PMID: 25013126 Ref: BRAF-activated long non-coding RNA contributes to colorectal cancer migration by inducing epithelial-mesenchymal transition. PMID: 25013510 Ref: SMO expression in colorectal cancer: associations with clinical, pathological, and molecular features. PMID: 25023548 Ref: Small bowel adenocarcinomas complicating Crohn's disease are associated with dysplasia: a pathological and molecular study. PMID: 25029614 Ref: Current approaches for predicting a lack of response to anti-EGFR therapy in KRAS wild-type patients. PMID: 25032217 Ref: KRAS and BRAF mutations and MSI status in precursor lesions of colorectal cancer detected by colonoscopy. PMID: 25050586 Ref: Use of BRAF V600E as a molecular marker in aggressive colorectal cancer. PMID: 25053682 Ref: Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. PMID: 25057166 Ref: Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. PMID: 25069797 Ref: Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma. PMID: 25073438 Ref: BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines. PMID: 25076244 Ref: Sporadic early-onset colorectal cancer is a specific sub-type of cancer: a morphological, molecular and genetics study. PMID: 25083765 Ref: Distinct molecular features of different macroscopic subtypes of colorectal neoplasms. PMID: 25093594 Ref: [Colorectal carcinoma in consideration of the new German S3 guideline 2013]. PMID: 25106124 Ref: Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer. PMID: 25110411 Ref: IGF2 differentially methylated region hypomethylation in relation to pathological and molecular features of serrated lesions. PMID: 25110432 Ref: Re: Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. PMID: 25114271 Ref: Mutations in POLE and survival of colorectal cancer patients--link to disease stage and treatment. PMID: 25124163 Ref: The clinical perspectives of CDX2 expression in colorectal cancer: a qualitative systematic review. PMID: 25126956 Ref: A further investigation of combined mismatch repair and BRAFV600E mutation specific immunohistochemistry as a predictor of overall survival in colorectal carcinoma. PMID: 25153715 Ref: Combined microsatellite instability and BRAF gene status as biomarkers for adjuvant chemotherapy in stage III colorectal cancer. PMID: 25154726 Ref: Epithelial-mesenchymal transition and somatic alteration in colorectal cancer with and without peritoneal carcinomatosis. PMID: 25157365 Ref: Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. PMID: 25164765 Ref: Copy number alterations of chromosomal regions enclosing protein tyrosine phosphatase receptor-like genes in colorectal cancer. PMID: 25169130 Ref: High prevalence of deficient mismatch repair phenotype and the V600E BRAF mutation in elderly patients with colorectal cancer. PMID: 25176643 Ref: A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy. PMID: 25183481 Ref: Tumor LINE-1 methylation level and microsatellite instability in relation to colorectal cancer prognosis. PMID: 25190725 Ref: [Screening for Lynch syndrome in colorectal cancer]. PMID: 25208990 Ref: MicroRNA-31 expression in colorectal serrated pathway progression. PMID: 25232271 Ref: TRAP1 is involved in BRAF regulation and downstream attenuation of ERK phosphorylation and cell-cycle progression: a novel target for BRAF-mutated colorectal tumors. PMID: 25239454 Ref: A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome. PMID: 25244061 Ref: hMLH1 promoter methylation and BRAF mutations in high-frequency microsatellite instability colorectal cancers not fulfilling the revised Bethesda guidelines. PMID: 25247165 Ref: 3'-Deoxy-3'-[18F]-Fluorothymidine PET imaging reflects PI3K-mTOR-mediated pro-survival response to targeted therapy in colorectal cancer. PMID: 25247710 Ref: High-throughput screening of extended RAS mutations based on high-resolution melting analysis for prediction of anti-EGFR treatment efficacy in colorectal carcinoma. PMID: 25262986 Ref: KRAS and BRAF mutational status in colon cancer from Albanian patients. PMID: 25267307 Ref: Gender-associated genomic differences in colorectal cancer: clinical insight from feminization of male cancer cells. PMID: 25268611 Ref: miR-524-5p suppresses the growth of oncogenic BRAF melanoma by targeting BRAF and ERK2. PMID: 25275294 Ref: Tumour MLH1 promoter region methylation testing is an effective prescreen for Lynch Syndrome (HNPCC). PMID: 25280751 Ref: Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues. PMID: 25287912 Ref: Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. PMID: 25293556 Ref: Biological and molecular effects of small molecule kinase inhibitors on low-passage human colorectal cancer cell lines. PMID: 25309914 Ref: Predictive biomarkers for anti-epidermal growth factor receptor therapy: beyond KRAS testing. PMID: 25313182 Ref: Colorectal cancer in Chinese patients: current and emerging treatment options. PMID: 25336973 Ref: Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer. PMID: 25337237 Ref: Cancer in silico drug discovery: a systems biology tool for identifying candidate drugs to target specific molecular tumor subtypes. PMID: 25349306 Ref: BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications. PMID: 25361007 Ref: BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients. PMID: 25367198 Ref: MAFG mediates CIMP in BRAF-mutant colorectal cancer. PMID: 25367952 Ref: The presence of telomere fusion in sporadic colon cancer independently of disease stage, TP53/KRAS mutation status, mean telomere length, and telomerase activity. PMID: 25379018 Ref: Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation. PMID: 25379021 Ref: Prognostic Impact of Deficient DNA Mismatch Repair and Mutations in KRAS, and BRAF(V600E) in Patients with Lymph Node-Positive Colon Cancer. PMID: 25386108 Ref: [Safety and efficacy analysis on modified FOLFOXIRI as first-line treatment for advanced colorectal cancer in China-single center experience]. PMID: 25421765 Ref: Efficacy of triplet combination chemotherapy with oxaliplatin, irinotecan and capecitabine (OCX) in metastatic colorectal cancer in relation to RAS/RAF mutation status: results of a retrospective analysis. PMID: 25427581 Ref: Boosting Wnt activity during colorectal cancer progression through selective hypermethylation of Wnt signaling antagonists. PMID: 25432628 Ref: CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas. PMID: 25484061 Ref: Isocitrate dehydrogenase 1 R132C mutation occurs exclusively in microsatellite stable colorectal cancers with the CpG island methylator phenotype. PMID: 25496513 Ref: Role of MGMT as biomarker in colorectal cancer. PMID: 25516857 Ref: BRAF mutation as a potential marker to identify the proximal colon serrated polyps with malignant potential. PMID: 25550768 Ref: Immunohistochemistry - microarray analysis of patients with peritoneal metastases of appendiceal or colorectal origin. PMID: 25593974 Ref: [Molecular characterization of hereditary colorectal cancer in Peru]. PMID: 25594752 Ref: Molecular pathology of colorectal cancer. PMID: 25693079 Ref: [The alternative way of colorectal cancer developing. The histogenetic and molecular features of serrated lesions (review, continued)]. PMID: 25842399 Ref: PMID: 25905152 Ref: High frequency of BRAF proto-oncogene hot spot mutation V600E in cohort of colorectal cancer patients from Ahvaz City, southwest Iran. PMID: 25911848 Ref: [Genome sequencing and personalized medicine: perspectives and limitations]. PMID: 26259290 Ref: Prevalence of KRAS mutations in metastatic colorectal cancer: A retrospective observational study from India. PMID: 26842186 Ref: Role of HGF-MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer. PMID: 28548075 |
Ref: A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity. PMID: 24469059 Ref: Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. PMID: 24806288 Ref: A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer. PMID: 24859797 Ref: Fluorescence virus-guided capturing system of human colorectal circulating tumour cells for non-invasive companion diagnostics. PMID: 24870621 Ref: KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX. PMID: 24889488 Ref: Distinct WNT/beta-catenin signaling activation in the serrated neoplasia pathway and the adenoma-carcinoma sequence of the colorectum. PMID: 24925057 Ref: Aberrant expression of annexin A10 is closely related to gastric phenotype in serrated pathway to colorectal carcinoma. PMID: 25081749 Ref: Transgenic expression of oncogenic BRAF induces loss of stem cells in the mouse intestine, which is antagonized by beta-catenin activity. PMID: 25109331 Ref: Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies. PMID: 25119972 Ref: Comprehensive screening for mutations associated with colorectal cancer in unselected cases reveals penetrant and nonpenetrant mutations. PMID: 25142776 Ref: A clinicopathological and molecular analysis of 200 traditional serrated adenomas. PMID: 25216220 Ref: Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy. PMID: 25248381 Ref: Identification of novel mutations by exome sequencing in African American colorectal cancer patients. PMID: 25250560 Ref: A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours. PMID: 25268371 Ref: Association between molecular subtypes of colorectal cancer and patient survival. PMID: 25280443 Ref: Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. PMID: 25305506 Ref: B-RAF mutation and accumulated gene methylation in aberrant crypt foci (ACF), sessile serrated adenoma/polyp (SSA/P) and cancer in SSA/P. PMID: 25314065 Ref: Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimens. PMID: 25318602 Ref: Prognostic significance and molecular features of signet-ring cell and mucinous components in colorectal carcinoma. PMID: 25326395 Ref: Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9. PMID: 25326806 Ref: Medullary carcinoma of the colon: can the undifferentiated be differentiated? PMID: 25339302 Ref: Is it all Lynch syndrome?: An assessment of family history in individuals with mismatch repair-deficient tumors. PMID: 25341111 Ref: Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial. PMID: 25361982 Ref: Aberrant methylation of ERBB pathway genes in sporadic colorectal cancer. PMID: 25366420 Ref: [Colorectal Carcinoma with Suspected Lynch Syndrome: A Multidisciplinary Algorithm]. PMID: 25372301 Ref: Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. PMID: 25373533 Ref: Ion Torrent next-generation sequencing for routine identification of clinically relevant mutations in colorectal cancer patients. PMID: 25378536 Ref: B-Raf inhibitors induce epithelial differentiation in BRAF-mutant colorectal cancer cells. PMID: 25381152 Ref: Genome-wide linkage analysis and tumoral characterization reveal heterogeneity in familial colorectal cancer type X. PMID: 25381643 Ref: Tyrosine kinase receptor B (TrkB) expression in colorectal cancers highlights anoikis resistance as a survival mechanism of tumour budding cells. PMID: 25382057 Ref: Annexin A10 is a marker for the serrated pathway of colorectal carcinoma. PMID: 25395067 Ref: MUC5AC hypomethylation is a predictor of microsatellite instability independently of clinical factors associated with colorectal cancer. PMID: 25403854 Ref: Rectal cancer profiling identifies distinct subtypes in India based on age at onset, genetic, epigenetic and clinicopathological characteristics. PMID: 25418895 Ref: Colorectal liver metastases are more often super wild type. Toward treatment based on metastatic site genotyping? PMID: 25420993 Ref: BRAF inhibitors: experience in thyroid cancer and general review of toxicity. PMID: 25467940 Ref: Association of MicroRNA-31-5p with Clinical Efficacy of Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer. PMID: 25472647 Ref: MicroRNAs associated with initiation and progression of colonic polyp: a feasibility study. PMID: 25496852 Ref: Oncogenic KRAS signalling promotes the Wnt/beta-catenin pathway through LRP6 in colorectal cancer. PMID: 25500543 Ref: Immunohistochemical detection of the BRAF V600E mutant protein in colorectal neoplasms. PMID: 25517872 Ref: IRS2 copy number gain, KRAS and BRAF mutation status as predictive biomarkers for response to the IGF-1R/IR inhibitor BMS-754807 in colorectal cancer cell lines. PMID: 25527633 Ref: Serrated and non-serrated precursor lesions of colorectal cancer. PMID: 25531494 Ref: Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy. PMID: 25532759 Ref: How does the serrated polyp pathway alter CRC screening and surveillance? PMID: 25556584 Ref: Prevalence of somatic mutl homolog 1 promoter hypermethylation in Lynch syndrome colorectal cancer. PMID: 25557234 Ref: KRAS mutation analysis by PCR: a comparison of two methods. PMID: 25568935 Ref: Economic evaluation of genetic screening for Lynch syndrome in Germany. PMID: 25569434 Ref: Combined methylation of p16 and hMLH1 (CMETH2) discriminates a subpopulation with better prognosis in colorectal cancer patients with microsatellite instability tumors. PMID: 25576161 Ref: Association of the colorectal CpG island methylator phenotype with molecular features, risk factors, and family history. PMID: 25587051 Ref: Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. PMID: 25589621 Ref: Colorectal cancer heterogeneity and targeted therapy: a case for molecular disease subtypes. PMID: 25593032 Ref: Sporadic microsatellite instability-high colon cancers rarely display immunohistochemical evidence of Wnt signaling activation. PMID: 25602793 Ref: Non-invasive sensitive detection of KRAS and BRAF mutation in circulating tumor cells of colorectal cancer patients. PMID: 25605225 Ref: Methylation and expression of the tumour suppressor, PRDM5, in colorectal cancer and polyp subgroups. PMID: 25613750 Ref: A pathway-centric survey of somatic mutations in Chinese patients with colorectal carcinomas. PMID: 25617745 Ref: Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer. PMID: 25623215 Ref: Deficient DNA mismatch repair is associated with favorable prognosis in Thai patients with sporadic colorectal cancer. PMID: 25624727 Ref: Dovitinib (TKI258), a multi-target angiokinase inhibitor, is effective regardless of KRAS or BRAF mutation status in colorectal cancer. PMID: 25628921 Ref: Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer. PMID: 25632202 Ref: Clinicopathological and molecular characteristics of serrated lesions in Japanese elderly patients. PMID: 25632919 Ref: The rare BRAF VK600-601E mutation as a possible indicator of poor prognosis in rectal carcinoma - a report of a case. PMID: 25636897 Ref: Development of a semi-conductor sequencing-based panel for genotyping of colon and lung cancer by the Onconetwork consortium. PMID: 25637035 Ref: Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases. PMID: 25639985 Ref: Association of HPV with genetic and epigenetic alterations in colorectal adenocarcinoma from Indian population. PMID: 25647260 Ref: External quality assessment unravels interlaboratory differences in quality of RAS testing for anti-EGFR therapy in colorectal cancer. PMID: 25657200 Ref: Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients. PMID: 25663765 Ref: KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients. PMID: 25663779 Ref: EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab. PMID: 25663927 Ref: FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study. PMID: 25666295 Ref: Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. PMID: 25673558 Ref: Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. PMID: 25673644 Ref: Novel molecular insights from routine genotyping of colorectal carcinomas. PMID: 25683705 Ref: Colorectal cancer in iran: molecular epidemiology and screening strategies. PMID: 25685149 Ref: Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. PMID: 25688736 Ref: KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer. PMID: 25688918 Ref: Left-sided early-onset vs late-onset colorectal carcinoma: histologic, clinical, and molecular differences. PMID: 25696795 Ref: Implications of epithelial-mesenchymal plasticity for heterogeneity in colorectal cancer. PMID: 25699236 Ref: Microsatellite instability: an update. PMID: 25701956 Ref: Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab. PMID: 25704501 Ref: Hyperplastic polyps of the colon and rectum - reclassification, BRAF and KRAS status in index polyps and subsequent colorectal carcinoma. PMID: 25708741 Ref: Evaluating patient-derived colorectal cancer xenografts as preclinical models by comparison with patient clinical data. PMID: 25712343 Ref: Prevalence of Lynch syndrome in a Middle Eastern population with colorectal cancer. PMID: 25712738 Ref: AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants. PMID: 25714871 Ref: Genetic characteristics of mitochondrial DNA was associated with colorectal carcinogenesis and its prognosis. PMID: 25734426 Ref: High MACC1 expression in combination with mutated KRAS G13 indicates poor survival of colorectal cancer patients. PMID: 25742883 Ref: BRAF V600E mutation-specific antibody: A review. PMID: 25744437 Ref: Does BRAF Mutation and Extracellular Signal Regulated Kinase Expression in Patients With Colorectal Cancer Have Any Prognostic Significance? PMID: 25745617 Ref: Clinicopathologic Significance of BRAF Mutation and Extracellular Signal Regulated Kinase 1/2 Expression in Patients With a Colorectal Adenocarcinoma. PMID: 25745621 Ref: Concurrent Targeting of KRAS and AKT by MiR-4689 Is a Novel Treatment Against Mutant KRAS Colorectal Cancer. PMID: 25756961 Ref: B-type proto-oncogene-mutated tumors of colon cancer: promising therapeutic approaches. PMID: 25774859 Ref: [Molecular pathology of colorectal cancer]. PMID: 25777075 Ref: Detection of BRAF mutation in Chinese tumor patients using a highly sensitive antibody immunohistochemistry assay. PMID: 25784606 Ref: Current Understanding of BRAF Alterations in Diagnosis, Prognosis, and Therapeutic Targeting in Pediatric Low-Grade Gliomas. PMID: 25785246 Ref: Distinctive Spatiotemporal Stability of Somatic Mutations in Metastasized Microsatellite-stable Colorectal Cancer. PMID: 25786087 Ref: MITF Modulates Therapeutic Resistance through EGFR Signaling. PMID: 25789707 Ref: Comparative effectiveness of screening strategies for Lynch syndrome. PMID: 25794514 Ref: Methionine adenosyltransferase 2B-GIT1 complex serves as a scaffold to regulate Ras/Raf/MEK1/2 activity in human liver and colon cancer cells. PMID: 25794709 Ref: Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis. PMID: 25797243 Ref: Active immunosurveillance in the tumor microenvironment of colorectal cancer is associated with low frequency tumor budding and improved outcome. PMID: 25797890 Ref: Marine omega-3 polyunsaturated fatty acids and risk of colorectal cancer according to microsatellite instability. PMID: 25810492 Ref: HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL. PMID: 25813020 Ref: Identification of KRAS and PIK3CA but not BRAF mutations in patients with gastric cancer. PMID: 25815786 Ref: Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. PMID: 25838391 Ref: Systemic Analysis of Predictive Biomarkers for Recurrence in Colorectal Cancer Patients Treated with Curative Surgery. PMID: 25840921 Ref: Selected case from the Arkadi M. Rywlin International Pathology Slide Club: carcinoma of the transverse colon in a young girl. PMID: 25844680 Ref: Old Habits Die Hard: Addiction of BRAF-Mutant Cancer Cells to MAP Kinase Signaling. PMID: 25847954 Ref: Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial. PMID: 25851630 Ref: The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors. PMID: 25854919 Ref: Antitumor activity of the MEK inhibitor trametinib on intestinal polyp formation in Apc(Delta716) mice involves stromal COX-2. PMID: 25855137 Ref: BRAF V600E mutation in colorectal cancer is associated with right-sided tumours and iron deficiency anaemia. PMID: 25862899 Ref: Validation of the Ion Torrent PGM sequencing for the prospective routine molecular diagnostic of colorectal cancer. PMID: 25872148 Ref: Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer. PMID: 25884297 Ref: Heterogeneity analysis of Metastasis Associated in Colon Cancer 1 (MACC1) for survival prognosis of colorectal cancer patients: a retrospective cohort study. PMID: 25884643 Ref: HGUE-C-1 is an atypical and novel colon carcinoma cell line. PMID: 25885658 Ref: Russian study of morphological prognostic factors characterization in BRAF-mutant cutaneous melanoma. PMID: 25888143 Ref: Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib. PMID: 25889309 Ref: TFF2-CXCR4 Axis Is Associated with BRAF V600E Colon Cancer. PMID: 25899003 Ref: Mutational analysis of circulating tumor cells from colorectal cancer patients and correlation with primary tumor tissue. PMID: 25902072 Ref: A model-based assessment of the cost-utility of strategies to identify Lynch syndrome in early-onset colorectal cancer patients. PMID: 25910169 Ref: Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients. PMID: 25918287 Ref: MicroRNA-224 is associated with colorectal cancer progression and response to 5-fluorouracil-based chemotherapy by KRAS-dependent and -independent mechanisms. PMID: 25919696 Ref: Neoadjuvant chemotherapy in locally advanced colon cancer. A phase II trial. PMID: 25920359 Ref: Tumor and Patient Characteristics of Individuals with Mismatch Repair Deficient Colorectal Cancer. PMID: 25924923 Ref: Established and Potential Predictive Biomarkers in Gastrointestinal Cancer--c-Kit, Her2, Ras and Beyond. PMID: 25924988 Ref: The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets. PMID: 25926053 Ref: Downregulated Long Noncoding RNA BANCR Promotes the Proliferation of Colorectal Cancer Cells via Downregualtion of p21 Expression. PMID: 25928067 Ref: Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages. PMID: 25929517 Ref: Biology of colorectal cancer. PMID: 25932044 Ref: Cancer mutation screening: Comparison of high-resolution melt analysis between two platforms. PMID: 25932046 Ref: A novel approach to detect KRAS/BRAF mutation for colon cancer: Highly sensitive simultaneous detection of mutations and simple pre-treatment without DNA extraction. PMID: 25936694 Ref: Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab. PMID: 25943333 Ref: Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody. PMID: 25943534 Ref: RAS testing in metastatic colorectal cancer: excellent reproducibility amongst 17 Dutch pathology centers. PMID: 25944693 Ref: Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing. PMID: 25954997 Ref: Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or PMID: 25956750 Ref: PD-L1 blockade for cancer treatment: MEDI4736. PMID: 25965366 Ref: Immune response gene expression in colorectal cancer carries distinct prognostic implications according to tissue, stage and site: a prospective retrospective translational study in the context of a hellenic cooperative oncology group randomised trial. PMID: 25970543 Ref: Endoscopic ultrasound fine-needle aspiration cytology mutation profiling using targeted next-generation sequencing: personalized care for rectal cancer. PMID: 25972331 Ref: A specific KRAS codon 13 mutation is an independent predictor for colorectal cancer metachronous distant metastases. PMID: 25973306 Ref: Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer. PMID: 25973534 Ref: AM251 induces apoptosis and G2/M cell cycle arrest in A375 human melanoma cells. PMID: 25974027 Ref: [Detection of KRAS,NRAS and BRAF gene mutations in colorectal carcinoma]. PMID: 25975908 Ref: The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors. PMID: 25975986 Ref: Prediagnostic Physical Activity and Colorectal Cancer Survival: Overall and Stratified by Tumor Characteristics. PMID: 25976417 Ref: MicroRNA-378-5p suppresses cell proliferation and induces apoptosis in colorectal cancer cells by targeting BRAF. PMID: 25977643 Ref: Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. PMID: 25979833 Ref: KRAS and BRAF Mutation Detection: Is Immunohistochemistry a Possible Alternative to Molecular Biology in Colorectal Cancer? PMID: 25983749 Ref: Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer. PMID: 25993166 Ref: PIK3CA Somatic Mutation Status in Relation to Patient and Tumor Factors in Racial/Ethnic Minorities with Colorectal Cancer. PMID: 25994739 Ref: Traditional serrated adenoma: an update. PMID: 26001333 Ref: N-(3-Ethynyl-2,4-difluorophenyl)sulfonamide Derivatives as Selective Raf Inhibitors. PMID: 26005530 Ref: [Molecular analysis of sporadic colon cancer]. PMID: 26005817 Ref: Genetic Alterations in Colorectal Cancer Have Different Patterns on 18F-FDG PET/CT. PMID: 26018692 Ref: PIK3CA Amplification Is Common in Left Side-Tubular Adenomas but Uncommon Sessile Serrated Adenomas Exclusively with KRAS Mutation. PMID: 26019684 Ref: Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy. PMID: 26027741 Ref: Molecular and histologic considerations in the assessment of serrated polyps. PMID: 26030242 Ref: Effects of RAL signal transduction in KRAS- and BRAF-mutated cells and prognostic potential of the RAL signature in colorectal cancer. PMID: 26033452 Ref: Association between body mass index and mortality for colorectal cancer survivors: overall and by tumor molecular phenotype. PMID: 26038390 Ref: Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer. PMID: 26044119 Ref: Activation of RAF1 (c-RAF) by the Marine Alkaloid Lasonolide A Induces Rapid Premature Chromosome Condensation. PMID: 26058013 Ref: Aberrant TET1 Methylation Closely Associated with CpG Island Methylator Phenotype in Colorectal Cancer. PMID: 26063725 Ref: Correlation between smoking history and molecular pathways in sporadic colorectal cancer: a meta-analysis. PMID: 26064214 Ref: Different treatment strategies and molecular features between right-sided and left-sided colon cancers. PMID: 26074686 Ref: Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population. PMID: 26077004 Ref: Identification and characterization of RET fusions in advanced colorectal cancer. PMID: 26078337 Ref: Targeting TRAP1 as a downstream effector of BRAF cytoprotective pathway: a novel strategy for human BRAF-driven colorectal carcinoma. PMID: 26084290 Ref: The epithelial polarity regulator LGALS9/galectin-9 induces fatal frustrated autophagy in KRAS mutant colon carcinoma that depends on elevated basal autophagic flux. PMID: 26086204 Ref: Expression of cancer stem cell markers in metastatic colorectal cancer correlates with liver metastasis, but not with metastasis to the central nervous system. PMID: 26092596 Ref: Multivariate analysis as a method for evaluating the pathogenicity of novel genetic MLH1 variants in patients with colorectal cancer and microsatellite instability. PMID: 26096739 Ref: EGFR and beta1-integrin targeting differentially affect colorectal carcinoma cell radiosensitivity and invasion. PMID: 26096850 Ref: Methylation changes in the TFAP2E promoter region are associated with BRAF mutation and poorer overall & disease free survival in colorectal cancer. PMID: 26097884 Ref: Epigenetics could explain some Moroccan population colorectal cancers peculiarities: microsatellite instability pathway exploration. PMID: 26104511 Ref: Lack of Association between Membrane-Type 1 Matrix Metalloproteinase Expression and Clinically Relevant Molecular or Morphologic Tumor Characteristics at the Leading Edge of Invasive Colorectal Carcinoma. PMID: 26106602 Ref: Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study. PMID: 26109816 Ref: A Meta-Regression Method for Studying Etiological Heterogeneity Across Disease Subtypes Classified by Multiple Biomarkers. PMID: 26116215 Ref: [DNA mismatch repair and BRAF status in colorectal cancer: Interest for the therapeutic management?]. PMID: 26118880 Ref: Genetic mutations in human rectal cancers detected by targeted sequencing. PMID: 26134512 Ref: Intra-tumor heterogeneity of BRAF V600E mutation in lung adenocarcinomas. PMID: 26136882 Ref: Rectal and colon cancer: Not just a different anatomic site. PMID: 26145760 Ref: Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients. PMID: 26160882 Ref: In vitro prediction of the efficacy of molecularly targeted cancer therapy by Raman spectral imaging. PMID: 26168967 Ref: MGL ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colon cancer patients. PMID: 26172302 Ref: Fusobacterium nucleatum and T Cells in Colorectal Carcinoma. PMID: 26181352 Ref: Axillary Lymph Node Involvement, a Unique Pattern of Metastasis in BRAF-Mutant Colorectal Cancer. PMID: 26182332 Ref: Computed tomography assessment of early response to neoadjuvant therapy in colon cancer. PMID: 26183044 Ref: Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance). PMID: 26187617 Ref: Screening for Lynch syndrome and referral to clinical genetics by selective mismatch repair protein immunohistochemistry testing: an audit and cost analysis. PMID: 26201544 Ref: Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer. PMID: 26206335 Ref: BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers. PMID: 26208524 Ref: Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer. PMID: 26216840 Ref: Molecular markers and pathway analysis of colorectal carcinoma in the Middle East. PMID: 26218848 Ref: Detection of KRAS, NRAS and BRAF by mass spectrometry - a sensitive, reliable, fast and cost-effective technique. PMID: 26220423 Ref: Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers. PMID: 26226847 Ref: Diagnostic yield of targeted next generation sequencing in various cancer types: an information-theoretic approach. PMID: 26227479 Ref: Durable recurrence-free survival after pneumonectomy for late lung metastasis from rectal cancer: case report with genetic and epigenetic analyses. PMID: 26231173 Ref: Molecular biomarkers in colorectal carcinoma. PMID: 26237292 Ref: HER2 activating mutations are targets for colorectal cancer treatment. PMID: 26243863 Ref: Can the histological type of colorectal cancer determine the carcinogenesis pathway? PMID: 26247523 Ref: SPINK1 promotes colorectal cancer progression by downregulating Metallothioneins expression. PMID: 26258891 Ref: MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer. PMID: 26272063 Ref: Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. PMID: 26287849 Ref: Comprehensive DNA Methylation Analysis Reveals a Common Ten-Gene Methylation Signature in Colorectal Adenomas and Carcinomas. PMID: 26291085 Ref: Fentanyl inhibits the invasion and migration of colorectal cancer cells via inhibiting the negative regulation of Ets-1 on BANCR. PMID: 26296467 Ref: Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance. PMID: 26299805 Ref: [Biochip detection of KRAS, BRAF, and PIK3CA somatic mutations in colorectal cancer patients]. PMID: 26299862 Ref: Wild-type APC predicts poor prognosis in microsatellite-stable proximal colon cancer. PMID: 26305864 Ref: Probing a 3,4'-bis-guanidinium diaryl derivative as an allosteric inhibitor of the Ras pathway. PMID: 26318998 Ref: MSIplus for Integrated Colorectal Cancer Molecular Testing by Next-Generation Sequencing. PMID: 26322950 Ref: KRAS, NRAS, BRAF mutation comparison of endoscopic and surgically removed primary CRC paired samples: is endoscopy biopsy material adequate for molecular evaluation? PMID: 26325103 Ref: Precision medicine in colorectal cancer: the molecular profile alters treatment strategies. PMID: 26327923 Ref: The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences. PMID: 26335936 Ref: Molecular phenotypes of colorectal cancer and potential clinical applications. PMID: 26337942 Ref: Precision medicine in colorectal cancer: evolving genomic landscape and emerging consensus. PMID: 26338658 Ref: Expression of tumor-related Rac1b antagonizes B-Raf-induced senescence in colorectal cells. PMID: 26341689 Ref: Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. PMID: 26343581 Ref: Expression of the hyaluronan-mediated motility receptor RHAMM in tumor budding cells identifies aggressive colorectal cancers. PMID: 26351067 Ref: Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors. PMID: 26351322 Ref: KRAS, NRAS, BRAF mutations and high counts of poorly differentiated clusters of neoplastic cells in colorectal cancer: observational analysis of 175 cases. PMID: 26352110 Ref: Young age of onset colorectal cancers. PMID: 26358068 Ref: A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. PMID: 26358176 Ref: Co-existence of BRAF V600E Gene Mutation in Tumor and Non-tumoral Surrounding Tissues in Colorectal Cancer. PMID: 26359417 Ref: Annexin A10 expression in colorectal cancers with emphasis on the serrated neoplasia pathway. PMID: 26361422 Ref: PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs. PMID: 26365186 Ref: Clinical Validation of Targeted Next Generation Sequencing for Colon and Lung Cancers. PMID: 26366557 Ref: High Prevalence and Clinical Relevance of Genes Affected by Chromosomal Breaks in Colorectal Cancer. PMID: 26375816 Ref: Non-p.V600E BRAF Mutations Are Common Using a More Sensitive and Broad Detection Tool. PMID: 26386083 Ref: Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. PMID: 26392102 Ref: BRAF Mutation in Colorectal Cancer: An Update. PMID: 26396549 Ref: Serrated colorectal polyps in inflammatory bowel disease. PMID: 26403785 Ref: Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers. PMID: 26404261 Ref: Postdiagnostic intake of one-carbon nutrients and alcohol in relation to colorectal cancer survival. PMID: 26423386 Ref: Cell hierarchies in colorectal cancer: focus on APC and BRAF. PMID: 26425654 Ref: Rapid targeted somatic mutation analysis of solid tumors in routine clinical diagnostics. PMID: 26435479 Ref: Assessment of BRAF V600E Status in Colorectal Carcinoma: Tissue-Specific Discordances between Immunohistochemistry and Sequencing. PMID: 26438153 Ref: Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts. PMID: 26439693 Ref: Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope. PMID: 26446234 Ref: Prognostic and Predictive Biomarkers in Colorectal Cancer. From the Preclinical Setting to Clinical Practice. PMID: 26452385 Ref: Hitting the Target in BRAF-Mutant Colorectal Cancer. PMID: 26460302 Ref: Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. PMID: 26460303 Ref: Large Bowel Genetic Background and Inflammatory Processes in Carcinogenesis--Systematic Review. PMID: 26469098 Ref: Mitochondrial DNA copy number in colorectal cancer: between tissue comparisons, clinicopathological characteristics and survival. PMID: 26476438 Ref: Global gene expression profiling analysis reveals reduction of stemness after B-RAF inhibition in colorectal cancer cell lines. PMID: 26484206 Ref: Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan. PMID: 26486455 Ref: VE1 immunohistochemistry predicts BRAF V600E mutation status and clinical outcome in colorectal cancer. PMID: 26496026 Ref: Clinical detection and categorization of uncommon and concomitant mutations involving BRAF. PMID: 26498038 Ref: [Molecular phenotypes of colorectal cancer is critical in clinical individual treatment]. PMID: 26499143 Ref: Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients. PMID: 26508446 Ref: Molecular profiling in the treatment of colorectal cancer: focus on regorafenib. PMID: 26508880 Ref: Mutational profiling of colorectal cancers with microsatellite instability. PMID: 26517354 Ref: Colorectal Cancers with the Uncommon Findings of KRAS Mutation and Microsatellite Instability. PMID: 26523369 Ref: Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. PMID: 26527776 Ref: Molecular pathological epidemiology of colorectal cancer in Chinese patients with KRAS and BRAF mutations. PMID: 26530529 Ref: Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. PMID: 26541605 Ref: Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer. PMID: 26553291 Ref: Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites. PMID: 26553611 Ref: Molecular Features and Methylation Status in Early Onset ( PMID: 26557847 Ref: Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy. PMID: 26561209 Ref: Pharmacokinetic and pharmacodynamic evaluation of panitumumab in the treatment of colorectal cancer. PMID: 26572750 Ref: Biomarker-directed Targeted Therapy in Colorectal Cancer. PMID: 26609516 Ref: Overcoming Resistance to Targeted Therapies in Cancer. PMID: 26615134 Ref: BRAF in metastatic colorectal cancer: the future starts now. PMID: 26615988 Ref: Treatment Individualization in Colorectal Cancer. PMID: 26617477 Ref: Microsatellite instability in colorectal cancer: clinicopathological significance. PMID: 26619098 Ref: Mutation of the PIK3CA gene as a prognostic factor in patients with colorectal cancer. PMID: 26622684 Ref: Epigenetic inactivation of the extracellular matrix metallopeptidase ADAMTS19 gene and the metastatic spread in colorectal cancer. PMID: 26634009 Ref: A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy. PMID: 26664139 Ref: Mutation profile of KRAS and BRAF genes in patients with colorectal cancer: association with morphological and prognostic criteria. PMID: 26681025 Ref: Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases. PMID: 26691448 Ref: Aberrant DNA methylation profiles of inherited and sporadic colorectal cancer. PMID: 26697123 Ref: Proficiency of DNA repair genes and microsatellite instability in operated colorectal cancer patients with clinical suspicion of lynch syndrome. PMID: 26697194 Ref: Impact of somatic mutations on patterns of metastasis in colorectal cancer. PMID: 26697197 Ref: New therapeutic strategies for BRAF mutant colorectal cancers. PMID: 26697198 Ref: BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies. PMID: 26697199 Ref: Implications of mismatch repair-deficient status on management of early stage colorectal cancer. PMID: 26697201 Ref: Hepatic resection, hepatic arterial infusion pump therapy, and genetic biomarkers in the management of hepatic metastases from colorectal cancer. PMID: 26697204 Ref: A kinome siRNA screen identifies HGS as a potential target for liver cancers with oncogenic mutations in CTNNB1. PMID: 26715116 Ref: [A Case of Serrated Polyposis Syndrome with Early Colon Cancer]. PMID: 26805315 Ref: BRAF inhibitors in colorectal cancer: Toward a differentiation therapy? PMID: 27308494 |
Ref: Phase II Trial of Target-guided Personalized Chemotherapy in First-line Metastatic Colorectal Cancer. PMID: 24517959 Ref: BRAFV600E Gene Mutation in Colonic Adenocarcinomas. Immunohistochemical Detection Using Tissue Microarray and Clinicopathologic Characteristics: An 86 Case Series. PMID: 25710585 Ref: Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer. PMID: 26001389 Ref: Serrated tubulovillous adenoma of the large intestine. PMID: 26212352 Ref: Lower prevalence of Lynch syndrome in colorectal cancer patients in a Japanese hospital-based population. PMID: 26249337 Ref: Correlation between DPYD gene variation and KRAS wild type status in colorectal cancer. PMID: 26281864 Ref: Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. PMID: 26311717 Ref: The distribution of BRAF gene fusions in solid tumors and response to targeted therapy. PMID: 26314551 Ref: Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial. PMID: 26350752 Ref: Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6. PMID: 26369631 Ref: Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers. PMID: 26376292 Ref: Involvement of Notch-1 in Resistance to Regorafenib in Colon Cancer Cells. PMID: 26419617 Ref: MicroRNA MIR21 and T Cells in Colorectal Cancer. PMID: 26419959 Ref: Clinical influence of cancer stem cells on residual disease after preoperative chemoradiotherapy for rectal cancer. PMID: 26456957 Ref: Mutation Spectra of Common Cancer-Associated Genes in Different Phenotypes of Colorectal Carcinoma Without Distant Metastasis. PMID: 26471487 Ref: The serrated neoplasia pathway of colorectal tumors: Identification of MUC5AC hypomethylation as an early marker of polyps with malignant potential. PMID: 26476272 Ref: Prognostic Utility of Molecular Factors by Age at Diagnosis of Colorectal Cancer. PMID: 26490308 Ref: Traditional serrated adenoma with BRAF mutation is associated with synchronous/metachronous BRAF-mutated serrated lesions. PMID: 26496853 Ref: Lauric acid can improve the sensitization of Cetuximab in KRAS/BRAF mutated colorectal cancer cells by retrievable microRNA-378 expression. PMID: 26496897 Ref: Frequent BRAF mutation in early-onset colorectal cancer in Taiwan: association with distinct clinicopathological and molecular features and poor clinical outcome. PMID: 26500331 Ref: Genetic and epigenetic aberrations occurring in colorectal tumors associated with serrated pathway. PMID: 26510091 Ref: Clinicopathologic Risk Factor Distributions for MLH1 Promoter Region Methylation in CIMP-Positive Tumors. PMID: 26512054 Ref: NDRG4 stratifies the prognostic value of body mass index in colorectal cancer. PMID: 26515606 Ref: Next-Generation Sequencing of Matched Primary and Metastatic Rectal Adenocarcinomas Demonstrates Minimal Mutation Gain and Concordance to Colonic Adenocarcinomas. PMID: 26536055 Ref: Automated PCR detection of BRAF mutations in colorectal adenocarcinoma: a diagnostic test accuracy study. PMID: 26537294 Ref: Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer. PMID: 26538496 Ref: Colorectal cancer: Targeting BRAF mutations equally? PMID: 26552951 Ref: Survival Benefit of Exercise Differs by Tumor IRS1 Expression Status in Colorectal Cancer. PMID: 26577117 Ref: Immunohistochemical detection of the BRAF V600E mutant protein in colorectal cancers in Taiwan is highly concordant with the molecular test. PMID: 26588428 Ref: Prediagnosis Plasma Adiponectin in Relation to Colorectal Cancer Risk According to KRAS Mutation Status. PMID: 26598515 Ref: Targeting BRAF aberrations in advanced colorectal carcinoma: from bench to bedside. PMID: 26616508 Ref: Molecular Taxonomy and Tumourigenesis of Colorectal Cancer. PMID: 26631427 Ref: Microsatellite instability in pulmonary adenocarcinomas: a comprehensive study of 480 cases. PMID: 26637197 Ref: A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer. PMID: 26644411 Ref: HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. PMID: 26690310 Ref: Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin. PMID: 26702772 Ref: Methylator phenotype in colorectal cancer: A prognostic factor or not? PMID: 26702883 Ref: BRAF Mutation Testing and Metastatic Colorectal Cancer in the Community Setting: Is There an Urgent Need for More Education? PMID: 26714964 Ref: KRAS mutation in lung metastases from colorectal cancer: prognostic implications. PMID: 26715198 Ref: Loss of CDH1 (E-cadherin) expression is associated with infiltrative tumour growth and lymph node metastasis. PMID: 26742007 Ref: BRAF V600E inhibition stimulates AMP-activated protein kinase-mediated autophagy in colorectal cancer cells. PMID: 26750638 Ref: Microsatellite Alterations With Allelic Loss at 9p24.2 Signify Less-Aggressive Colorectal Cancer Metastasis. PMID: 26752111 Ref: Quantitative Detection and Resolution of BRAF V600 Status in Colorectal Cancer Using Droplet Digital PCR and a Novel Wild-Type Negative Assay. PMID: 26762843 Ref: Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis. PMID: 26775732 Ref: Critical Pitfalls in the use of BRAF Mutation as a Diagnostic Tool in Thyroid Nodules: a Case Report. PMID: 26782803 Ref: Common BRAF(V600E)-directed pathway mediates widespread epigenetic silencing in colorectal cancer and melanoma. PMID: 26787892 Ref: BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells. PMID: 26802026 Ref: EBI-907, a novel BRAF(V600E) inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile. PMID: 26810733 Ref: Right Sided Colon Cancer as a Distinct Histopathological Subtype with Reduced Prognosis. PMID: 26824772 Ref: Clinical significance of fibroblast growth factor receptor 2 expression in patients with residual rectal cancer after preoperative chemoradiotherapy: relationship with KRAS or BRAF mutations and MSI status. PMID: 26831663 Ref: Biomarkers for the identification of precursor polyps of colorectal serrated adenocarcinomas. PMID: 26832730 Ref: New Therapeutic Opportunities Based on DNA Mismatch Repair and BRAF Status in Metastatic Colorectal Cancer. PMID: 26861657 Ref: Integrative modeling of multi-omics data to identify cancer drivers and infer patient-specific gene activity. PMID: 26864072 Ref: Multikinase inhibitor regorafenib inhibits the growth and metastasis of colon cancer with abundant stroma. PMID: 26865419 Ref: Patients with colorectal cancer associated with Lynch syndrome and MLH1 promoter hypermethylation have similar prognoses. PMID: 26866578 Ref: Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer. PMID: 26867820 Ref: Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS. PMID: 26869800 Ref: Expression of hepatocyte growth factor and c-Met is characteristic of alpha-fetoprotein-producing colorectal adenocarcinoma: A report of three cases. PMID: 26870275 Ref: The relationship between EZH2 expression and microRNA-31 in colorectal cancer and the role in evolution of the serrated pathway. PMID: 26871294 Ref: Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer. PMID: 26872400 Ref: Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway. PMID: 26883113 Ref: The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis. PMID: 26887348 Ref: Clinicopathologic and prognostic associations of KRAS and BRAF mutations in small intestinal adenocarcinoma. PMID: 26892442 Ref: Association between the expression levels of TAZ, AXL and CTGF and clinicopathological parameters in patients with colon cancer. PMID: 26893723 Ref: Sessile Serrated Polyps are Precursors of Colon Carcinomas With Deficient DNA Mismatch Repair. PMID: 26898652 Ref: Molecular characterization of colorectal cancer patients and concomitant patient-derived tumor cell establishment. PMID: 26909603 Ref: Clinicopathologic distribution of KRAS and BRAF mutations in a Chinese population with colorectal cancer precursor lesions. PMID: 26910894 Ref: A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation. PMID: 26916115 Ref: Genotyping of colorectal cancer for cancer precision medicine: Results from the IPH Center for Molecular Pathology. PMID: 26917275 Ref: Value of KRAS, BRAF, and PIK3CA Mutations and Survival Benefit from Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis. PMID: 26925640 Ref: Mutation Analysis of KRAS and BRAF Genes in Metastatic Colorectal Cancer: a First Large Scale Study from Iran. PMID: 26925650 Ref: MicroRNA MIR21 (miR-21) and PTGS2 Expression in Colorectal Cancer and Patient Survival. PMID: 26957558 Ref: Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation. PMID: 26959608 Ref: Oncologists' Selection of Genetic and Molecular Testing in the Evolving Landscape of Stage II Colorectal Cancer. PMID: 26962170 Ref: Tracking the Correlation Between CpG Island Methylator Phenotype and Other Molecular Features and Clinicopathological Features in Human Colorectal Cancers: A Systematic Review and Meta-Analysis. PMID: 26963001 Ref: Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells. PMID: 26983878 Ref: BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis. PMID: 26991109 Ref: Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases. PMID: 26991344 Ref: Medullary carcinoma in the colorectum: a systematic review and meta-analysis. PMID: 27001432 Ref: Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX. PMID: 27002107 Ref: Reconsidering the benefit of intermittent versus continuous treatment in the maintenance treatment setting of metastatic colorectal cancer. PMID: 27002945 Ref: RAS mutation is a prognostic biomarker in colorectal cancer patients with metastasectomy. PMID: 27004837 Ref: Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm. PMID: 27009213 Ref: Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015. PMID: 27010906 Ref: Dual targeting of HER3 and EGFR in colorectal tumors might overcome anti-EGFR resistance. PMID: 27017409 Ref: Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels. PMID: 27022117 Ref: Colorectal cancer in Crohn's colitis is comparable to sporadic colorectal cancer. PMID: 27026089 Ref: Gene Signature in Sessile Serrated Polyps Identifies Colon Cancer Subtype. PMID: 27026680 Ref: The Prognostic Influence of BRAF Mutation and other Molecular, Clinical and Laboratory Parameters in Stage IV Colorectal Cancer. PMID: 27033063 Ref: BRAF mutation may have different prognostic implications in early- and late-stage colorectal cancer. PMID: 27034263 Ref: Molecular testing to optimize therapeutic decision making in advanced colorectal cancer. PMID: 27034809 Ref: Localization of active, dually phosphorylated extracellular signal-regulated kinase 1 and 2 in colorectal cancer with or without activating BRAF and KRAS mutations. PMID: 27036313 Ref: Systematic review: brain metastases from colorectal cancer--Incidence and patient characteristics. PMID: 27037031 Ref: Distribution of KRAS and BRAF Mutations in Metastatic Colorectal Cancers in Turkish Patients. PMID: 27039744 Ref: BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy. PMID: 27048246 Ref: Serrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapy. PMID: 27053844 Ref: A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility. PMID: 27058664 Ref: [Pathological Diagnosis and Its Molecular Basis in Colorectal Cancer]. PMID: 27067845 Ref: Prognostic impact of mutation profiling in patients with stage II and III colon cancer. PMID: 27074743 Ref: MicroRNA Expression Signatures Associated With BRAF-Mutated Versus KRAS-Mutated Colorectal Cancers. PMID: 27082577 Ref: Sporadic colorectal cancer: Studying ways to an end. PMID: 27087959 Ref: Lack of BRAFV600E mutation in stage I and II of colorectal cancer. PMID: 27099668 Ref: Validation and Application of a Custom-Designed Targeted Next-Generation Sequencing Panel for the Diagnostic Mutational Profiling of Solid Tumors. PMID: 27101000 Ref: BRAF-Like Colorectal Cancer Cells Are Selectively Dependent on RANBP2. PMID: 27102074 Ref: Neuroendocrine Differentiation of a Primary BRAF Mutant Colon Cancer in a Patient With a History of Hairy Cell Leukemia. PMID: 27117521 Ref: Biobanking of Fresh-Frozen Human Adenocarcinomatous and Normal Colon Tissues: Which Parameters Influence RNA Quality? PMID: 27124490 Ref: Microsatellite instability and B-type Raf proto-oncogene mutation in colorectal cancer: Clinicopathological characteristics and effects on survival. PMID: 27131021 Ref: Prognostic Role of BRAF Mutation in Stage II/III Colorectal Cancer Receiving Curative Resection and Adjuvant Chemotherapy: A Meta-Analysis Based on Randomized Clinical Trials. PMID: 27138801 Ref: (18)F-FDG PET/CT imaging in rectal cancer: relationship with the RAS mutational status. PMID: 27146067 Ref: Systematic immunohistochemical screening for Lynch syndrome in colorectal cancer: a single centre experience of 486 patients. PMID: 27152634 Ref: Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory. PMID: 27154421 Ref: Driver Gene Mutations in Stools of Colorectal Carcinoma Patients Detected by Targeted Next-Generation Sequencing. PMID: 27155048 Ref: Significant association and synergistic adverse prognostic effect of podocalyxin-like protein and epidermal growth factor receptor expression in colorectal cancer. PMID: 27160084 Ref: Relative telomere lengths in tumor and normal mucosa are related to disease progression and chromosome instability profiles in colorectal cancer. PMID: 27167335 Ref: [Insights on colorectal carcinoma based on the biological differences between left-sided and right- sided colon cancers]. PMID: 27188617 Ref: Clinical impact and network of determinants of tumour necrosis in colorectal cancer. PMID: 27195424 Ref: Diagnostic Accuracy of BRAF Immunohistochemistry in Colorectal Cancer: a Meta-Analysis and Diagnostic Test Accuracy Review. PMID: 27197524 Ref: PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. PMID: 27198569 Ref: Colorectal tumor molecular phenotype and miRNA: expression profiles and prognosis. PMID: 27198570 Ref: Linking Nucleoporins, Mitosis, and Colon Cancer. PMID: 27203373 Ref: [Clinicopathological characteristics of colorectal carcinoma in the elderly]. PMID: 27215512 Ref: Copy number changes of clinically actionable genes in melanoma, non-small cell lung cancer and colorectal cancer-A survey across 822 routine diagnostic cases. PMID: 27218826 Ref: Immunohistochemical staining for p16 and BRAFV600E is useful to distinguish between sporadic and hereditary (Lynch syndrome-related) microsatellite instable colorectal carcinomas. PMID: 27220764 Ref: TGFbeta signaling directs serrated adenomas to the mesenchymal colorectal cancer subtype. PMID: 27221051 Ref: Screening for Lynch Syndrome in Young Colorectal Cancer Patients from Saudi Arabia Using Microsatellite Instability as the Initial Test. PMID: 27221876 Ref: Longitudinal molecular characterization of endoscopic specimens from colorectal lesions. PMID: 27239120 Ref: Increased incidence of FBXW7 and POLE proofreading domain mutations in young adult colorectal cancers. PMID: 27244218 Ref: ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. PMID: 27246726 Ref: Recurrent, truncating SOX9 mutations are associated with SOX9 overexpression, KRAS mutation, and TP53 wild type status in colorectal carcinoma. PMID: 27248473 Ref: BRAF V600E mutation in metastatic colorectal cancer: Methods of detection and correlation with clinical and pathologic features. PMID: 27261210 Ref: The prognostic yield of biomarkers harvested in chemotherapy-naive stage II colon cancer: can we separate the wheat from the chaff? PMID: 27262159 Ref: Comparison of KRAS mutation status between primary tumor and metastasis in Chinese colorectal cancer patients. PMID: 27270901 Ref: Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer. PMID: 27272216 Ref: Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance. PMID: 27283768 Ref: Efficacy of cetuximab-based chemotherapy in metastatic colorectal cancer according to RAS and BRAF mutation subgroups: A meta-analysis. PMID: 27284437 Ref: [Lynch Syndrome - the Pathologist's Diagnosis]. PMID: 27296402 Ref: Clinicopathologic and Molecular Features of Colorectal Adenocarcinoma with Signet-Ring Cell Component. PMID: 27300552 Ref: Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes. PMID: 27302833 Ref: RNF43 Is an Early and Specific Mutated Gene in the Serrated Pathway, With Increased Frequency in Traditional Serrated Adenoma and Its Associated Malignancy. PMID: 27305845 Ref: Effective MAPK Inhibition is critical for therapeutic responses in colorectal cancer with BRAF mutations. PMID: 27308562 Ref: Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer. PMID: 27312529 Ref: Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer. PMID: 27314237 Ref: Could gut microbiota serve as prognostic biomarker associated with colorectal cancer patients' survival? A pilot study on relevant mechanism. PMID: 27323816 Ref: MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer. PMID: 27325282 Ref: FAT1: a potential target for monoclonal antibody therapy in colon cancer. PMID: 27328312 Ref: Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and Beyond Targeted Therapies in Colon Cancer Today and Tomorrow. PMID: 27332557 Ref: Diagnostic RAS mutation analysis by polymerase chain reaction (PCR). PMID: 27335808 Ref: Oncogenic KRAS and BRAF Drive Metabolic Reprogramming in Colorectal Cancer. PMID: 27340238 Ref: Biomarker in Colorectal Cancer. PMID: 27341592 Ref: Targeting the serrated pathway of colorectal cancer with mutation in BRAF. PMID: 27345584 Ref: Frequency of BRAF V600E mutations in 969 central nervous system neoplasms. PMID: 27350555 Ref: BRAFV600E-dependent Mcl-1 stabilization leads to everolimus resistance in colon cancer cells. PMID: 27351224 Ref: Distinct Transcriptional Changes and Epithelial-Stromal Interactions Are Altered in Early-Stage Colon Cancer Development. PMID: 27353028 Ref: Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literature. PMID: 27355330 Ref: Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer. PMID: 27382031 Ref: Reactivation of ERK and Akt confers resistance of mutant BRAF colon cancer cells to the HSP90 inhibitor AUY922. PMID: 27391062 Ref: Tumor LINE-1 methylation level and colorectal cancer location in relation to patient survival. PMID: 27391152 Ref: Challenging a dogma: co-mutations exist in MAPK pathway genes in colorectal cancer. PMID: 27401719 Ref: Colorectal Cancer with BRAF D594G Mutation Is Not Associated with Microsatellite Instability or Poor Prognosis. PMID: 27404270 Ref: Highly sensitive detection of the PIK3CA (H1047R) mutation in colorectal cancer using a novel PCR-RFLP method. PMID: 27405731 Ref: SOX2 expression is associated with a cancer stem cell state and down-regulation of CDX2 in colorectal cancer. PMID: 27411517 Ref: HIF-1alpha expression and high microvessel density are characteristic features in serrated colorectal cancer. PMID: 27421843 Ref: Serrated polyposis associated with a family history of colorectal cancer and/or polyps: The preferential location of polyps in the colon and rectum defines two molecular entities. PMID: 27430658 Ref: CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer. PMID: 27435270 Ref: MLH1-deficient Colorectal Carcinoma With Wild-type BRAF and MLH1 Promoter Hypermethylation Harbor KRAS Mutations and Arise From Conventional Adenomas. PMID: 27438990 Ref: Clinical and Molecular Characteristics of Post-Colonoscopy Colorectal Cancer: A Population-based Study. PMID: 27443823 Ref: Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells. PMID: 27461218 Ref: Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study). PMID: 27468920 Ref: Sur8 mediates tumorigenesis and metastasis in colorectal cancer. PMID: 27469030 Ref: Ursolic acid synergistically enhances the therapeutic effects of oxaliplatin in colorectal cancer. PMID: 27472952 Ref: Regular Aspirin Use Associates With Lower Risk of Colorectal Cancers With Low Numbers of Tumor-Infiltrating Lymphocytes. PMID: 27475305 Ref: Cost-Effectiveness Analysis of Different Genetic Testing Strategies for Lynch Syndrome in Taiwan. PMID: 27482709 Ref: Quantitative analysis of wild-type and V600E mutant BRAF proteins in colorectal carcinoma using immunoenrichment and targeted mass spectrometry. PMID: 27497007 Ref: The infiltration, and prognostic importance, of Th1 lymphocytes vary in molecular subgroups of colorectal cancer. PMID: 27499912 Ref: The molecular characteristics of colonic neoplasms in serrated polyposis: a systematic review and meta-analysis. PMID: 27499922 Ref: Somatic mutation profiles in primary colorectal cancers and matching ovarian metastases: Identification of driver and passenger mutations. PMID: 27499925 Ref: Molecular differences in the microsatellite stable phenotype between left-sided and right-sided colorectal cancer. PMID: 27509333 Ref: IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis. PMID: 27520705 Ref: Epigenetic Homogeneity Within Colorectal Tumors Predicts Shorter Relapse-Free and Overall Survival Times for Patients With Locoregional Cancer. PMID: 27521480 Ref: Carrier molecules and extraction of circulating tumor DNA for next generation sequencing in colorectal cancer. PMID: 27526306 Ref: KRAS, BRAF oncogene mutations and tissue specific promoter hypermethylation of tumor suppressor SFRP2, DAPK1, MGMT, HIC1 and p16 genes in colorectal cancer patients. PMID: 27540971 Ref: Colorectal cancer in the very young: a comparative study of tumor markers, pathology and survival in early onset and adult onset patients. PMID: 27558481 Ref: High sensitivity isoelectric focusing to establish a signaling biomarker for the diagnosis of human colorectal cancer. PMID: 27562229 Ref: Two subtypes of colorectal tumor with distinct molecular features in familial adenomatous polyposis. PMID: 27563825 Ref: Molecular markers of prognosis and therapeutic targets in metastatic colorectal cancer. PMID: 27566022 Ref: Diagnostic value of immunohistochemistry for the detection of the BRAF V600E mutation in colorectal carcinoma. PMID: 27569082 Ref: Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy. PMID: 27570430 Ref: Identification and Characterization of Small-Molecule Inhibitors to Selectively Target the DFG-in over the DFG-out Conformation of the B-Raf Kinase V600E Mutant in Colorectal Cancer. PMID: 27624806 Ref: Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer. PMID: 27626067 Ref: Prognostic Role of BRAF Mutations in Colorectal Cancer Liver Metastases. PMID: 27630332 Ref: [Prognostic biomarkers for metastatic colorectal cancer]. PMID: 27638531 Ref: [Pathogenetic aspects in precursor lesions of gastrointestinal tumors]. PMID: 27638535 Ref: How the lab is changing our view of colorectal cancer. PMID: 27647226 Ref: MEK and TAK1 Regulate Apoptosis in Colon Cancer Cells with KRAS-Dependent Activation of Proinflammatory Signaling. PMID: 27655129 Ref: Oncogene Mutations in Colorectal Polyps Identified in the Norwegian Colorectal Cancer Prevention (NORCCAP) Screening Study. PMID: 27656095 Ref: RNF43 and ZNRF3 are commonly altered in serrated pathway colorectal tumorigenesis. PMID: 27661107 Ref: Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G. PMID: 27712015 Ref: Genomic profiling of stage II and III colon cancers reveals APC mutations to be associated with survival in stage III colon cancer patients. PMID: 27729614 Ref: Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study. PMID: 27737711 Ref: MicroRNA let-7, T Cells, and Patient Survival in Colorectal Cancer. PMID: 27737877 Ref: Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. PMID: 27743922 Ref: RAS and BRAF in metastatic colorectal cancer management. PMID: 27747083 Ref: Beyond RAS and BRAF: a target rich disease that is ripe for picking. PMID: 27747084 Ref: Biomarkers for immune therapy in colorectal cancer: mismatch-repair deficiency and others. PMID: 27747085 Ref: Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer. PMID: 27764839 Ref: Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer. PMID: 27765849 Ref: Triple Therapy Improves Colorectal Cancer Response. PMID: 27770002 Ref: Oncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancer. PMID: 27777877 Ref: [Research progress of serrated polyposis syndrome]. PMID: 27781259 Ref: KRAS Mutant Status, p16 and beta-catenin Expression May Predict Local Recurrence in Patients Who Underwent Transanal Endoscopic Microsurgery (TEMS) for Stage I Rectal Cancer. PMID: 27798894 Ref: No association of CpG island methylator phenotype and colorectal cancer survival: population-based study. PMID: 27811854 Ref: FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc. PMID: 27825133 Ref: The evolving role of microsatellite instability in colorectal cancer: A review. PMID: 27838401 Ref: Multimodal tumor suppression by miR-302 cluster in melanoma and colon cancer. PMID: 27840154 Ref: Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer. PMID: 27863403 Ref: Hypoxic resistance of KRAS mutant tumor cells to 3-Bromopyruvate is counteracted by Prima-1 and reversed by N-acetylcysteine. PMID: 27863474 Ref: Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance). PMID: 27881709 Ref: Role of specific DNA mutations in the peripheral blood of colorectal cancer patients for the assessment of tumor stage and residual disease following tumor resection. PMID: 27900004 Ref: Favorable control of advanced colon adenocarcinoma with severe bone marrow metastasis: A case report. PMID: 27900088 Ref: High Intra- and Inter-Tumoral Heterogeneity of RAS Mutations in Colorectal Cancer. PMID: 27916952 Ref: Role of Biologics in First-Line Treatment of Colorectal Cancer. PMID: 27943689 Ref: Colorectal Choriocarcinoma in a Patient with Probable Lynch Syndrome. PMID: 27965933 Ref: Association between proto-oncogene mutations and clinicopathologic characteristics and overall survival in colorectal cancer in East Azerbaijan, Iran. PMID: 27994469 Ref: Genomic landscape of colorectal cancer in Japan: clinical implications of comprehensive genomic sequencing for precision medicine. PMID: 28007036 Ref: Personalized oncogenomics in the management of gastrointestinal carcinomas-early experiences from a pilot study. PMID: 28050146 Ref: Molecular spectrum of KRAS, NRAS, BRAF, PIK3CA, TP53, and APC somatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern. PMID: 28078112 Ref: Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein. PMID: 28082821 Ref: Impact of microsatellite status on chemotherapy for colorectal cancer patients with KRAS or BRAF mutation. PMID: 28101205 Ref: [Evaluation of BRAF V600E Mutations in High-Level Microsatellite Instability(MSI-H)Colon Cancer - Comparison Between Genetic Testing and Immunohistochemical Staining]. PMID: 28133101 Ref: [A Case of Metastatic Colon Cancer Dramatically Affected by Anti-EGFR Antibody Therapy]. PMID: 28133136 Ref: [A Systematic Analysis of Oncogene and Tumor Suppressor Genes for Panitumumab-Resistant Rectal Cancer with Wild RAS Gene - A Case Report]. PMID: 28133295 Ref: [A Case of Metastatic Colorectal Cancer with HER2 Overexpression/Amplification]. PMID: 28133304 Ref: Evaluation and identification of factors related to KRAS and BRAF gene mutations in colorectal cancer: A meta-analysis. PMID: 28230016 Ref: Significance of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving Bevacizumab: a single institution experience. PMID: 28356789 Ref: Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial. PMID: 28848656 Ref: Vitamin C, a Multi-Tasking Molecule, Finds a Molecular Target in Killing Cancer Cells. PMID: 29780883 |
Ref: Clinicopathological and molecular features of sessile serrated adenomas with dysplasia or carcinoma. PMID: 26475632 Ref: The Lymphocyte-to-Monocyte Ratio is a Superior Predictor of Overall Survival in Comparison to Established Biomarkers of Resectable Colorectal Cancer. PMID: 27070934 Ref: Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. PMID: 27196573 Ref: Small Bowel Adenocarcinoma Frequently Exhibits Lynch Syndrome-associated Mismatch Repair Protein Deficiency But Does Not Harbor Sporadic MLH1 Deficiency. PMID: 27258561 Ref: Tumor testing to identify lynch syndrome in two Australian colorectal cancer cohorts. PMID: 27273229 Ref: Inhibition of the CRAF/prohibitin interaction reverses CRAF-dependent resistance to vemurafenib. PMID: 27321184 Ref: Evaluation of [(18)F]Fluorothymidine as a Biomarker for Early Therapy Response in a Mouse Model of Colorectal Cancer. PMID: 27324368 Ref: RNF43 germline and somatic mutation in serrated neoplasia pathway and its association with BRAF mutation. PMID: 27329244 Ref: BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression. PMID: 27354468 Ref: Clinicopathological characteristics of serrated polyps as precursors to colorectal cancer: Current status and management. PMID: 27376251 Ref: Paired Primary and Metastatic Tumor Analysis of Somatic Mutations in Synchronous and Metachronous Colorectal Cancer. PMID: 27384156 Ref: FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation. PMID: 27399335 Ref: Micropapillary colorectal carcinoma: clinical, pathological and molecular properties, including evidence of epithelial-mesenchymal transition. PMID: 27560620 Ref: Mucinous and Signet Ring Cell Differentiation Affect Patterns of Metastasis in Colorectal Carcinoma and Influence Survival. PMID: 27571790 Ref: Colorectal cancer heterogeneity and targeted therapy: Clinical implications, challenges and solutions for treatment resistance. PMID: 27578007 Ref: Comparison of the molecular profile of brain metastases from colorectal cancer and corresponding primary tumors. PMID: 27578453 Ref: Subclonal diversity arises early even in small colorectal tumours and contributes to differential growth fates. PMID: 27609830 Ref: A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors. PMID: 27650277 Ref: Prognostic value of BRAF V600E mutation and microsatellite instability in Japanese patients with sporadic colorectal cancer. PMID: 27672042 Ref: Colorectal carcinomas with submucosal invasion (pT1): analysis of histopathological and molecular factors predicting lymph node metastasis. PMID: 27713420 Ref: Non-Invasive Glutamine PET Reflects Pharmacological Inhibition of BRAF(V600E) In Vivo. PMID: 27770401 Ref: Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer. PMID: 27771609 Ref: Clinicopathologic profile, immunophenotype, and genotype of CD274 (PD-L1)-positive colorectal carcinomas. PMID: 27813511 Ref: BRAF and NRAS Locus-Specific Variants Have Different Outcomes on Survival to Colorectal Cancer. PMID: 27815357 Ref: A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803. PMID: 27821793 Ref: Associations of defect mismatch repair genes with prognosis and heredity in sporadic colorectal cancer. PMID: 27836416 Ref: EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer. PMID: 27879995 Ref: Evolutionary biologic changes of gut microbiota in an 'adenoma-carcinoma sequence' mouse colorectal cancer model induced by 1, 2-Dimethylhydrazine. PMID: 27880935 Ref: CpG Island Methylator Phenotype-High Colorectal Cancers and Their Prognostic Implications and Relationships with the Serrated Neoplasia Pathway. PMID: 27885175 Ref: BRAF-Mutated Colorectal Cancer Exhibits Distinct Clinicopathological Features from Wild-Type BRAF-Expressing Cancer Independent of the Microsatellite Instability Status. PMID: 27914130 Ref: Clinicopathological Features and Predictive Factors for Colorectal Cancer Outcome in the Kingdom of Saudi Arabia. PMID: 27915339 Ref: Prevalence of Lynch syndrome and Lynch-like syndrome among patients with colorectal cancer in a Japanese hospital-based population. PMID: 27920101 Ref: Chemotherapeutic drug selectivity between wild-type and mutant BRaf kinases in colon cancer. PMID: 27921184 Ref: Lifetime alcohol intake is associated with an increased risk of KRAS+ and BRAF-/KRAS- but not BRAF+ colorectal cancer. PMID: 27943267 Ref: BRAF-mutated cells activate GCN2-mediated integrated stress response as a cytoprotective mechanism in response to vemurafenib. PMID: 27965097 Ref: Cytotoxic T Cells and Granzyme B Associated with Improved Colorectal Cancer Survival in a Prospective Cohort of Older Women. PMID: 27979806 Ref: Morphological characterization of colorectal cancers in The Cancer Genome Atlas reveals distinct morphology-molecular associations: clinical and biological implications. PMID: 27982025 Ref: Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials. PMID: 27993800 Ref: LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer. PMID: 27999210 Ref: High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases. PMID: 28000889 Ref: Targeted exome sequencing reveals distinct pathogenic variants in Iranians with colorectal cancer. PMID: 28002797 Ref: Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells. PMID: 28002807 Ref: Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials. PMID: 28006055 Ref: Clinical relevance of colorectal cancer molecular subtypes. PMID: 28010901 Ref: Metastatic Pattern of Stage IV Colorectal Cancer with High-Frequency Microsatellite Instability as a Prognostic Factor. PMID: 28011498 Ref: Detection of Sessile Serrated Adenomas in the Proximal Colon Using Wide-Field Fluorescence Endoscopy. PMID: 28012848 Ref: Analysis of KRAS, NRAS, PIK3CA, and BRAF mutational profile in poorly differentiated clusters of KRAS-mutated colon cancer. PMID: 28025078 Ref: EGFR Gene Amplification and KRAS Mutation Predict Response to Combination Targeted Therapy in Metastatic Colorectal Cancer. PMID: 28025786 Ref: Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients. PMID: 28031175 Ref: Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer. PMID: 28040692 Ref: Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer. PMID: 28040715 Ref: A tailored approach to BRAF and MLH1 methylation testing in a universal screening program for Lynch syndrome. PMID: 28059100 Ref: Response to Chemotherapy and Prognosis in Metastatic Colorectal Cancer With DNA Deficient Mismatch Repair. PMID: 28063788 Ref: Translating genomic profiling to gastrointestinal cancer treatment. PMID: 28067073 Ref: Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients. PMID: 28068936 Ref: BRAF(V600E) cooperates with CDX2 inactivation to promote serrated colorectal tumorigenesis. PMID: 28072391 Ref: KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma. PMID: 28074351 Ref: Molecular subtypes of colorectal cancers determined by PCR-based analysis. PMID: 28083970 Ref: Detection of Rare Mutations by Routine Analysis of KRAS, NRAS, and BRAF Oncogenes. PMID: 28091917 Ref: Genetic and Epigenetic Intra-tumour Heterogeneity in Colorectal Cancer. PMID: 28097409 Ref: [Improvement of prognostic and predictive network of colorectal cancer based upon the 8th edition of AJCC colorectal cancer staging system]. PMID: 28105615 Ref: Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer. PMID: 28106826 Ref: A Prospective Study of Smoking and Risk of Synchronous Colorectal Cancers. PMID: 28117362 Ref: The Influence of BRAF and KRAS Mutation Status on the Association between Aspirin Use and Survival after Colon Cancer Diagnosis. PMID: 28125730 Ref: EZH2 expression is a prognostic biomarker in patients with colorectal cancer treated with anti-EGFR therapeutics. PMID: 28147317 Ref: A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. PMID: 28152546 Ref: Drug Combo Beats Vemurafenib Alone for Colorectal Cancer. PMID: 28153858 Ref: Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients. PMID: 28170370 Ref: Enhanced dependency of KRAS-mutant colorectal cancer cells on RAD51-dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae. PMID: 28173629 Ref: Comparative Study of Mutations in Single Nucleotide Polymorphism Loci of KRAS and BRAF Genes in Patients Who Underwent Screening Colonoscopy, With and Without Premalignant Intestinal Polyps. PMID: 28179313 Ref: Heat-shock protein 27 (HSP27, HSPB1) is synthetic lethal to cells with oncogenic activation of MET, EGFR and BRAF. PMID: 28182330 Ref: Chromosome 20q Amplification Defines a Subtype of Microsatellite Stable, Left-Sided Colon Cancers with Wild-type RAS/RAF and Better Overall Survival. PMID: 28184012 Ref: Perioperative bevacizumab improves survival following lung metastasectomy for colorectal cancer in patients harbouring v-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue exon 2 codon 12 mutationsdagger. PMID: 28186237 Ref: Time-resolved Phosphoproteome Analysis of Paradoxical RAF Activation Reveals Novel Targets of ERK. PMID: 28188228 Ref: KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior. PMID: 28188750 Ref: BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment? PMID: 28214977 Ref: Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis. PMID: 28216246 Ref: Epigenetic silencing of diacylglycerol kinase gamma in colorectal cancer. PMID: 28218473 Ref: Molecular Testing for Gastrointestinal Cancer. PMID: 28219002 Ref: In Vivo Efficacy of Umbilical Cord Blood Stem Cell-Derived NK Cells in the Treatment of Metastatic Colorectal Cancer. PMID: 28220124 Ref: Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study. PMID: 28222664 Ref: Construction of a multiplex mutation hot spot PCR panel: the first step towards colorectal cancer genotyping on the GS Junior platform. PMID: 28243320 Ref: [Does the sidedness determine the first line treatment of irresectable metastatic colorectal cancer?] PMID: 28245681 Ref: Dietary Patterns and Risk of Colorectal Cancer: Analysis by Tumor Location and Molecular Subtypes. PMID: 28249812 Ref: Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study. PMID: 28252533 Ref: Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. PMID: 28267766 Ref: Dietary glycemic and insulin scores and colorectal cancer survival by tumor molecular biomarkers. PMID: 28268248 Ref: Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. PMID: 28275037 Ref: Right Versus Left Colon Cancer Biology: Integrating the Consensus Molecular Subtypes. PMID: 28275039 Ref: Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system. PMID: 28278514 Ref: Family history of colorectal cancer and its impact on survival in patients with resected stage III colon cancer: results from NCCTG Trial N0147 (Alliance). PMID: 28280603 Ref: Differences in symptom occurrence, severity, and distress ratings between patients with gastrointestinal cancers who received chemotherapy alone or chemotherapy with targeted therapy. PMID: 28280616 Ref: Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis. PMID: 28280620 Ref: Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie. PMID: 28280626 Ref: BRAF mutations are associated with increased iron regulatory protein-2 expression in colorectal tumorigenesis. PMID: 28281325 Ref: Strategies for Overcoming Resistance in Tumours Harboring BRAF Mutations. PMID: 28282860 Ref: Validating a fully automated real-time PCR-based system for use in the molecular diagnostic analysis of colorectal carcinoma: a comparison with NGS and IHC. PMID: 28292978 Ref: Identification of Methylation Profiles of Cancer-related Genes in Circulating Tumor Cells Population. PMID: 28314271 Ref: KRAS Mutant Status May Be Associated with Distant Recurrence in Early-stage Rectal Cancer. PMID: 28314302 Ref: Sessile Serrated Polyps and Colon Cancer Prevention. PMID: 28325827 Ref: Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance). PMID: 28327908 Ref: CpG island methylator phenotype in adenocarcinomas from the digestive tract: Methods, conclusions, and controversies. PMID: 28344746 Ref: Mitochondrial DNA alteration in primary and metastatic colorectal cancer: Different frequency and association with selected clinicopathological and molecular markers. PMID: 28345467 Ref: Novel Palladium(II) Complexes that Influence Prominin-1/CD133 Expression and Stem Cell Factor Release in Tumor Cells. PMID: 28358339 Ref: A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer. PMID: 28363909 Ref: Cell-free DNA as biomarker and source for mutation detection in primary colorectal cancer. PMID: 28365952 Ref: Rational design, synthesis, and biological evaluation of Pan-Raf inhibitors to overcome resistance. PMID: 28368067 Ref: Methylation of WNT target genes AXIN2 and DKK1 as robust biomarkers for recurrence prediction in stage II colon cancer. PMID: 28368388 Ref: DNA methylation epigenotype and clinical features of NRAS-mutation(+) colorectal cancer. PMID: 28378457 Ref: The prognostic value of simultaneous tumor and serum RAS/RAF mutations in localized colon cancer. PMID: 28378527 Ref: Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer. PMID: 28382467 Ref: Circulating DNA Demonstrates Convergent Evolution and Common Resistance Mechanisms during Treatment of Colorectal Cancer. PMID: 28400427 Ref: Tumor SQSTM1 (p62) expression and T cells in colorectal cancer. PMID: 28405513 Ref: Prognostic implication of CD274 (PD-L1) protein expression in tumor-infiltrating immune cells for microsatellite unstable and stable colorectal cancer. PMID: 28405764 Ref: Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status. PMID: 28406723 Ref: Mechanistic characterization of a copper containing thiosemicarbazone with potent antitumor activity. PMID: 28415818 Ref: The molecular heterogeneity of sporadic colorectal cancer with different tumor sites in Chinese patients. PMID: 28416767 Ref: Panitumumab-Conjugated Pt-Drug Nanomedicine for Enhanced Efficacy of Combination Targeted Chemotherapy against Colorectal Cancer. PMID: 28418176 Ref: FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. PMID: 28424412 Ref: Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma. PMID: 28424871 Ref: Mapping clinicopathological entities within colorectal mucinous adenocarcinomas: a hierarchical clustering approach. PMID: 28429715 Ref: NRASQ61R immunohistochemistry detects both NRASQ61R and KRASQ61R mutations in colorectal cancer. PMID: 28433252 Ref: Clinicopathological, immunohistochemical, and mutational analyses of pulmonary enteric adenocarcinoma: usefulness of SATB2 and beta-catenin immunostaining for differentiation from metastatic colorectal carcinoma. PMID: 28438615 Ref: Risk factors for brain metastases in patients with metastatic colorectal cancer. PMID: 28447565 Ref: Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy. PMID: 28453690 Ref: Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study. PMID: 28453697 Ref: Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer. PMID: 28459468 Ref: HMG-CoA synthase 1 is a synthetic lethal partner of BRAF(V600E) in human cancers. PMID: 28468827 Ref: Screening for mismatch repair deficiency in colorectal cancer: data from three academic medical centers. PMID: 28470797 Ref: (Non-V600) BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. PMID: 28486044 Ref: Endoscopic and molecular characterization of colorectal sessile serrated adenoma/polyps with cytologic dysplasia. PMID: 28501592 Ref: What We Know About Stage II and III Colon Cancer: It's Still Not Enough. PMID: 28504299 Ref: Detection of an ALK Fusion in Colorectal Carcinoma by Hybrid Capture-Based Assay of Circulating Tumor DNA. PMID: 28507204 Ref: Retraction: Evaluation and identification of factors related to KRAS and BRAF gene mutations in colorectal cancer: A meta analysis. PMID: 28508855 Ref: A Systematic Analysis of Oncogenic Gene Fusions in Primary Colon Cancer. PMID: 28512242 Ref: Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer. PMID: 28513830 Ref: KRAS and BRAF mutations in serum exosomes from patients with colorectal cancer in a Chinese population. PMID: 28521461 Ref: Identification of "BRAF-Positive" Cases Based on Whole-Slide Image Analysis. PMID: 28523274 Ref: AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes. PMID: 28536078 Ref: Lack of Aberrant Methylation in an Adjacent Area of Left-Sided Colorectal Cancer. PMID: 28540987 Ref: CpG island methylator phenotype identifies high risk patients among microsatellite stable BRAF mutated colorectal cancers. PMID: 28542846 Ref: Predictive model for high-frequency microsatellite instability in colorectal cancer patients over 50 years of age. PMID: 28544821 Ref: MEK162 Enhances Antitumor Activity of 5-Fluorouracil and Trifluridine in KRAS-mutated Human Colorectal Cancer Cell Lines. PMID: 28551618 Ref: Extramural vascular invasion and response to neoadjuvant chemoradiotherapy in rectal cancer: Influence of the CpG island methylator phenotype. PMID: 28567185 Ref: Targeting of super-enhancers and mutant BRAF can suppress growth of BRAF-mutant colon cancer cells via repression of MAPK signaling pathway. PMID: 28576751 Ref: Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination Strategies. PMID: 28576843 Ref: Coexistence of KRAS and BRAF Mutations in Colorectal Cancer: A Case Report Supporting The Concept of Tumoral Heterogeneity. PMID: 28580315 Ref: The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients. PMID: 28583095 Ref: Intratumoral Fusobacterium nucleatum abundance correlates with macrophage infiltration and CDKN2A methylation in microsatellite-unstable colorectal carcinoma. PMID: 28597080 Ref: Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy. PMID: 28598398 Ref: Targeting the Wnt Pathway and Cancer Stem Cells with Anti-progastrin Humanized Antibodies as a Potential Treatment for K-RAS-Mutated Colorectal Cancer. PMID: 28600477 Ref: A Novel Combination Treatment Targeting BCL-XL and MCL1 for KRAS/BRAF-mutated and BCL2L1-amplified Colorectal Cancers. PMID: 28611106 Ref: Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations. PMID: 28611205 Ref: BRAF mutation is associated with poor clinicopathological outcomes in colorectal cancer: A meta-analysis. PMID: 28611337 Ref: Timing of Aspirin and Other Nonsteroidal Anti-Inflammatory Drug Use Among Patients With Colorectal Cancer in Relation to Tumor Markers and Survival. PMID: 28617623 Ref: Genomic Profiling of Small-Bowel Adenocarcinoma. PMID: 28617917 Ref: Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insights. PMID: 28618197 Ref: Extreme assay sensitivity in molecular diagnostics further unveils intratumour heterogeneity in metastatic colorectal cancer as well as artifactual low-frequency mutations in the KRAS gene. PMID: 28618430 Ref: Biomarker correlation network in colorectal carcinoma by tumor anatomic location. PMID: 28623901 Ref: Investigation of patterns of nodal metastases in BRAF mutant lung cancer. PMID: 28625649 Ref: The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab. PMID: 28632725 Ref: Significant Improvement in Detecting BRAF, KRAS, and EGFR Mutations Using Next-Generation Sequencing as Compared with FDA-Cleared Kits. PMID: 28639239 Ref: Clinical Case of the Month: A 57-Year-Old Man with an Axillary Mass. PMID: 28644156 Ref: Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF(V600E) mutant cancer. PMID: 28645859 Ref: Associations of red and processed meat intake with major molecular pathological features of colorectal cancer. PMID: 28646407 Ref: Screening for Lynch Syndrome in Cases with Colorectal Carcinoma from Mashhad. PMID: 28646840 Ref: Clinical responses to ERK inhibition in BRAF(V600E)-mutant colorectal cancer predicted using a computational model. PMID: 28649441 Ref: Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. PMID: 28651158 Ref: RAS screening in colorectal cancer: a comprehensive analysis of the results from the UK NEQAS colorectal cancer external quality assurance schemes (2009-2016). PMID: 28653203 Ref: Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer. PMID: 28654634 Ref: BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity. PMID: 28655712 Ref: Cetuximab promotes SN38 sensitivity via suppression of heat shock protein 27 in colorectal cancer cells with wild-type RAS. PMID: 28656305 Ref: PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation. PMID: 28659148 Ref: Oncogene mutation profile predicts tumor regression and survival in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and radical surgery. PMID: 28671043 Ref: Molecular and Clinicopathological Differences by Age at the Diagnosis of Colorectal Cancer. PMID: 28678173 Ref: The current value of determining the mismatch repair status of colorectal cancer: A rationale for routine testing. PMID: 28693799 Ref: Molecular genetic changes in benign colorectal tumors synchronous with microsatellite unstable carcinomas do not support a field defect. PMID: 28694923 Ref: EGFR Downregulation after Anti-EGFR Therapy Predicts the Antitumor Effect in Colorectal Cancer. PMID: 28698359 Ref: Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment. PMID: 28708103 Ref: [Leptomeningeal carcinomatosis as a rare metastatic spreading of BRAF-mutated microsatellite stable colon cancer]. PMID: 28709170 Ref: BRAF p.V600E-specific immunohistochemical assessment in colorectal cancer endoscopy biopsies is consistent with the mutational profiling. PMID: 28722262 Ref: Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies. PMID: 28736627 Ref: [Characterization of patients with sporadic colorectal cancer following the new Consensus Molecular Subtypes (CMS)]. PMID: 28748988 Ref: Opposing effects of low versus high concentrations of water soluble vitamins/dietary ingredients Vitamin C and niacin on colon cancer stem cells (CSCs). PMID: 28755485 Ref: Thyroid cancer in a patient with Lynch syndrome - case report and literature review. PMID: 28769567 Ref: Immunoscore in mismatch repair-proficient and -deficient colon cancer. PMID: 28770104 Ref: A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis. PMID: 28775144 Ref: Squirrel Primer-Based PCR Assay for Direct and Targeted Sanger Sequencing of Short Genomic Segments. PMID: 28785174 Ref: Potential Role of Metabolic Intervention in the Management of Advanced Differentiated Thyroid Cancer. PMID: 28791253 Ref: Recent developments in the treatment of metastatic colorectal cancer. PMID: 28794806 Ref: Differences of protein expression profiles, KRAS and BRAF mutation, and prognosis in right-sided colon, left-sided colon and rectal cancer. PMID: 28801584 Ref: Are All Mutations the Same? A Rare Case Report of Coexisting Mutually Exclusive KRAS and BRAF Mutations in a Patient with Metastatic Colon Adenocarcinoma. PMID: 28811946 Ref: MAP2K1 Mutation in Colorectal Cancer Patients: Therapeutic Challenge Using Patient-Derived Tumor Cell Lines. PMID: 28819429 Ref: Gastric Medullary Carcinoma with Sporadic Mismatch Repair Deficiency and a TP53 R273C Mutation: An Unusual Case with Wild-Type BRAF. PMID: 28840050 Ref: Measurement of Telomere Length in Colorectal Cancers for Improved Molecular Diagnosis. PMID: 28850092 Ref: Tumor expression of calcium sensing receptor and colorectal cancer survival: Results from the nurses' health study and health professionals follow-up study. PMID: 28856682 Ref: Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations. PMID: 28859058 Ref: The prognostic role of microsatellite instability in colorectal cancer patients. PMID: 28874631 Ref: Erratum: Clinical responses to ERK inhibition in BRAF(V600E)-mutant colorectal cancer predicted using a computational model. PMID: 28879057 Ref: BRAF mutation in colorectal carcinomas with signet ring cell component. PMID: 28884045 Ref: Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation. PMID: 28895526 Ref: Implementation and utilization of the molecular tumor board to guide precision medicine. PMID: 28915716 Ref: The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer. PMID: 28928870 Ref: Methylation associated transcriptional repression of ELOVL5 in novel colorectal cancer cell lines. PMID: 28931069 Ref: Ex vivo treatment of patient biopsies as a novel method to assess colorectal tumour response to the MEK1/2 inhibitor, Selumetinib. PMID: 28931905 Ref: Integrating TYMS, KRAS and BRAF testing in patients with metastatic colorectal cancer. PMID: 28932083 Ref: EGFR pathway subgroups in Chilean colorectal cancer patients, detected by mutational and expression profiles, associated to different clinicopathological features. PMID: 28936923 Ref: Major challenges related to tumor biological characteristics in accurate mutation detection of colorectal cancer by next-generation sequencing. PMID: 28942013 Ref: Tubulin-binding anticancer polysulfides induce cell death via mitotic arrest and autophagic interference in colorectal cancer. PMID: 28943451 Ref: Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches. PMID: 28946014 Ref: High mRNA expression of splice variant SYK short correlates with hepatic disease progression in chemonaive lymph node negative colon cancer patients. PMID: 28957395 Ref: Upregulation of lncRNA BANCR associated with the lymph node metastasis and poor prognosis in colorectal cancer. PMID: 28969673 Ref: BANCR: a cancer-related long non-coding RNA. PMID: 28979803 Ref: Colorectal carcinoma with osseous metaplasia. PMID: 29029440 Ref: Enhanced Specificity of BRAF V600E Genotyping Using Wild-Type Blocker Coupled with Internal Competitive Reference in a Single Tube. PMID: 29035465 Ref: Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study. PMID: 29037218 Ref: Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer. PMID: 29038297 Ref: BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives. PMID: 29045527 Ref: Increased Frequency of KRAS Mutations in African Americans Compared with Caucasians in Sporadic Colorectal Cancer. PMID: 29048416 Ref: Application of in vivo imaging techniques to monitor therapeutic efficiency of PLX4720 in an experimental model of microsatellite instable colorectal cancer. PMID: 29050239 Ref: Acquired somatic TP53 or PIK3CA mutations are potential predictors of when polyps evolve into colorectal cancer. PMID: 29069792 Ref: [Personalized Treatment for Colorectal Carcinomas]. PMID: 29078210 Ref: Histopathological and genotypic characterization of metastatic colorectal carcinoma with PD-L1 (CD274)-expression: Possible roles of tumour micro environmental factors for CD274 expression. PMID: 29085667 Ref: Establishing a colorectal cancer liver metastasis patient-derived tumor xenograft model for the evaluation of personalized chemotherapy. PMID: 29094026 Ref: Familial Colorectal Cancer Type X (FCCTX) and the correlation with various genes-A systematic review. PMID: 29096939 Ref: Meta-analysis of the mutational status of circulation tumor cells and paired primary tumor tissues from colorectal cancer patients. PMID: 29100436 Ref: Real-time PCR-based method for the rapid detection of extended RAS mutations using bridged nucleic acids in colorectal cancer. PMID: 29111094 Ref: microRNA-193a-3p is specifically down-regulated and acts as a tumor suppressor in BRAF-mutated colorectal cancer. PMID: 29115941 Ref: Pulmonary metastasectomy for colorectal cancer: analysis of prognostic factors affecting survival. PMID: 29119016 Ref: Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer. PMID: 29123263 Ref: Immunohistochemistry with Anti-BRAF V600E (VE1) Mouse Monoclonal Antibody is a Sensitive Method for Detection of the BRAF V600E Mutation in Colon Cancer: Evaluation of 120 Cases with and without KRAS Mutation and Literature Review. PMID: 29127628 Ref: Analysis of factors influencing molecular testing at diagnostic of colorectal cancer. PMID: 29137623 Ref: Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. PMID: 29156800 Ref: Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer. PMID: 29169325 Ref: Molecular Landscape and Treatment Options for Patients with Metastatic Colorectal Cancer. PMID: 29203992 Ref: Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study. PMID: 29209533 Ref: Comprehensive genomic sequencing detects important genetic differences between right-sided and left-sided colorectal cancer. PMID: 29212173 Ref: Exome sequencing characterizes the somatic mutation spectrum of early serrated lesions in a patient with serrated polyposis syndrome (SPS). PMID: 29213343 Ref: Robust RNA-based in situ mutation detection delineates colorectal cancer subclonal evolution. PMID: 29222441 Ref: [Immunotherapy of Colorectal and Anal Carcinoma]. PMID: 29239195 Ref: Bliss and Loewe interaction analyses of clinically relevant drug combinations in human colon cancer cell lines reveal complex patterns of synergy and antagonism. PMID: 29262612 Ref: BRAF V600E Mutation Across Multiple Tumor Types: Correlation Between DNA-based Sequencing and Mutation-specific Immunohistochemistry. PMID: 29271794 Ref: Degree of Tissue Differentiation Dictates Susceptibility to BRAF-Driven Colorectal Cancer. PMID: 29281831 Ref: Targeted next generation sequencing in Chinese colorectal cancer patients guided anti-EGFR treatment and facilitated precision cancer medicine. PMID: 29285234 Ref: ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. PMID: 29370427 Ref: A Computational Workflow Translates a 58-Gene Signature to a Formalin-Fixed, Paraffin-Embedded Sample-Based Companion Diagnostic for Personalized Treatment of the BRAF-Mutation-Like Subtype of Colorectal Cancers. PMID: 29479053 Ref: Biomarker-driven and molecular targeted therapies for colorectal cancers. PMID: 30262397 |
Ref: The Role of SATB2 as a Diagnostic Marker of Sinonasal Intestinal-type Adenocarcinoma. PMID: 27258560 Ref: Correlations of IGF-1R and COX-2 Expressions with Ras and BRAF Genetic Mutations, Clinicopathological Features and Prognosis of Colorectal Cancer Patients. PMID: 28188432 Ref: Extent of field change in colorectal cancers with BRAF mutation. PMID: 28210747 Ref: Effects of PHA-665752 and Cetuximab Combination Treatment on In Vitro and Murine Xenograft Growth of Human Colorectal Cancer Cells with KRAS or BRAF Mutations. PMID: 28359236 Ref: The therapeutic potential of targeting the BRAF mutation in patients with colorectal cancer. PMID: 28407239 Ref: RNF43 is mutated less frequently in Lynch Syndrome compared with sporadic microsatellite unstable colorectal cancers. PMID: 28573495 Ref: Constitutional mismatch repair deficiency and Lynch syndrome among consecutive Arab Bedouins with colorectal cancer in Israel. PMID: 28608265 Ref: Clinicopathologic and Molecular Characteristics of Synchronous Colorectal Carcinoma With Mismatch Repair Deficiency. PMID: 28877066 Ref: Clinical performance evaluation of the Idylla NRAS-BRAF mutation test on retrospectively collected formalin-fixed paraffin-embedded colorectal cancer tissue. PMID: 28899979 Ref: Associations of alcohol intake, smoking, physical activity and obesity with survival following colorectal cancer diagnosis by stage, anatomic site and tumor molecular subtype. PMID: 28921583 Ref: Early genetic aberrations in patients with sporadic colorectal cancer. PMID: 28926134 Ref: Optimal detection of clinically relevant mutations in colorectal carcinoma: sample pooling overcomes intra-tumoral heterogeneity. PMID: 29027537 Ref: Association between clinicopathological characteristics and RAS mutation in colorectal cancer. PMID: 29052598 Ref: MLK3 phosphorylation by ERK1/2 is required for oxidative stress-induced invasion of colorectal cancer cells. PMID: 29084209 Ref: Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience. PMID: 29128266 Ref: Universal determination of microsatellite instability using BAT26 as a single marker in an Argentine colorectal cancer cohort. PMID: 29128931 Ref: Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control Study. PMID: 29129559 Ref: Wnt/beta-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer. PMID: 29167314 Ref: Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. PMID: 29180604 Ref: MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E-mutant colorectal adenocarcinoma. PMID: 29193645 Ref: Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer. PMID: 29195807 Ref: Proximal Aberrant Crypt Foci Associate with Synchronous Neoplasia and Are Primed for Neoplastic Progression. PMID: 29222172 Ref: Molecular profiling and genome-wide analysis based on somatic copy number alterations in advanced colorectal cancers. PMID: 29230882 Ref: Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer. PMID: 29233910 Ref: Oncogenic BRAF mutation induces DNA methylation changes in a murine model for human serrated colorectal neoplasia. PMID: 29235923 Ref: Site-specific Differences in Colonic Adenocarcinoma: KRAS Mutations and High Tumor Budding Are More Frequent in Cecal Adenocarcinoma. PMID: 29240583 Ref: Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial. PMID: 29254887 Ref: Specificity of Phosphorylation Responses to Mitogen Activated Protein (MAP) Kinase Pathway Inhibitors in Melanoma Cells. PMID: 29255136 Ref: Phase II Study of Panitumumab in RAS Wild-Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater. PMID: 29259073 Ref: Cancer, Colon PMID: 29262132 Ref: Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. PMID: 29267900 Ref: beta-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models. PMID: 29282298 Ref: Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors. PMID: 29295962 Ref: Which Lynch syndrome screening programs could be implemented in the "real world"? A systematic review of economic evaluations. PMID: 29300371 Ref: Linking FOXO3, NCOA3, and TCF7L2 to Ras pathway phenotypes through a genome-wide forward genetic screen in human colorectal cancer cells. PMID: 29301589 Ref: MLH1-93 G/a polymorphism is associated with MLH1 promoter methylation and protein loss in dysplastic sessile serrated adenomas with BRAF(V600E) mutation. PMID: 29304767 Ref: Locked Nucleic Acid Technology for Highly Sensitive Detection of Somatic Mutations in Cancer. PMID: 29304903 Ref: Associations Between Molecular Classifications of Colorectal Cancer and Patient Survival: A Systematic Review. PMID: 29306042 Ref: Genomic heterogeneity in primary colorectal carcinomas and their metastases: born bad or brought up a villain? PMID: 29307628 Ref: Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. PMID: 29316426 Ref: Mutations of key driver genes in colorectal cancer progression and metastasis. PMID: 29322354 Ref: BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines. PMID: 29326440 Ref: Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer? PMID: 29335867 Ref: The relationship between right-sided tumour location, tumour microenvironment, systemic inflammation, adjuvant therapy and survival in patients undergoing surgery for colon and rectal cancer. PMID: 29337962 Ref: Contribution of MLH1 constitutional methylation for Lynch syndrome diagnosis in patients with tumor MLH1 downregulation. PMID: 29341452 Ref: The clinicopathological features and prognosis of tumor MSI in East Asian colorectal cancer patients using NCI panel. PMID: 29366338 Ref: Significance of Liquid Biopsy for Monitoring and Therapy Decision of Colorectal Cancer. PMID: 29367069 Ref: MicroRNA Expression in KRAS- and BRAF-mutated Colorectal Cancers. PMID: 29374690 Ref: Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer. PMID: 29380640 Ref: Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes. PMID: 29382774 Ref: Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. PMID: 29387480 Ref: Clinical Impact of PI3K/BRAF Mutations in RAS Wild Metastatic Colorectal Cancer: Meta-analysis Results. PMID: 29388061 Ref: Association of rs2282679 A>C polymorphism in vitamin D binding protein gene with colorectal cancer risk and survival: effect modification by dietary vitamin D intake. PMID: 29409465 Ref: KRAS and 2 rare PI3KCA mutations coexisting in a metastatic colorectal cancer patient with aggressive and resistant disease. PMID: 29409955 Ref: Tumor Heterogeneity in Colorectal Cancer: What Do We Know So Far? PMID: 29414818 Ref: Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer. PMID: 29416939 Ref: Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAF(V600E) Colorectal Cancer. PMID: 29431697 Ref: Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF(V600E)-Mutant Colorectal Cancer. PMID: 29431699 Ref: Epigenetic silencing of SMOC1 in traditional serrated adenoma and colorectal cancer. PMID: 29435136 Ref: Double somatic mutations in mismatch repair genes are frequent in colorectal cancer after Hodgkin's lymphoma treatment. PMID: 29439113 Ref: Effects of PHA-665752 and vemurafenib combination treatment on in vitro and murine xenograft growth of human colorectal cancer cells with BRAF(V600E) mutations. PMID: 29456739 Ref: First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients. PMID: 29470838 Ref: The Unfolded Protein Response: A Novel Therapeutic Target for Poor Prognostic BRAF Mutant Colorectal Cancer. PMID: 29483217 Ref: Systemic Therapy for Colon Cancer. PMID: 29496087 Ref: Clinical Trials and Progress in Metastatic Colon Cancer. PMID: 29496094 Ref: Genetic Biopsy for Prediction of Surveillance Intervals after Endoscopic Resection of Colonic Polyps: Results of the GENESIS Study. PMID: 29511559 Ref: CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer. PMID: 29518181 Ref: Phase II Study of Preoperative Treatment with External Radiotherapy Plus Panitumumab in Low-Risk, Locally Advanced Rectal Cancer (RaP Study/STAR-03). PMID: 29523646 Ref: Phosphorylation of p70 Ribosomal Protein S6 Kinase beta-1 is an Independent Prognostic Parameter in Metastatic Colorectal Cancer. PMID: 29526493 Ref: Exploratory pooled analysis evaluating the effect of sequence of biological therapies on overall survival in patients with RAS wild-type metastatic colorectal carcinoma. PMID: 29531837 Ref: Clinical Aspects of Microsatellite Instability Testing in Colorectal Cancer. PMID: 29531926 Ref: BRAF and EGFR inhibitors synergize to increase cytotoxic effects and decrease stem cell capacities in BRAF(V600E)-mutant colorectal cancer cells. PMID: 29534162 Ref: RET fusions in a small subset of advanced colorectal cancers at risk of being neglected. PMID: 29538669 Ref: Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. PMID: 29540830 Ref: Use of Liquid Biopsy in Monitoring Colorectal Cancer Progression Shows Strong Clinical Correlation. PMID: 29549923 Ref: Surface Enhanced Raman Spectroscopy (SERS) for the Multiplex Detection of Braf, Kras, and Pik3ca Mutations in Plasma of Colorectal Cancer Patients. PMID: 29556349 Ref: Evolution of regorafenib from bench to bedside in colorectal cancer: Is it an attractive option or merely a "me too" drug? PMID: 29563833 Ref: Extracted metabolite from Streptomyces Levis ABRIINW111 altered the gene expression in colon cancer. PMID: 29564063 Ref: Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF-mutant stage II and III colon cancer. PMID: 29568398 Ref: Polo-like kinase 2 promotes chemoresistance and predicts limited survival benefit from adjuvant chemotherapy in colorectal cancer. PMID: 29568868 Ref: Sessile Serrated Adenomas in Young Patients may have Limited Risk of Malignant Progression. PMID: 29570172 Ref: Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies. PMID: 29588308 Ref: Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview. PMID: 29589315 Ref: Utility of BRAF VE1 Immunohistochemistry as a Screening Tool for Colorectal Cancer Harboring BRAF V600E Mutation. PMID: 29590746 Ref: Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer. PMID: 29596542 Ref: Racial Disparities in the Molecular Landscape of Cancer. PMID: 29599344 Ref: Adaptive Resistance to Chemotherapy, A Multi-FAK-torial Linkage. PMID: 29610281 Ref: Advances on the BRAF Front in Colorectal Cancer. PMID: 29610287 Ref: A Network Pharmacology Approach to Uncover the Multiple Mechanisms of Hedyotis diffusa Willd. on Colorectal Cancer. PMID: 29619072 Ref: Emerging treatment options for BRAF-mutant colorectal cancer. PMID: 29628780 Ref: [Prediction of EGFR blockade responses in metastatic colorectal carcinoma]. PMID: 29631407 Ref: NCCN Guidelines Insights: Colon Cancer, Version 2.2018. PMID: 29632055 Ref: Differential clinicopathological and molecular features within late-onset colorectal cancer according to tumor location. PMID: 29632645 Ref: [ASCO- and ESMO-update 2017 - highlights of the 53. meeting of the American Society of Clinical Oncology/ASCO 2017 and European Society for Medical Oncology/ESMO congress 2017]. PMID: 29642252 Ref: Predictive and Prognostic Implications of Mutation Profiling and Microsatellite Instability Status in Patients with Metastatic Colorectal Carcinoma. PMID: 29643917 Ref: Costs and outcomes of Lynch syndrome screening in the Australian colorectal cancer population. PMID: 29645364 Ref: Phenotypic and genotypic differences in colorectal carcinoma among Caucasians, Asians, and Hispanics lack statistical significance. PMID: 29650442 Ref: The Association Between Mutations in BRAF and Colorectal Cancer-Specific Survival Depends on Microsatellite Status and Tumor Stage. PMID: 29660527 Ref: Clinical outcomes of women with ovarian metastases of colorectal cancer treated with oophorectomy with respect to their somatic mutation profiles. PMID: 29662660 Ref: Cyclin-dependent kinase 1 targeting improves sensitivity to radiation in BRAF V600E colorectal carcinoma cells. PMID: 29663854 Ref: Genetic editing of colonic organoids provides a molecularly distinct and orthotopic preclinical model of serrated carcinogenesis. PMID: 29666172 Ref: Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients. PMID: 29666387 Ref: The prognostic impact of CDX2 correlates with the underlying mismatch repair status and BRAF mutational status but not with distant metastasis in colorectal cancer. PMID: 29675807 Ref: Frequency of NRAS Gene Mutation in Wild Type KRAS and BRAF Colorectal Cancers; a Single Center Study. PMID: 29682243 Ref: One-carbon metabolism biomarkers and genetic variants in relation to colorectal cancer risk by KRAS and BRAF mutation status. PMID: 29694444 Ref: Performance validation of an amplicon-based targeted next-generation sequencing assay and mutation profiling of 648 Chinese colorectal cancer patients. PMID: 29705968 Ref: RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients. PMID: 29707525 Ref: BRAF-mutant colorectal cancer, a different breed evolving. PMID: 29708446 Ref: Double KRAS and BRAF Mutations in Surgically Treated Colorectal Cancer Liver Metastases: An International, Multi-institutional Case Series. PMID: 29715113 Ref: Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer. PMID: 29718453 Ref: Update on Sporadic Colorectal Cancer Genetics. PMID: 29720900 Ref: Upregulation of c-mesenchymal epithelial transition expression and RAS mutations are associated with late lung metastasis and poor prognosis in colorectal carcinoma. PMID: 29725370 Ref: Downregulation of BRAF-activated non-protein coding RNA in patients with hepatitis B virus-associated hepatocellular carcinoma. PMID: 29725471 Ref: Immunohistochemical and genetic characteristics of a colorectal mucin-rich variant of traditional serrated adenoma. PMID: 29729192 Ref: Comprehensive expression analysis of TNF-related apoptosis-inducing ligand and its receptors in colorectal cancer: Correlation with MAPK alterations and clinicopathological associations. PMID: 29731264 Ref: Serrated epithelial colorectal polyps (hyperplastic polyps, sessile serrated adenomas) with perineurial stroma: Clinicopathological and molecular analysis of a new series. PMID: 29747061 Ref: Universal screening of both endometrial and colon cancers increases the detection of Lynch syndrome. PMID: 29750335 Ref: Promising New Agents for Colorectal Cancer. PMID: 29752549 Ref: AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status. PMID: 29755114 Ref: Clinical application of targeted next-generation sequencing for colorectal cancer patients: a multicentric Belgian experience. PMID: 29755687 Ref: Clinicopathological and molecular differences between right-sided and left-sided colorectal cancer in Japanese patients. PMID: 29767751 Ref: Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis. PMID: 29771009 Ref: Molecular Diagnostics in Colorectal Carcinoma: Advances and Applications for 2018. PMID: 29776633 Ref: Centrosome Linker-induced Tetraploid Segregation Errors Link Rhabdoid Phenotypes and Lethal Colorectal Cancers. PMID: 29784668 Ref: Optimizing Adjuvant Therapy for Localized Colon Cancer and Treatment Selection in Advanced Colorectal Cancer. PMID: 29784738 Ref: Novel insights into transcriptional dysregulation in colorectal cancer. PMID: 29788743 Ref: Colorectal Cancer: Why Does Side Matter? PMID: 29790124 Ref: Colorectal Liver Metastases: A Pathologist's Guide to Creating an Informative Report and Improving Patient Care. PMID: 29790787 Ref: Comprehensive molecular analysis based on somatic copy number alterations in intramucosal colorectal neoplasias and early invasive colorectal cancers. PMID: 29796160 Ref: Right Versus Left Colon Cancer: Resectable and Metastatic Disease. PMID: 29796712 Ref: Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer. PMID: 29799910 Ref: Prevalence and prognostic relevance of BrafV600E mutation in colorectal carcinomas from Kashmir (North India) valley. PMID: 29800258 Ref: Molecular subtypes in early colorectal cancer associated with clinical features and patient prognosis. PMID: 29802524 Ref: The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer. PMID: 29805705 Ref: SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo. PMID: 29808006 Ref: High-serum MMP-8 levels are associated with decreased survival and systemic inflammation in colorectal cancer. PMID: 29808017 Ref: miR-550a-3-5p acts as a tumor suppressor and reverses BRAF inhibitor resistance through the direct targeting of YAP. PMID: 29844307 Ref: Combined assessment of the TNM stage and BRAF mutational status at diagnosis in sporadic colorectal cancer patients. PMID: 29844874 Ref: Phase III study with FOLFIRI + cetuximab versus FOLFIRI + cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC. PMID: 29846100 Ref: BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report. PMID: 29850361 Ref: How should BRAF V600E-mutated colorectal cancer be treated? PMID: 29851929 Ref: Simultaneous identification of clinically relevant single nucleotide variants, copy number alterations and gene fusions in solid tumors by targeted next-generation sequencing. PMID: 29854313 Ref: Combination drug development in BRAF mutant colorectal cancer. PMID: 29854866 Ref: Targeting parallel bypass signaling to combat adaptive resistance to BRAF inhibition in colorectal cancer. PMID: 29854868 Ref: Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping. PMID: 29855806 Ref: Development of ultra-short PCR assay to reveal BRAF V600 mutation status in Thai colorectal cancer tissues. PMID: 29879227 Ref: Oncogenic BRAFV600E drives expression of MGL ligands in the colorectal cancer cell line HT29 through N-acetylgalactosamine-transferase 3. PMID: 29894293 Ref: TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas. PMID: 29900052 Ref: Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis. PMID: 29900061 Ref: Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer. PMID: 29900672 Ref: Alterations of mTOR signaling impact metabolic stress resistance in colorectal carcinomas with BRAF and KRAS mutations. PMID: 29907857 Ref: Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer. PMID: 29908105 Ref: Colorectal cancer genomics and designing rational trials. PMID: 29911107 Ref: The Endosomal Protein CEMIP Links WNT Signaling to MEK1-ERK1/2 Activation in Selumetinib-Resistant Intestinal Organoids. PMID: 29915160 Ref: PTPRS Regulates Colorectal Cancer RAS Pathway Activity by Inactivating Erk and Preventing Its Nuclear Translocation. PMID: 29915291 Ref: Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy. PMID: 29921730 Ref: Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence. PMID: 29937183 Ref: Brain metastases in colorectal cancer: prognostic factors and survival analysis. PMID: 29943356 Ref: Gene promoter and exon DNA methylation changes in colon cancer development - mRNA expression and tumor mutation alterations. PMID: 29945573 Ref: Assessing colorectal cancer mismatch repair status in the modern era: a survey of current practices and re-evaluation of the role of microsatellite instability testing. PMID: 29955148 Ref: Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal Cancer. PMID: 29959022 Ref: Evaluating the Combination of Microsatellite Instability and Mutation in BRAF as Prognostic Factors for Patients With Colorectal Cancer. PMID: 29966708 Ref: [Impacts of microsatellite status, RAS and BRAF mutation on postoperative follow-up strategy in stage II( and III( colorectal cancer]. PMID: 29968248 Ref: A System-wide Approach to Monitor Responses to Synergistic BRAF and EGFR Inhibition in Colorectal Cancer Cells. PMID: 29970458 Ref: Differences in gene mutations according to gender among patients with colorectal cancer. PMID: 29976257 Ref: Colorectal Cancer Stratification in the Routine Clinical Pathway: A District General Hospital Experience. PMID: 29985199 Ref: ERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancer. PMID: 29988110 Ref: [Feasibility of amplicon-based targeted next-generation sequencing of colorectal cancer in endoscopic biopsies]. PMID: 29996313 Ref: Loss of SATB2 Expression in Colorectal Carcinoma Is Associated With DNA Mismatch Repair Protein Deficiency and BRAF Mutation. PMID: 30001238 Ref: Immunohistochemistry is a feasible method to screen BRAF V600E mutation in colorectal and papillary thyroid carcinoma. PMID: 30009773 Ref: Targeted therapy for metastatic colorectal cancer. PMID: 30019590 Ref: A Rare Missense Variant in TCF7L2 Associates with Colorectal Cancer Risk by Interacting with a GWAS-Identified Regulatory Variant in the MYC Enhancer. PMID: 30026326 Ref: Genomic alterations accompanying tumour evolution in colorectal cancer: tracking the differences between primary tumours and synchronous liver metastases by whole-exome sequencing. PMID: 30029640 Ref: The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern. PMID: 30035653 Ref: Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations. PMID: 30036146 Ref: Expression Profile of LGR5 and Its Prognostic Significance in Colorectal Cancer Progression. PMID: 30036518 Ref: Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial. PMID: 30036739 Ref: Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series. PMID: 30042065 Ref: The First Molecular Screening of MLH1 and MSH2 Genes in Moroccan Colorectal Cancer Patients Shows a Relatively High Mutational Prevalence. PMID: 30044143 Ref: HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features. PMID: 30056472 Ref: Vemurafenib. PMID: 30069761 Ref: Clinical, Pathological, and Molecular Characteristics of CpG Island Methylator Phenotype in Colorectal Cancer: A Systematic Review and Meta-analysis. PMID: 30071442 Ref: Computational Analysis of miRNA and their Gene Targets Significantly Involved in Colorectal Cancer Progression. PMID: 30073936 Ref: Molecular characteristics of colorectal cancer in a Middle Eastern population in a single institution. PMID: 30078023 Ref: Synthesis, Computational Docking Study, and Biological Evaluation of a Library of Heterocyclic Curcuminoids with Remarkable Antitumor Activity. PMID: 30079563 Ref: Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predict metastases in colorectal cancer: A preliminary study. PMID: 30085422 Ref: The atypical cyclin CNTD2 promotes colon cancer cell proliferation and migration. PMID: 30087414 Ref: Endoscopic diagnosis of sessile serrated adenoma/polyp with and without dysplasia/carcinoma. PMID: 30090005 Ref: HER2: An emerging target in colorectal cancer. PMID: 30100092 Ref: Inhibition of YAP reverses primary resistance to EGFR inhibitors in colorectal cancer cells. PMID: 30106444 Ref: Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer. PMID: 30122982 Ref: LncRNA BANCR promotes tumorigenesis and enhances adriamycin resistance in colorectal cancer. PMID: 30144787 Ref: Impact of the Localization of the Primary Tumor and RAS/BRAF Mutational Status on Maintenance Strategies After First-line Oxaliplatin, Fluoropyrimidine, and Bevacizumab in Metastatic Colorectal Cancer: Results From the AIO 0207 Trial. PMID: 30145148 Ref: Quality and practical aspects of pathological and molecular diagnostics in metastatic colorectal cancer (mCRC). PMID: 30150883 Ref: EXOSC4 functions as a potential oncogene in development and progression of colorectal cancer. PMID: 30155936 Ref: Prevalence and clinicopathological characteristics of mismatch repair-deficient colorectal carcinoma in early onset cases as compared with late-onset cases: a retrospective cross-sectional study in Northeastern Iran. PMID: 30166308 Ref: MOLECULAR FEATURES AND MOUSE MODELS OF COLORECTAL CANCER. PMID: 30166699 Ref: The gene mutational discrepancies between primary and paired metastatic colorectal carcinoma detected by next-generation sequencing. PMID: 30171333 Ref: Targeting BRAF Mutations in High-Grade Neuroendocrine Carcinoma of the Colon. PMID: 30181415 Ref: Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy. PMID: 30188916 Ref: MEK inhibitors induce apoptosis via FoxO3a-dependent PUMA induction in colorectal cancer cells. PMID: 30190455 Ref: PDEdelta inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRas. PMID: 30194764 Ref: The location of the primary colon cancer has no impact on outcomes in patients undergoing cytoreductive surgery for peritoneal metastasis. PMID: 30197280 Ref: Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases. PMID: 30202242 Ref: Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics. PMID: 30205948 Ref: Ascorbic Acid in Colon Cancer: From the Basic to the Clinical Applications. PMID: 30217071 Ref: Electrostatic mechanism of V600E mutation-induced B-Raf constitutive activation in colorectal cancer: molecular implications for the selectivity difference between type-I and type-II inhibitors. PMID: 30218115 Ref: Vitamin D status after colorectal cancer diagnosis and patient survival according to immune response to tumour. PMID: 30219720 Ref: Fusobacterium nucleatum in Colorectal Cancer Relates to Immune Response Differentially by Tumor Microsatellite Instability Status. PMID: 30228205 Ref: Liquid Biopsy to Identify Actionable Genomic Alterations. PMID: 30231331 Ref: Molecular Subtypes and the Evolution of Treatment Decisions in Metastatic Colorectal Cancer. PMID: 30231342 Ref: Diagnosis and clinical behavior in patients with Lynch-like syndrome. PMID: 30237080 Ref: The Amount of Bifidobacterium Genus in Colorectal Carcinoma Tissue in Relation to Tumor Characteristics and Clinical Outcome. PMID: 30243655 Ref: CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathway. PMID: 30257705 Ref: Small RNA sequencing of sessile serrated polyps identifies microRNA profile associated with colon cancer. PMID: 30265426 Ref: Efficacy of a Covalent ERK1/2 Inhibitor, CC-90003, in KRAS Mutant Cancer Models Reveals Novel Mechanisms of Response and Resistance. PMID: 30275173 Ref: Current mismatch repair deficiency tumor testing practices and capabilities: A survey of Australian pathology providers. PMID: 30294856 Ref: Reply to comment of "ERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancer". PMID: 30297771 Ref: Comment on "ERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancer". PMID: 30297772 Ref: Prognostic value of the combination of microsatellite instability and BRAF mutation in colorectal cancer. PMID: 30310312 Ref: Smoking and Risk of Colorectal Cancer Sub-Classified by Tumor-Infiltrating T Cells. PMID: 30312431 Ref: ACTH-Secreting Neuroendocrine Carcinoma of the Cecum: Case Report and Review of the Literature. PMID: 30314823 Ref: Evaluation of a novel liquid biopsy-based ColoScape assay for mutational analysis of colorectal neoplasia and triage of FIT+ patients: a pilot study. PMID: 30315134 Ref: Signal transducer and activator of transcription 3 inhibition enhances vemurafenib sensitivity in colon cancers harboring the BRAF(V600E) mutation. PMID: 30320916 Ref: EPA significantly improves anti-EGFR targeted therapy by regulating miR-378 expression in colorectal cancer. PMID: 30333883 Ref: Circulating cell-free DNA- diagnostic and prognostic applications in personalized cancer therapy. PMID: 30335711 Ref: Early Detection of Colorectal Cancer: a Multi-Center Pre-Clinical Case Cohort Study for Validation of a Combined DNA Stool Test. PMID: 30336540 Ref: Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE, a global phase 3 study. PMID: 30339194 Ref: Genetic and immunological biomarkers predict metastatic disease recurrence in stage III colon cancer. PMID: 30340556 Ref: Clinical, Histologic, and Immunophenotypic Features of Serrated Polyps in Patients With Inflammatory Bowel Disease. PMID: 30344807 Ref: Spatio-temporal tumor heterogeneity in metastatic CRC tumors: a mutational-based approach. PMID: 30344942 Ref: Recent advances in understanding colorectal cancer. PMID: 30345013 Ref: Aspects of the Natural History of Sessile Serrated Adenomas/Polyps: Risk Indicators for Carcinogenesis in the Colorectal Mucosa? PMID: 30346367 Ref: Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer. PMID: 30353166 Ref: Simple and Low-Cost Sampling of Cell-Free Nucleic Acids from Blood Plasma for Rapid and Sensitive Detection of Circulating Tumor DNA. PMID: 30356899 Ref: Prognostic Values of EPDR1 Hypermethylation and Its Inhibitory Function on Tumor Invasion in Colorectal Cancer. PMID: 30360391 Ref: Positive association of PIK3CA mutation with KRAS mutation but not BRAF mutation in colorectal cancer suggests co-selection is gene specific but not pathway specific. PMID: 30361395 Ref: Intratumoral infiltrating lymphocytes correlate with improved survival in colorectal cancer patients: Independent of oncogenetic features. PMID: 30370522 Ref: Tumour budding is associated with the mesenchymal colon cancer subtype and RAS/RAF mutations: a study of 1320 colorectal cancers with Consensus Molecular Subgroup (CMS) data. PMID: 30385823 Ref: Association of Aspirin and Nonsteroidal Anti-Inflammatory Drugs With Colorectal Cancer Risk by Molecular Subtypes. PMID: 30388256 |